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ABSTRACT 
COAGULATION AND THE ENDOTHELIUM IN MALAWIAN 
CHILDREN WITH CEREBRAL MALARIA 
Christopher Moxon, Liverpool School of Tropical Medicine, Pembroke Place, 
Liverpool L3 5QA. Email: cmoxon@liverpool.ac.uk 
 
BACKGROUND  
Cerebral malaria is a major cause of mortality and morbidity in African children. 
Pathology is related to interactions between malaria-infected red blood cells (iRBC) 
and the endothelium but the aetiology of the neurological compromise remains 
unclear.  
 
METHODS 
This thesis involved direct and downstream investigation of the endothelium in 
Malawian children with cerebral malaria and controls in post-mortem samples, 
plasma and through developing a novel ex vivo method to examine endothelium in 
subcutaneous tissue.  
 
RESULTS 
In post-mortem samples of brain in fatal cerebral malaria, there was thrombosis and 
loss of endothelial protein C receptor (EPCR) associated with iRBC sequestration. 
iRBC associated loss of EPCR and thrombomodulin was also demonstrated in post-
mortem samples of gut and subcutaneous tissue but this was less marked than in 
the brain and rarely associated with thrombosis. Subcutaneous biopsies taken on 
admission with cerebral malaria demonstrated reduced EPCR and thrombomodulin 
ex vivo, showing that loss of these receptors is present at the time of presentation 
and are not just agonal events.  
 
Examination of coagulation in blood demonstrated activation of coagulation, as 
indicated by raised thrombin-anti-thrombin complexes and reduced protein C and 
antithrombin levels. However this was compensated as there was normal 
prothrombin fragment (F1+2)-to-activated protein C ratios and only mildly altered 
clotting times.  
 
Examination of markers of endothelial activation (soluble Intracellular Adhesion 
 3 
Molecule-1 [sICAM-1] and Angiopoetin-2 [Ang-2]) and inflammation (C-reactive 
protein [CRP]) revealed endothelial activation and inflammation at presentation and 
during recovery and demonstrated that in cerebral malaria and in uncomplicated 
malaria there is persistent endothelial activation after parasites are cleared, up to a 
month after presentation. Complexes of very low density lipoprotein (VLDL) and 
CRP were also raised in cerebral and uncomplicated malaria.   
 
CONCLUSIONS 
In cerebral malaria in Malawian children there is localised microvascular loss of 
endothelial anticoagulant receptors at sites of iRBC sequestration. In the brain, 
where constitutive expression of EPCR and thrombomodulin is low, this is 
accompanied by thrombosis; outside the brain, where constitutive EPCR and 
thrombomodulin expression is high, coagulation is compensated.  
This activation of coagulation and of the endothelium in response to acute infection 
leaves a residual imprint as detected by markers of endothelial activation and 
inflammation even in uncomplicated malaria several weeks after parasites are 
cleared. Since children in sub-Saharan African frequently suffer repeated infections 
these endothelial alterations may have important consequences both for 
subsequent infections and for long-term health. 
These mechanisms highlight potential targets for therapy.  
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1.1 A new look at an old disease 
Malaria is an ancient disease of mankind (Miao, Yang et al. 2012). Malaria antigen 
was isolated from lung and skin samples of 3000 year old Egyptian mummies (Miller, 
Ikram et al. 1994). Periodic fever was described in many of the early civilizations: by 
the Assyrian’s in early cuneiform clay tablets circa 2000 BC, in Ancient India during 
the Vedic Period in Sanskrit (Sherman 1998), in ancient Greece by Hippocrates 
circa 400 BC (Cunha and Cunha 2008) and in ancient China in the Huangdi Neijing 
in the Warring States Period circa 300 BC (Sherman 1998). Yet it wasn’t until 1880 
that Plasmodium parasites were recognized in the blood as the causative agent by 
Charles Louis Alphonse Laveran (Laveran 1881), for which he won the Nobel Prize 
in 1907. Shortly after the Italian scientists Marchiafava and Bignami recognized the 
process of sequestration and its contribution to pathology in malaria (Marchiafava 
and Bignami 1892). In 1917 the Pathologists Dudgeon and Clarke described a 
combination of thrombosis and haemorrhage in microvessels in post-mortems of 
soldiers who had died of malaria in Macedonia during the First World War and 
recognized that these might indicate that a coagulopathic state contributed to 
disease (Dudgeon and Clarke 1917). Although several studies have looked at 
coagulation in malaria, the question of whether a coagulopathic state contributes to 
severe malaria pathogenesis remains unresolved almost a hundred years later 
(Moxon, Heyderman et al. 2009).  
 
1.2 Malaria: Brief epidemiology 
Malaria is the most important parasitic disease in man causing approximately half a 
billion infectious episodes (Snow, Guerra et al. 2005) and 1.2 million deaths per 
year (Murray, Rosenfeld et al. 2012). Approximately a third of the world lives in 
areas in which they are exposed to malaria (Snow, Guerra et al. 2005) but the 
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burden is disproportionately suffered by children in sub-Saharan Africa in whom 
malaria causes over 700,000 deaths annually and accounts for nearly a quarter of 
all childhood deaths (Murray, Rosenfeld et al. 2012).  
Five species of the Apicomplexan phylum Plasmodium infect and cause malaria 
disease in man: Plasmodium falciparum, P. ovale2, P. malariae, P. vivax and P. 
knowlesi. This thesis focuses on disease caused by P. falciparum infection, the 
most common species in sub-Saharan Africa, which leads to the majority of severe 
disease and deaths.   
Even though P. falciparum is the most likely malaria species to cause severe 
disease, the majority of P. falciparum infections in sub-Saharan Africa cause a self-
limiting febrile illness or are asymptomatic (Snow, Guerra et al. 2005). Acquisition of 
immunity – which occurs following repeated exposure to infection (reviewed in 
(Langhorne, Ndungu et al. 2008; Pierce and Miller 2009; Hafalla, Silvie et al. 2011) - 
contributes to this and largely explains a higher proportion of severe disease in non-
immune travellers, low-endemicity areas and the concentration of deaths in young 
children. Yet it does not explain why among young children in sub-Saharan Africa 
who have not developed solid immunity, some individuals get cerebral malaria and 
die and others get a self-limiting febrile illness. Before exploring current 
understanding of severe and cerebral malaria pathogenesis I will briefly outline the 
clinical classification of malaria severity and disease syndromes and the parasite life 
cycle.  
                                                
2
Recently it has in fact been shown that there are two non-recombining forms of P. ovale  (Sutherland, Tanomsing, 
et al. 2010). Therefore it is in fact two species P. ovale curtisi and P. ovale wallikeri (Oguike, Betson, et al. 2011). 
(Fuehrer, Habler, et al. 2012). It remains uncertain whether or not the two P. ovale species exhibit differences in 
their pathogenicity or drug sensitivity. 
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Figure 1.1: Pyramid demonstrating the relative contributions of different disease severities of 
Plasmodium falciparum malaria in an endemic area.  
The area of the pyramid in red orange and yellow indicates the proportion of people who get each 
disease severity. Figure is intended to be illustrative only and proportions are approximate only. Figure 
reproduced with permission from Malcolm Molyneux.  
 
 
1.3 Malaria life cycle 
Malaria is transmitted by the bite of female anopheline mosquitoes, there is no 
person to person spread although rare incidence of infection through blood 
transfusion have been described (Tagny, Owusu-Ofori et al. 2010). 
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Figure 1.2: Malaria life cycle. 
Sporozoites are injected into the blood stream by infected female anopheline mosquito. Sporozoites 
invade hepatocytes in the liver where they multiply. Hepatocytes rupture releasing merozoites into the 
bloodstream. Merozoites invade circulating red blood cells. The parasite matures in the red blood cell 
and divides and eventually ruptures releasing new merozoites into the bloodstream (schizognony). In 
P. falciparum because the mature forms cytoadhere and sequester in the capillaries and post-capillary 
venules schizognoy occurs principally at sites of sequestration. Some trophozoites differentiate into 
male or female gametocyte forms, which infect a new mosquito during feeding. The sexual phase of 
the life cycle occurs in the mosquito mid gut. Reproduced with permission courtesy Dumizulu Tembo.  
 
The parasite asexual life cycle occurs in the human host (Figure 1.2). Sporozoites 
injected by the mosquito initially infect hepatocytes but malaria symptoms begin 
after merozoites exit from hepatocytes and invade red blood cells [RBC (White 
2003)]. Following invasion the P. falciparum parasite induces a complex series of 
changes to the RBC including the export of multiple parasite derived proteins into 
and onto the membrane; reviewed in (Moxon, Grau et al. 2011) – copy in appendix. 
One role of the surface proteins is to enable adherence of the maturing infected 
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RBC (iRBC) to the endothelium allowing it to sequester in the capillaries and post-
capillary venules. This exposes the parasite to a high carbon dioxide and low 
oxygen environment, which is optimal for its growth and also evades passage 
through the spleen (David, Hommel et al. 1983); where abnormal and poorly 
deformable RBC are removed from circulation. Cytoadherence is also implicated as 
a key process in P. falciparum malaria pathogenesis, both because of the 
biomechanical effects of sequestration itself (Berendt, Tumer et al. 1994; Ponsford, 
Medana et al. 2012) and secondly because adherence of iRBC to the endothelium 
induces changes to endothelial phenotype (Francischetti, Seydel et al. 2007; 
Jenkins, Wu et al. 2007; Tripathi, Sullivan et al. 2007; Wu, Szestak et al. 2011).  
 
1.4 Severe malaria: definition and classification and differences 
between paediatric and adult disease 
 
When malaria is accompanied by one or more features of vital organ compromise 
the risk of deterioration or death is increased and it is termed ‘severe malaria’ [Table 
1-1 (WHO 2000)]. P. falciparum infection with no features of severe malaria is 
termed ‘uncomplicated malaria’. As can be seen from the table (Table 1-1) severe 
malaria encompasses compromise in several different organs. However while renal 
failure and pulmonary oedema or acute respiratory distress syndrome (ARDS) are 
important complications in South East Asian and non-immune adults (Dondorp and 
Day 2007; Bruneel, Tubach et al. 2010), in African children renal failure and 
pulmonary oedema are rare (Marsh, Forster et al. 1995). Deep breathing, an 
important sign of compromise in African children, is normally due to acidosis and not 
to pulmonary compromise (English, Waruiru et al. 1996).  
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Three overlapping syndromes are typically recognized in severe malaria in African 
children: severe anaemia, acidosis and cerebral malaria (Marsh, Forster et al. 1995; 
Newton, Taylor et al. 1998). Acidosis is not always recognized as a separate 
disease entity in epidemiological studies but increased blood lactate, acidosis or 
acidotic deep (Kussmaul’s) breathing have been recognized to be a features 
associated with increased risk of mortality (Marsh, Forster et al. 1995). Severe 
anaemia (Haemoglobin [Hb] <5g/ dL) is also associated with increased mortality and 
is a leading indication for blood transfusion in African hospitals (English, Ahmed et 
al. 2002). The peak age for severe malaria anaemia varies depending on the 
prevalence of malaria but tends to occur in younger children than cerebral malaria 
(Roca-Feltrer, Carneiro et al. 2010). Severe anaemia is associated with repeated 
infections (Phiri, Calis et al. 2008) and can be reduced by intermittent preventative 
therapy (Phiri, Calis et al. 2008; Phiri, Esan et al. 2012). Indeed the importance of 
malaria in causing anaemia is such that iron deficiency, an important cause of 
anaemia in other parts of the world, is in fact protective against anaemia in Malawi 
(Calis, Phiri et al. 2008); with the protective effect putatively explained by the high 
iron requirement of the parasite. Acidosis and severe anaemia have complex 
aetiologies. Severe malarial anaemia is caused mainly by a combination of 
haemolysis of iRBC and sequestration, may be associated with non-typhoidal 
Salmonella co-infection and with recurrent malaria infections (Calis, Phiri et al. 2008; 
Phiri, Calis et al. 2008). Malarial acidosis is a lactic acidosis often associated with 
severe malarial anaemia although it may present in children without anaemia. It is 
proposed to be due to poor tissue perfusion due to sequestration and decreased red 
cell deformability but a poor correlation with oxygen consumption indicates that it 
has more complex aetiology (English, Muambi et al. 1997). Since this thesis focuses 
on cerebral malaria we will not detail these other syndromes further.  
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Table 1-1: Criteria for the diagnosis of severe malaria.  
Presence of one or more of these clinical or laboratory criteria in the context of P. falciparum infection 
indicates severe malaria.  Adapted from (WHO 2000) 
 
Clinical Laboratory 
Impaired consciousness or unrousable coma 
Hypoglycaemia (blood glucose < 2.2 mmol/l or < 40 
mg/dl) 
Prostration: (unable to walk or sit up in adult or child or 
failure to feed in an infant) 
Metabolic acidosis (plasma bicarbonate < 15 mmol/l) 
Multiple convulsions (more than two episodes in 24 h) Hyperlactataemia (lactate > 5 mmol/l) 
Deep breathing, respiratory distress (acidotic breathing) 
Severe anaemia (Hb < 5 g/dl, packed cell volume < 
15%) 
Circulatory collapse or shock (systolic blood pressure < 70 
mm Hg in adults and < 50 mm Hg in children) 
Hyperparasitaemia (> 2% or 100 000/µl in low intensity 
transmission areas or > 5% or 250 000/µl in areas of 
high stable malaria transmission intensity) 
Clinical jaundice plus evidence of other vital organ 
dysfunction 
 
Haemoglobinuria 
 
Abnormal spontaneous bleeding 
 
Pulmonary oedema (radiological) 
 
 
1.5 Cerebral malaria  
1.5.1 Cerebral malaria: Definition and classification  
Cerebral malaria is defined as unrousable coma (Blantyre coma score ≤2 3 ; 
equivalent approximately to a Glasgow coma score of <9) when there is an asexual 
                                                
3 The Blantyre coma score (BCS) is a coma score developed in Blantyre, Malawi specifically for assessing coma in 
children with cerebral malaria Molyneux, M. E. (1989). "Malaria--clinical features in children." Journal of the Royal 
Society of Medicine 82 Suppl 17: 35-38.. Best verbal and motor responses to pain are scored from 0-2 and eye 
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parasitaemia on a peripheral blood smear and when other causes of 
encephalopathy have been excluded (Newton, Taylor et al. 1998). Some specific 
exclusions are febrile convulsion (with the stipulation that coma should be present 
for at least 1 hour after a convulsion to be included) meningitis, hypoglycaemia and 
drug intoxication or poisoning. A difficulty with this definition is that encephalopathy 
has a wide differential diagnosis and exclusion of all ‘other causes of 
encephalopathy’ is not feasible in a low resource setting. Indeed a large autopsy 
study of fatal cerebral malaria demonstrated that even in the specialist research 
facility in Blantyre with highly experienced clinicians, 23% of patients who met this 
clinical definition of cerebral malaria during life were found to have an alternative 
cause of coma and death at autopsy examination (Taylor, Fu et al. 2004). This 
seminal study demonstrated that cases in which no other cause of death was found 
were associated with sequestration of P. falciparum-infected red blood cells (iRBC) 
in the cerebral microvessels (and therefore could be regarded as definitive cerebral 
malaria), whereas those in which an alternative cause of death was identified did not 
have sequestration of iRBC in cerebral vessels.  Moreover there was a strong 
association between the finding of at least one of four distinctive changes to the 
retina (Beare, Taylor et al. 2006) during life and the presence of cerebral 
sequestration at autopsy. Insights from this large pathogenesis study have led to the 
adoption of a new classification system for cerebral malaria:  
CM1 = sequestration of iRBC in cerebral vessels and absence of 
haemorrhagic lesions on histology. 
CM2 = sequestration of iRBC in cerebral vessels and presence of 
haemorrhagic lesions on histology 
CM3 = absence of iRBC sequestration in cerebral vessels on histology. 
                                                                                                                                     
movement (tracking a moving object) is scored as either 0 or 1. A score of 5 represents full consciousness and of 2 
or less as coma.   
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A number of different diseases contributed to the alternative cause of death in CM3 
including Reyes syndrome, Rabies, arterio-venous malformation and head injury 
(Taylor, Fu et al. 2004). The implication of these findings is that in approximately a 
quarter of patients diagnosed with cerebral malaria the signs of an alternative cause 
of encephalopathy is subtle and not picked up by routine examination or laboratory 
tests (including a lumbar puncture) and that the finding of a parasitaemia in a 
comatose child misleadingly gives rise to a diagnosis of cerebral malaria. Since up 
to 40% of children in the community in Malawi may be parasitaemic4 it seems likely 
that in many children this parasitaemia is incidental; however it should be noted that 
in some of the children the malaria infection – although not the primary cause of 
coma and death - may have influenced the development or outcome of the other 
disease process (Mallewa, unpublished observations).   
While the autopsy classification is very important for further research in which 
autopsies are done, it is the potential of retinal findings to distinguish retinopathy 
positive children with definitive cerebral malaria from retinopathy negative children 
with parasitaemia but with an alternative cause of coma (Birbeck, Beare et al. 2010; 
Beare, Lewallen et al. 2011) that has the widest implication for clinical practice and 
for further research. This classification system has been used for all the patients 
included in the studies described in this thesis. 
                                                
4 In a community study measuring parasitaemia by rapid diagnostic test in households in Chikwawa 
district (an adjacent district to Blantyre) prevalence of parasitaemia in children under 5 years old was 
43.2% (Terlouw, unpublished data).  
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Figure 1.3: Cerebral malaria retinopathy; four changes to the retina associated with cerebral 
malaria.  
Panel A shows retinal whitening in this case concentrated around the macula, Panel B shows vessel 
changes, Panel C shows white centred retinal haemorrhages and Panel D shows papilledema (in a 
retina that also has considerable retinal whitening). Images courtesy Nick Beare & Simon Glover 
 
1.5.2 Cerebral malaria: Burden and neurological sequelae in African children 
Although a recent detailed study to estimate malaria mortality has been recently 
published (Murray, Rosenfeld et al. 2012), surprisingly there are very few data on 
the estimates of the incidence of cerebral malaria. The one study that specifically 
examined incidence of cerebral malaria in sub-Saharan Africa estimated that in 
children under 5 years of age there are approximately 575,000 cases of cerebral 
malaria causing 110,000 deaths per year (Murphy and Breman 2001). The same 
study estimated 9000-19,000 children suffered long-term (>6months) neurological 
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sequelae; a rate of approximately 2%.  It seems likely that the latter is a significant 
underestimate of the true burden as other studies have estimated that 10-20% of 
children who survive cerebral malaria develop neurological sequelae (Brewster, 
Kwiatkowski et al. 1990; van Hensbroek, Palmer et al. 1997; Idro, Kakooza-
Mwesige et al. 2010). Indeed a recent large study which included the refinement of 
the diagnosis by retinal examination, careful follow up, and the use of non-comatose 
controls to identify the background rate of development of neurological complication 
in the population, found that 23% of children with cerebral malaria developed 
neurological sequelae, 9% developed epilepsy and 11% developed a ‘disruptive 
behavioural’ disorder similar to attention deficit hyperactivity disorder (Birbeck, 
Molyneux et al. 2010). Considering overlap between the different categories of 
sequelae these results indicated that approximately a quarter of children with 
retinopathy positive cerebral malaria develop neurological sequelae or epilepsy and 
that this number increases to a third if the definition is broadened to 
neurodevelopmental sequelae and thus includes the more subtle, but still very 
important, behaviour sequelae (Birbeck, Molyneux et al. 2010). Similar rates and 
also the finding of higher rates of attention deficit hyperactivity disorder in cerebral 
malaria survival were reported in an Ugandan study (John, Bangirana et al. 2008). 
1.5.3 Cerebral malaria: treatment 
Treatment of cerebral malaria consists of parenteral antimalarial drugs and 
supportive care (WHO 2000; Taylor 2009). Recently a large multicentre randomised 
placebo controlled trial of artesunate compared to quinine in severe malaria showed 
a mortality reduction in the artesunate arm from 21% to 18% in the subgroup of 
children with cerebral malaria (Dondorp, Fanello et al. 2010). Although the study 
highlighted a statistically significant benefit of artesunate it also highlights that 
despite highly effective anti-malarial therapy and considerable research into cerebral 
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malaria pathogenesis, in-hospital mortality for African children with cerebral malaria 
mortality has changed little in the past 20 years (Marsh, Forster et al. 1995; Taylor, 
Fu et al. 2004; Dondorp, Fanello et al. 2010). Although many adjunctive therapies 
have been effective in murine models of cerebral malaria none has proven effective 
in randomized controlled studies in humans (John, Kutamba et al. 2010). Among 
treatments tested in adequately powered studies most showed evidence of harm: 
dexamethasone increased coma duration and mucosal bleeding (Warrell, 
Looareesuwan et al. 1982); merozoite surface protein 1 (msp1)-specific intravenous 
immunoglobulin showed a trend towards increased mortality and sequelae (Taylor, 
Molyneux et al. 1992); anti-TNF antibody increased the rate of neurological 
sequelae (van Hensbroek, Palmer et al. 1996); prophylactic seizure prevention with 
phenobarbitone increased mortality (Crawley, Waruiru et al. 2000) and - although 
few of the patients had cerebral malaria - fluid resuscitation with saline or albumin in 
African children with fever and shock increased mortality (Maitland, Kiguli et al. 
2011). The other treatments tested in adequately powered studies showed no 
evidence of benefit or harm: chelation therapy with desferoxamine (Thuma, Mabeza 
et al. 1998); mannitol and single dose dexamethasone to reduce intracranial 
pressure (Namutangula, Ndeezi et al. 2007) and antioxidant therapy with N-
acetylcysteine (Charunwatthana, Abul Faiz et al. 2009). The immunomodulatory 
agent pentoxifylline has been tested in 4 different studies: in an open study of 56 
children with cerebral malaria it showed shorter coma times in the pentoxifylline 
treated children although no significant effect on mortality (Di Perri, Di Perri et al. 
1995) but in 3 similar sized studies in adults it showed no difference (Hemmer, Hort 
et al. 1997; Looareesuwan, Wilairatana et al. 1998; Das, Mishra et al. 2003).  
Since this thesis focuses on coagulation, even though they were neither adequately 
powered nor specific to cerebral malaria it is worth mentioning the two studies that 
looked at modulation of coagulation using heparin. Hemmer, Kern et al.,  (1991) 
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conducted a study in European adults with P. falciparum malaria in which 31 
patients were randomized to 70 units per kg/ day of heparin and 33 were 
randomized to no adjunctive treatment. The majority of the patients had 
uncomplicated malaria, with only 7 patients in the heparin arm and 6 in the control 
arm having features of severe malaria; none of the patients in either arm met criteria 
for cerebral malaria. No patients died and no patients had any reported sequelae. 
There was no statistical difference in functional coagulation tests or clinical 
parameters during recovery in either group (Hemmer, Kern et al. 1991). A second 
small study in Indonesia compared 300 units per kg of heparin in 21 children to 
placebo in 20 children. None of the children in either group died and other indicators 
of outcome were similar (Rampengan 1991).  
 
1.6 Cerebral malaria pathogenesis 
Cerebral malaria pathogenesis models have historically invoked one of two main 
principle processes: (1) ‘The sequestration hypothesis’ that proposes that pathology 
is caused by the biomechanical effects of sequestration of iRBC in microvessels, 
which obstruct vessels, divert blood supply and impede tissue oxygen delivery and 
toxin clearance (Marchiafava and Bignami 1892; MacPherson, Warrell et al. 1985; 
Berendt, Tumer et al. 1994; Silamut, Phu et al. 1999); ‘and (2) ‘The cytokine 
hypothesis’ that proposes that pathology is mediated by dysregulation of pro- 
inflammatory cytokines  (Maegraith 1948; Clark 1982; Clark and Rockett 1994; Hunt 
and Grau 2003; Schofield and Grau 2005) leading to endothelial activation and 
damage and to disruption of normal metabolic pathways. However neither of these 
processes in isolation seems to be adequate to explain pathogenesis. 
Considering sequestration, while the results of the Malawian pathogenesis study 
described above (Taylor, Fu et al. 2004) and a recent autopsy study in Vietnam 
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(Ponsford, Medana et al. 2012) show that cerebral malaria does not occur in either 
African children or South Asian adults in the absence of sequestration - indicating 
that it is necessary -  it does not appear to be sufficient. While a post-mortem study 
in South East Asian adults showed higher levels of iRBC in the brain than in other 
organs (Silamut, Phu et al. 1999), in a study in Malawi there were similar levels of 
iRBC in the gut and lung to the brain (Seydel, Milner et al. 2006). Some of these 
discrepancies may be explained by methodological differences; the Thai study 
quantified iRBC by counting the number of iRBC per vessel on histological sections 
whereas the Malawian study quantified parasites using Plasmodium falciparum 
lactose dehydrogenase (pLDH) concentration in tissue – measuring pLDH by ELISA. 
These technical differences aside, in African children there are clearly high levels of 
sequestration in tissues such as the gut and lung in which there is minimal 
pathology or organ dysfunction (Haldar, Murphy et al. 2007). Furthermore, even 
discounting the evidence from Malawi, considering sequestration as the principle 
determinant of disease does not explain why more parasites would sequester in the 
brain than in other organs. An additional factor or factors are needed to explain 
disease. 
The cytokine hypothesis proposes that pro-inflammatory cytokines produced in 
response to the infection cause derangement in metabolic pathways and that 
dysregulation in these is a critical determinant of disease (Clark and Rockett 1994). 
In murine models of cerebral malaria, raised pro-inflammatory cytokines and 
particularly TNF and lymphotoxin do appear to be necessary for disease as anti-
TNF antibody reverses mortality (Grau, Fajardo et al. 1987) and lymphotoxin 
knockout mice do not get cerebral malaria (Hunt, Golenser et al. 2006). In human 
disease immunomodulation with anti-TNF antibody not only did not decrease 
mortality but in fact increased morbidity (van Hensbroek, Palmer et al. 1996)(see 
above) and attempts to reduce the pro-inflammatory cytokines with pentoxifylline 
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have also failed to decrease fatality (Di Perri, Di Perri et al. 1995; Hemmer, Hort et 
al. 1997; Looareesuwan, Wilairatana et al. 1998) – also see above. In addition to 
differences in TNF levels – the most widely studied pro-inflammatory cytokine in this 
disease - do not reliably predict disease severity. While one study showed higher 
levels of TNF in fatal cerebral malaria than in non-fatal cerebral malaria (Grau, 
Taylor et al. 1989) and another study confirmed this and also showed higher TNF 
levels in cerebral malaria than in uncomplicated malaria (Kwiatkowski, Hill et al. 
1990) a more recent study did not find a significant difference between cerebral and 
uncomplicated malaria (Lovegrove, Tangpukdee et al. 2009). Further in a study of 
adults in Papua New Guinea; TNF levels were higher in P. vivax, in which cerebral 
malaria is very rare, than in P. falciparum (Yeo, Lampah et al. 2010). Furthermore 
no mechanism has been demonstrated that would explain why circulating cytokines 
would affect the brain preferentially over other tissues. 
While proposed as separate theories, the consideration of these as independent 
seems to be simplistic. It now seems clear that dynamic interaction occurs between 
cytokine-induced inflammation and sequestration: inflammation upregulates pro-
adhesive receptors on the endothelial surface(Ho and White 1999; Newbold, Craig 
et al. 1999; Chakravorty, Hughes et al. 2008) and the binding of parasite antigens to 
endothelial receptors induces signalling events that alter endothelial phenotype 
(Yipp, Robbins et al. 2003; Tripathi, Sullivan et al. 2006; Jenkins, Wu et al. 2007; 
Wu, Szestak et al. 2011). Yet even this combined theory does not indicate why the 
pathology occurs disproportionately in the brain. In the following section is a 
description of why lesions detected in the brain post-mortem might indicate a 
cerebral specific process and why consideration of coagulation and the coagulation-
inflammation interface might be a missing link in the pathogenic processes that have 
potential for the development of effective adjunctive therapies. 
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1.7 Clinical evidence for involvement of coagulation and cerebral 
malaria 
1.7.1 Haemorrhagic lesions in the brain and retina indicate a cerebral 
focused coagulopathic process in cerebral malaria 
Examination of the brain post-mortem in cerebral malaria reveals striking 
haemorrhagic, petechiae-like lesions (Figure 1.4) in approximately 75% of cases of 
retinopathy positive cerebral malaria (Taylor, Fu et al. 2004). Petechiae like lesions 
in the brain in fatal cerebral malaria were first described nearly a century ago by 
Dudgeon and Clarke (Dudgeon 1917). These lesions are also seen in adults who 
have died from cerebral malaria but are less common (MacPherson, Warrell et al. 
1985; SenGupta and Naraqi 1992). In children there are also thrombi in 
microvessels of other organs that show sequestration; namely the gut, lung and 
kidney although these are far less numerous than in the brain (Whitten RO, personal 
communication). In the brain, haemorrhages are associated with vessels with high 
iRBC sequestration (Dorovini-Zis, Schmidt et al. 2011). Surprisingly, no study has 
specifically investigated the composition of lesions although they have been 
proposed to be thrombi on the basis of their histological appearance by 
haematoxylin and eosin staining (Taylor, Fu et al. 2004; Dorovini-Zis, Schmidt et al. 
2011). 
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Figure 1.4: Appearance of the brain post-mortem in Malawian child with fatal cerebral malaria.  
Pictures show the fresh brain after removal at autopsy from a child who has died from retinopathy 
positive cerebral malaria. The brain has been cut in half in coronal section (Photographs courtesy of 
Terrie Taylor).  
 
Lesions seen at autopsy could be caused by peri-morbid events and might not be 
representative of pathology in vivo. However similar lesions are also seen on the 
retina and retinal haemorrhages correlate strongly with haemorrhages in the brain at 
autopsy (White, Lewallen et al. 2001). Retinal haemorrhages are also seen in the 
majority of surviving patients with retinopathy positive cerebral malaria (Lewallen, 
Harding et al. 1999; White, Lewallen et al. 2001; Beare, Taylor et al. 2006), implying 
that these lesions are a component of pathology in the acute phase of the disease. 
Retinal haemorrhages have a central white area, which have been proposed to 
represent thrombi (White, Lewallen et al. 2001). In addition progression of retinal 
haemorrhages has been found to be the strongest clinical indicator of worsening 
prognosis (Beare, Southern et al. 2004). These data show that in African children 
with cerebral, although gross coagulopathy is not common, microvascular 
coagulopathy occurs frequently and is associated with poor prognosis.  
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Figure 1.5: Retinal haemorrhages in Malawian children with cerebral malaria. 
Image on left shows large haemorrhage (centre left of image). Image on right shows extensive retinal 
haemorrhages many of which have white centres (Photographs courtesy of Simon Glover) 
 
1.7.2 Clinically overt bleeding and thrombosis in cerebral malaria are rare  
While gross haemorrhagic or thrombotic events are uncommon in cerebral malaria 
their occurrence highlights a clear interaction between P. falciparum infection and 
coagulation. Overt bleeding is rare and occurred in only 2 of 1844 Kenyan children 
with a primary diagnosis of malaria, 185 of whom were comatose (Marsh, Forster et 
al. 1995), but in South East Asian adults occurs in approximately 5% of cerebral 
malaria cases of cerebral malaria, most commonly from the gastrointestinal tract 
(Warrell, White et al. 1982). Bleeding events have been described from other sites 
in association with cerebral malaria, including rare severe bleeding episodes such 
as pulmonary haemorrhage (Corne, Landreau et al. 2001) and intracranial bleeding 
(Murugavel, Saravanapavananthan et al. 1989; Mathur, Hakim et al. 1992; Saraswat 
1994; Gall, Spuler et al. 1999). Gross thrombotic events have also been described 
at post-mortem in case reports; intracranially in the Dural sinus (Krishnan, Karnad et 
al. 2004), in the lungs as thromboembolism (Biswas, Fogla et al. 1996) and in the 
legs leading to gangrene and requiring limb amputation (Liechti, Zumsteg et al. 
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2003). Purpura fulminans, a condition associated with extensive bruising on the skin 
associated with a combination of intravascular coagulation and haemorrhage has 
also been described (Keri, Thomas et al. 2000; Kato, Ohnishi et al. 2007). 
 
1.8 Cross-talk between coagulation and inflammation and 
endothelial homeostasis: activation of coagulation can be 
important without overt coagulopathy 
 
Normal haemostasis is a complex balance between pro- and anti-thrombotic 
pathways that take place on endothelial or platelet cell surfaces. This process 
involves the recruitment and tethering of several other cellular components including 
neutrophils and monocytes.  Over the past 20 years, coagulation factors have 
emerged as important mediators of inflammation that demonstrate cross-talk with 
inflammatory cytokines (Esmon, Taylor et al. 1991; Esmon 2004; Niessen, 
Schaffner et al. 2008; Griffin, Zlokovic et al. 2012): (1) thrombin has pleotropic 
inflammatory effects reviewed in (Coughlin 2000) including induction of platelet and 
endothelial microparticle production and induction of cytokine production from 
endothelium and leukocytes through PAR1 activation (see Figure 7.1 in the 
discussion chapter); (2) the protein C pathway has pleotropic anti-inflammatory 
properties (reviewed in (Mosnier, Zlokovic et al. 2007) and discussed below in 
1.10.3); (3) pro-inflammatory cytokines can increase thrombin production by 
inducing tissue factor expression on the endothelium (Liu, Pelekanakis et al. 2004) 
and can decrease the function of the protein C pathway by causing downregulation 
of thrombomodulin and EPCR (Nachman, Hajjar et al. 1986; Fukudome and Esmon 
1994). These effects are involved in the pathogenesis of a number of acute and 
chronic inflammatory conditions as diverse as atherosclerosis (Owens, Passam et al. 
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2012) and asthma (Yuda, Adachi et al. 2004). The signalling events initiated by 
thrombin, a central coagulation molecule, are the best characterised. Thrombin is 
capable of activating protease activating receptor 1 (PAR1), a G-protein coupled 
receptor that, through modification of nuclear transcription factors, can stimulate a 
multitude of events involved in the regulation of endothelial homeostasis and of 
inflammatory events, including recruitment and activation of platelets and leukocytes 
and liberation of several pro-inflammatory cytokines (Coughlin 2000) and that also 
regulates endothelial permeability (Niessen, Furlan-Freguia et al. 2009).  
Considering the inflammatory component, it has become apparent that such 
inflammatory events may be initiated by coagulation molecules without overt clinical 
signs of a coagulopathy, such as bleeding or thrombi. A state in which coagulation is 
activated but balanced by regulatory pathways, termed compensated disseminated 
intravascular coagulation (DIC) (Taylor, Toh et al. 2001), has been shown in large 
prospective clinical studies to be predictive of poor outcome in bacterial sepsis in 
advance of clinical signs (Toh and Downey 2005). Further evidence of the 
importance of such a compensated state comes from therapeutic trials with 
anticoagulants. Treatment with infusions of the anticoagulants Antithrombin III (AT 
III) and activated protein C can attenuate mortality in animal models of bacterial 
sepsis (Kessler, Tang et al. 1997; Suzuki and Hayashi 2007) and activated protein 
C improved outcome in a placebo controlled trial in humans (Bernard, Vincent et al. 
2001). Furthermore, activated protein C and AT III have anti-inflammatory effects 
and a protective effect on the endothelium in vitro (Joyce, Gelbert et al. 2001). While 
therapeutic trials of these factors in humans have not had the dramatic effect that 
was anticipated from animal trials and indeed follow up trials of activated protein C 
have failed to replicate the efficacy of the initial trail (Bernard, Vincent et al. 2001; 
Ranieri, Thompson et al. 2012; Thachil, Toh et al. 2012), this field nonetheless 
remains a highly active area of investigation for treatment. Blocking PAR1 directly 
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attenuated mortality even after development of the sepsis syndrome in a mouse 
model of gram negative sepsis (Niessen, Schaffner et al. 2008) and modified 
activated protein C factors that influence inflammation without increasing risk of 
bleeding may also allow more complete anti-inflammatory effects with lower risk of 
dangerous side effects (Mosnier, Yang et al. 2007).  
There are both similarities and differences between the pathogenesis of P. 
falciparum infection and bacterial sepsis (see Figure 7.1 of the discussion chapter). 
Widespread endothelial dysfunction resulting in shock in malaria, like that seen in 
fulminant bacterial sepsis, is rare. However P. falciparum infection does result in 
activation of inducible endothelial receptors including ICAM-1, VCAM-1 and E-
selectin (Turner, Ly et al. 1998), in focal endothelial damage (Dorovini-Zis, Schmidt 
et al. 2011) and in the release of pro-inflammatory cytokines TNF, IL-1 and IL-6 
(Mshana, Boulandi et al. 1991) and therefore some similarities in the dysregulation 
of coagulation between the two conditions seem likely and merits use of the much 
larger availability of research on coagulation in sepsis as an indicator of 
mechanisms that might be implicated in malaria. 
 
1.9 Consideration of possible mechanisms for activation of 
coagulation 
 
Before outlining current evidence of the involvement of coagulation factors in the 
pathogenesis of cerebral malaria we consider mechanisms by which malaria 
infection might activate coagulation and the evidence for the involvement of these 
different mechanisms. 
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In contrast to bacterial sepsis malaria lacks a potent toxin, like lipopolysaccharide or 
lipoteichoic acid. Although the P. falciparum derived molecules 
glycosylphosphotidylinositol (Schofield and Hackett 1993) and hemozoin (Coban, 
Ishii et al. 2005) have been shown to have Toll-like receptor activity in vitro, it 
remains unclear how important these effects are in vivo (Parroche, Lauw et al. 2007; 
Togbe, Schofield et al. 2007) and the ability of individuals with partial immunity to 
tolerate very high parasitaemias with minimal ill effects would seem to indicate 
against a toxin having the critical effect on pathogenesis that bacterial toxins do!
(White 2003).  
P. falciparum malaria is an intravascular disease; whereas bacteria and many viral 
infections traverse the endothelium into the parenchyma of the organs where they 
cause disease. P. falciparum rarely exits the vessel lumen. Endothelial pathology 
occurs at sites of iRBC sequestration in the capillaries and post capillary venules 
(Dorovini-Zis, Schmidt et al. 2011) and the pathology of malaria in these tissues is 
therefore determined by disruption of the normal intravascular environment. This 
may lead to activation of the coagulation system in 5 different ways: 1) endothelial 
activation; 2) pro-inflammatory cytokines; 3) circulating microparticles and activated 
platelets; 4) endothelial damage; 5) contact or binding between parasite derived 
proteins on the iRBC surface and coagulation based receptors on the endothelium 
or on circulating blood cells!(Moxon, Heyderman et al. 2009).  
1.9.1 Endothelial Activation 
Endothelial activation in P. falciparum infection results in upregulation of adhesion 
molecules on the endothelial surface that are implicated in iRBC adherence and 
pathogenesis: von Willebrand Factor (vWF), VCAM-1, ICAM-1, P-selectin and E-
selectin (Turner, Morrison et al. 1994; Viebig, Wulbrand et al. 2005). This may occur 
indirectly via an intermediate factor that is affected by iRBC, for which inflammatory 
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cytokines are the main candidate, or directly by interaction between parasite-derived 
molecules and endothelial receptors. A recent study performed in human volunteers 
demonstrated that vWF and vWF propeptide release from the Weibel-Palade bodies 
were significantly increased early in P. falciparum blood-stage infection, implying 
acute endothelial activation (de Mast, Groot et al. 2007). vWF is a large multimeric 
glycoprotein involved both in platelet adhesion and aggregation, and is produced 
predominately by activated endothelial cells. When released, vWF is in an activated 
conformation, which allows interaction with the platelet receptor gpIa/V/IV and 
triggers intravascular platelet aggregation (Groot, de Groot et al. 2007). This 
function primarily occurs under high shear stress conditions on the arteriolar side of 
the microcirculation (Ruggeri 2003). Interestingly, the activity of the vWF-cleaving 
protease ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin 
type 1 motif, member 13) has been shown to be reduced in other conditions 
associated with a pro-coagulant state including severe sepsis and thrombotic 
thrombocytopenic purpura (Groot, de Groot et al. 2007) as well as in malaria (Larkin, 
de Laat et al. 2009). In malaria vWF is also able to increase cytoadherence as large 
multimers of vWF and adherent platelets provide multiple binding sites for iRBC 
(Bridges, Bunn et al. 2010). Higher vWF levels are associated with retinopathy 
positive cerebral malaria compared to uncomplicated malaria but are also 
significantly raised in retinopathy negative cerebral malaria(Phiri, Bridges et al. 
2011).  
In vitro, endothelial nitric oxide (NO) decreases tissue factor expression (Yang and 
Loscalzo 2000) and is the major inhibitor of the exocytosis of Weibel-Palade bodies. 
It has recently been shown that endothelial NO is reduced in severe malaria in 
adults and is associated with increased concentrations of angiopoietin-2 (Ang-2), an 
angiogenic factor also stored in Weibel-Palade bodies (Yeo, Lampah et al. 2008). 
As vWF is co-packaged with angiopoietin-2 in Weibel-Palade bodies, these results 
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might explain the increase of vWF release in adult cerebral malaria, leading to 
endothelial activation. Ang-2 levels are also raised in paediatric cerebral malaria and 
are a sensitive and specific predictor of cerebral malaria compared with 
uncomplicated malaria (Lovegrove, Tangpukdee et al. 2009). It has been proposed 
that decreased NO availability might simultaneously explain: 1) an increased 
expression of tissue factor by microvascular endothelial cells, leading to an 
activation of the coagulation cascade; and 2) a substantial augmentation in 
exocytosis of Weibel-Palade bodies with a subsequent increase of vWF release. 
Indeed a trial of inhaled NO as an adjunctive therapy in cerebral malaria in children 
in Uganda is underway (International clinical trial registry number: NCT01388842). 
However while decreased NO availability might compound tissue factor expression 
on endothelial cells, endothelial tissue factor expression was also induced by iRBC 
contact (Francischetti, Seydel et al. 2007). In addition, a preferential effect of Weibel 
Palade body associated factors on the brain would be anticipated to be most 
biologically plausible if Weibel Palade bodies were more numerous or more 
inducible in the brain but conversely there are very few Weibel Palade bodies in the 
endothelial cells of cerebral vessels (Dan Milner, personal communication).  
1.9.2 Pro-inflammatory cytokines 
The role of the cytokine TNF (formerly TNF-α) has been widely investigated in 
cerebral malaria both in mouse models and human disease (Grau, Fajardo et al. 
1987; Grau, Taylor et al. 1989; Kwiatkowski, Hill et al. 1990; Hunt and Grau 2003). 
In addition to its well-known pro-inflammatory effects, TNF can also activate 
coagulation. It is a potent stimulator of tissue factor, the major initiator of the 
coagulation cascade (Liu, Pelekanakis et al. 2004), which occurs through activation 
of NFκB (Bierhaus, Zhang et al. 1995) and this effect is upregulated synergistically 
in the presence of thrombin via MAP kinase signalling (Liu, Pelekanakis et al. 2004).  
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TNF can also impair protein C activation by downregulating transcription of the 
protein C pathway receptors (pathway discussed below) thrombomodulin (Lentz, 
Tsiang et al. 1991) and endothelial protein C receptor [EPCR (Fukudome and 
Esmon 1994)]. Similarly the pro-inflammatory cytokine interleukin-1 beta is also 
increased in malaria (Mshana, Boulandi et al. 1991) and induces downregulation of 
thrombomodulin in endothelial cells (Nachman, Hajjar et al. 1986; Archipoff, Beretz 
et al. 1991). 
1.9.3 Microparticles 
Microparticles found in the blood are vesiculations of the plasma membrane of 
eukaryotic cells, shed during physiological or pathogenic processes such as 
activation or apoptosis; they have been a topic of increasing interest in a number of 
disease states. Although many aspects of microparticle function are still unclear, a 
picture develops in which microparticles play an important role in inflammation, 
coagulation, and vascular homoeostasis (Combes, Simon et al. 1999). They have 
recently been shown to activate coagulation in vitro and to participate in thrombus 
formation in a model of vessel injury via their surface expression of tissue factor and 
phosphatidylserine (Hrachovinova, Cambien et al. 2003). TNF is a potent agonist of 
endothelial vesiculation, leading to a dramatic increase in the production of 
endothelial microparticles. These microparticles display a pathogenic phenotype by 
expressing both cell adhesion and catalytic surface phospholipids able to trigger the 
extrinsic pathway independently of tissue factor (Combes, Simon et al. 1999; 
Wassmer, Cianciolo et al. 2005; Wassmer, de Souza et al. 2006). A study in 
Malawian children demonstrated significantly higher levels of circulating endothelial 
microparticles during the acute phase of cerebral malaria compared to levels 
observed in parasitaemic controls. Levels of endothelial microparticles correlate 
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positively with plasma levels of TNF and return to normal following recovery 
(Combes, Taylor et al. 2004).  
Analyses in a mouse model of cerebral malaria (Hunt and Grau 2003) provided 
evidence for both pro-inflammatory and procoagulant effects of microparticles 
produced acutely in the plasma of cerebral malaria susceptible mice. Indeed, 
microparticle-stimulated peritoneal macrophages were able to produce extremely 
high levels of TNF, reaching the production observed when stimulated by bacterial 
lipopolysaccharide, one of the most potent TNF inducers. In addition, microparticles 
were able to reduce significantly the clotting time of uninfected mouse plasma 
(Combes, Coltel et al. 2005). Further investigations of the direct role of 
microparticles in human cerebral malaria are needed.  
1.9.4 Platelet adhesion to endothelium 
Thrombocytopenia is an almost invariable feature of acute P. falciparum infection 
and appears to involve immune mechanisms, removal by the reticulo-endothelial 
system and platelet activation with consumption in different steps of coagulation 
(Kelton, Keystone et al. 1983). The accumulation of platelets in cerebral 
microvessels in human cerebral malaria was first described by electron microscopy 
(Pongponratn, Riganti et al. 1985), and more recently a post-mortem study 
performed in Malawian children revealed that the accumulation of platelets in the 
brain was specific to children with a diagnosis of cerebral malaria, as opposed to 
children who were parasitaemic but who had another cause of death  (Grau, 
Mackenzie et al. 2003). 
Several studies performed with an in vitro model of the cerebral pathology showed 
that platelets can either adhere directly to the surface of TNF-stimulated 
endothelium via specific molecules such as platelet CD41 and endothelial CD40 
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(Wassmer, Lepolard et al. 2004), or adhere to vWF multimers at the surface of 
activated endothelium (Bridges, Bunn et al. 2010). Having adhered to the 
endothelial surface, platelets are able to form bridges between iRBC and cerebral 
endothelium by providing new parasite receptors to brain endothelial cells initially 
devoid of them (Wassmer, Lepolard et al. 2004). This phenomenon has been 
demonstrated in vitro and platelets lining the brain microvasculature between 
endothelial cells and iRBC have been described in a histopathological study of the 
brain of Malawian children who succumbed to cerebral malaria (Grau, Mackenzie et 
al. 2003). Interestingly, iRBC can activate platelets in vitro by contact (Windsor, 
Imray et al. 2008) leading to the transfer of tissue factor stored in their alpha-
granules to the platelet surface. Activated platelet surface tissue factor may also 
derive from binding of tissue factor-positive microparticles but also splicing of tissue 
factor pre-mRNA and translation of the mature mRNA into protein. Indeed, human 
platelets express tissue factor pre-mRNA and, in response to activation, splice this 
intronic-rich message into mature mRNA. Splicing of tissue factor pre-mRNA is 
associated with increased tissue factor protein expression (Laszik, Zhou et al. 2001). 
Once at the cell surface, tissue factor may require activation to reveal its 
procoagulant activity. Provided that this phenomenon occurs in vivo, it might lead to 
a dramatic platelet activation loop by initiating coagulation and promoting endothelial 
apoptosis, with both phenomena leading to an increase in platelet activation.  As 
with the other components considered, a mechanism by which pathology caused by 
platelets or microparticles might disproportionately affect the brain has not been 
described.  
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1.9.5 Endothelial damage and apoptosis 
The endothelium acts as a protective envelope of cells devoid of tissue factor, 
separating the blood from the highly negatively charged and tissue factor-
expressing connective tissue. Under normal physiological conditions this allows the 
blood to circulate without activation of coagulation factors. When endothelial 
damage occurs, these circulating blood factors are exposed to both tissue factor 
and a negative charged surface, leading to the activation of the intrinsic (contact) 
pathway of the coagulation cascade. While this mechanism is protective in case of 
haemorrhage due to vascular trauma, it also contributes to the pathogenesis of 
conditions in which endothelial cells are altered through inflammation, apoptosis or 
hypoxia. This leads to coagulopathies and organ dysfunctions observed in sepsis 
(Reinhart, Bayer et al. 2002) and dengue haemorrhagic fever (Chen, Yang et al. 
2007).  
In mouse models of severe malaria several lines of evidence suggest that there is 
damage to the endothelium causing an increase in permeability of vessels, 
particularly in the brain (Hunt and Grau 2003). Surrogate markers for endothelial 
apoptosis are raised (Potter, Chan-Ling et al. 2006; Lackner, Burger et al. 2007) and 
endothelial damage on retinal whole mounts of mice with experimentally induced 
cerebral malaria has been described (Potter, Chan-Ling et al. 2006). 
Such severe endothelial damage is rare in humans with P. falciparum infection but 
there is evidence to support a more subtle involvement of microvascular endothelial 
damage in the development of cerebral malaria. Post-mortem histological 
examination of cerebral microvessels in Thai adults by electron microscopy showed 
patchy areas of damaged endothelial cells amidst microvascular walls (MacPherson, 
Warrell et al. 1985) and a post-mortem study in Malawian children showed localized 
changes to endothelial cell morphology particularly in association with thrombosis 
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(Dorovini-Zis, Schmidt et al. 2011). In vivo, assessment of retinal perfusion in 
patients with cerebral malaria using angiography occasionally revealed multiple tiny 
areas of leakage, demonstrating focal areas of breakdown of the blood retinal 
barrier (Beare, Harding et al. 2009) which is structurally analogous to the blood 
brain barrier (Kim, Park et al. 2006). However, extracellular oedema to imply gross 
blood retinal barrier breakdown is rare. Evidence that subtle endothelial damage 
occurs in a wider group of patients is also implied because levels of the endothelial 
bound receptor thrombomodulin is raised in peripheral blood, presumably because it 
is shed from the endothelial surface and levels are higher in patients with more 
severe disease (Hemmer, Bierhaus et al. 1994).  
A cause of endothelial damage that might be important in cerebral malaria is 
apoptosis, which is also a cause of activation of coagulation (Choy, Granville et al. 
2001). The importance of apoptosis in vivo is controversial but in vitro iRBC 
adhesion on TNF-stimulated endothelial cells is strongly pro-apoptotic (Pino, 
Vouldoukis et al. 2003; Wassmer, Combes et al. 2006), an effect exacerbated by a 
prior co-culture with platelets (Wassmer, Combes et al. 2006). This effect is 
mediated by the cytokine TGF-β released from alpha granules of activated platelets 
(Wassmer, de Souza et al. 2006). Such a pathogenic mechanism might promote 
endothelial apoptosis at sites of platelet- iRBC sequestration particularly in the 
presence of high levels of circulating TNF or thrombin.  
In contrast to the other mechanisms discussed to be involved in activation of 
coagulation and in cerebral malaria pathogenesis , the high degree of vascular bed 
specificity of endothelial cells might explain differential effects of disease in different 
organs (Aird 2012), including specifically increased vulnerability to pathology in the 
brain. A possible specific explanation, discussed below (see 1.10.3), is that the anti-
coagulant molecules involved in the protein C pathway, EPCR and thrombomodulin 
are expressed at substantially lower levels in the brain than in other organs (Wong, 
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Hofman et al. 1991; Laszik, Mitro et al. 1997). Furthermore there is heterogeneity in 
endothelial expression between individuals (Aird 2007; Aird 2012) and we have 
demonstrated that endothelium isolated from subcutaneous tissue from Malawian 
children with cerebral malaria has increased response to stimulation with the 
cytokine TNF than endothelium from children with uncomplicated malaria even after 
several passages in culture (Wassmer, Moxon et al. 2011). Yet since the cerebral 
microvascular haemorrhagic lesions and other pathologic hallmarks of disease do 
not occur in the absence of infection, a ‘triggering event’ is required. While cytokines 
produced in the immune response to infection are one possible trigger, another is 
direct interaction between parasite-derived proteins on the iRBC and the 
endothelium. 
 
1.9.6 Receptor-ligand interactions between infected red blood cells and the 
host endothelium 
Infection with P. falciparum leads to the expression of multiple parasite-derived 
proteins on the surface of the iRBC. Several families of these proteins have been 
described; they are highly variable, with coding regions generally located in sub-
telomeric zones. Parasite-derived proteins enable cytoadherence of iRBC and 
sequestration. However, it has become apparent that these interactions may also 
have other important effects downstream. Binding of parasite-derived proteins on 
iRBC to dendritic cell receptors prevents dendritic cell maturation (Urban, Ferguson 
et al. 1999). In addition, signalling events induced by iRBC adhesion can modify the 
surface expression of endothelial receptors (Yipp, Robbins et al. 2003; Jenkins, Wu 
et al. 2007; Tripathi, Sullivan et al. 2007; Wu, Szestak et al. 2011). The importance 
of low affinity interactions between parasite derived proteins and endothelial 
receptors, including those that regulate coagulation, has received surprisingly little 
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attention and yet the potential of these interactions seems large; both as iRBC roll 
along the endothelium prior to binding and during binding when the iRBC and its 
surface proteins are brought into direct apposition with the endothelium. Given the 
expression of several coagulation receptors at the endothelial surface, receptor-
ligand interactions with iRBC may either interfere with the normal physiological 
interactions or induce signalling events that alter the regulation of coagulation. 
Although a specific ligand- receptor interaction has not been demonstrated, a 
signalling mechanism is implicated in the activation of tissue factor by iRBC 
(Francischetti, Seydel et al. 2007); detailed in (1.10.1). The thrombomodulin 
receptor involved in the activation of protein C and heparin sulphate, involved in the 
activation of AT III are other potential candidates since a portion of these molecules 
are binding sites for iRBC. The effects of these interactions on coagulation have not 
yet been explored. 
 
1.10 Effect of P. falciparum on Coagulation Pathways 
 
Although coagulation is a complex interlinked system, for clarity we consider current 
evidence of involvement of coagulation in cerebral malaria in three principle 
components of the coagulation cascade for which there is the greatest evidence for 
involvement in pathogenesis (Table 1-2): (1) Tissue factor; (2) Antithrombin and (3) 
the protein C pathway. The protein C pathway will be covered last and in greater 
detail, as it is a major focus of this thesis.  
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Table 1-2: Coagulation molecules and published evidence of role in malaria pathogenesis 
Molecule 
 
Function 
 
SF 
or 
TMR 
Site of expression. 
 
Effect in P. falciparum malaria 
 
TF 
 
 
Main activator of 
coagulation cascade. 
 
TMR 
 
Expressed in all vessels on underlying 
cells of basal lamina and the 
basement membrane. Expressed on 
activated endothelial cells, monocytes, 
platelets and microparticles. 
 
SM: NI 
CM: TF expression on endothelium in 
cerebral vessels in CM and associated with 
thrombi (Francischetti, Seydel et al. 2007). 
Mechanism:  iRBC cause upregulation of 
TF on endothelium in vitro in contact 
dependant manner (Bierhaus, Zhang et al. 
1995; Francischetti, Seydel et al. 2007) 
 
Thrombin 
 
 
Converts fibrinogen to 
fibrin. Inflammatory 
mediator via PAR1 
signalling. 
 
SF 
 
Produced from prothrombin on 
activation of coagulation. Very rapidly 
inactivated and therefore difficult to 
measure directly. 
 
 
Severe malaria: Raised TAT complexes 
(Hemmer, Kern et al. 1991; Clemens, 
Pramoolsinsap et al. 1994; Vogetseder, 
Ospelt et al. 2004) and Fibrinopeptide A 
(Jimmy, Saliu et al. 2003) indicate increased 
thrombin generation. Correlate with severity 
of infection (Hemmer, Kern et al. 1991; 
Vogetseder, Ospelt et al. 2004). 
CM: NI 
 
Protein C 
 
Inhibits production of 
thrombin and anti- 
inflammatory when 
activated. 
 
SF 
 
Circulates in inactive form until 
activated by thrombomodulin and 
EPCR- initiated by the binding of 
thrombin to thrombomodulin.  
 
SM : Decreased antigen & activity 
(Hemmer, Kern et al. 1991; Mohanty, Ghosh 
et al. 1997; Vogetseder, Ospelt et al. 2004). 
CM: NI 
 
 
Thrombo-
modulin 
 
Inhibits thrombin by 
binding; involved in 
activation of protein C 
 
TMR 
 
Expressed on all vascular endothelium 
although at a lower lever in the brain. 
Cleaved from the membrane to 
become a soluble factor when there is 
endothelial damage. 
 
 
SM: Circulating thrombomodulin increased 
(Hemmer, Bierhaus et al. 1994); effect on 
endothelial thrombomodulin expression not 
reported. 
CM: NI 
 
 
EPCR 
 
Involved in activating 
protein C and is a 
receptor for activated 
protein C 
 
TMR 
 
Expressed on all vascular 
endothelium; lower level in 
microvessels. 
 
NI 
 
AT III 
 
Inhibits thrombin both 
directly and upstream.  
 
SF 
  
Activated by heparin sulphate. 
 
SM: Antigen and activity levels decreased 
(Mohanty, Ghosh et al. 1997; Vogetseder, 
Ospelt et al. 2004).  
 
CM: NI 
 
 
Fibrin 
 
Fibrin strands form a 
 
N/A 
 
Produced from fibrinogen in presence 
 
Severe malaria:  Evidence for increased 
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mesh that associates 
with platelets to form a 
clot. Also pro-
inflammatory. 
of thrombin. Once produced forms 
clumps and can only by measured by 
surrogate markers of its breakdown. 
fibrin generation in some studies (Dennis 
and Conrad 1968; Jaroonvesama, 
Harinasuta et al. 1975) but ambiguous. 
 
CM: Deposits of fibrin or thrombi in vessels 
in diseased organs (MacPherson, Warrell et 
al. 1985; White, Lewallen et al. 2001; 
Taylor, Fu et al. 2004). 
SF= Soluble factor; TMR= Trans-membrane receptor; NI= not investigated; CM= cerebral malaria. 
Adapted from (Moxon, Heyderman et al. 2009)  
1.10.1 Tissue Factor 
Tissue factor is a transmembrane receptor expressed constitutively in most vessels 
in the cells under the endothelium. When it binds to factor VII, tissue factor acts as 
the principal activator of coagulation. Tissue factor can be presented to factor VII as 
a result of endothelial damage, but also by circulating macrophages, platelets or 
microparticles or when it is upregulated at the endothelial surface. Many stimuli can 
induce such endothelial tissue factor expression, including TNF (Steffel, Hermann et 
al. 2005), interferon gamma (Napoleone, Di Santo et al. 1997) and thrombin (Galdal, 
Lyberg et al. 1985). Upregulation of tissue factor by lipopolysaccharide in bacterial 
sepsis leads to a reinforcing interplay between inflammation and coagulation 
(Pawlinski, Pedersen et al. 2004). In influenza and cytomegalovirus infections there 
is an upregulation of surface tissue factor on monocytes, associated with both acute 
symptoms and an increased risk of atherosclerosis (Bouwman, Visseren et al. 2002).  
 
In vitro, iRBC can induce expression of surface tissue factor on purified monocytes 
(Pernod, Polack et al. 1992) and on cultured endothelial cells (Bierhaus, Zhang et al. 
1995; Francischetti, Seydel et al. 2007). Although TNF is a candidate mediator, in 
vitro experiments suggest that iRBC induction of tissue factor on endothelial cells is 
mediated by contact (Francischetti, Seydel et al. 2007). Interestingly, the 
upregulation of tissue factor on endothelial cells is only induced by iRBC in their late 
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life cycle, implying the involvement of an antigen that is only expressed in mature 
stages. 
In vivo, the upregulation of tissue factor has been associated with placental malaria 
and cerebral malaria pathologies. In placental malaria, fibrin deposits impinging on 
the intervillous spaces are associated with the expression of tissue factor on 
macrophages (Imamura, Sugiyama et al. 2002). In cerebral malaria, paediatric brain 
autopsy sections show tissue factor expression on the endothelium of pre- and post-
capillary vessels (Francischetti, Seydel et al. 2007), a feature associated with 
thrombi and ring haemorrhages.  
A drug developed to block tissue factor activity which is a conjugate of the natural 
inhibitor of the tissue factor pathway - tissue factor pathway inhibitor - reduced 
mortality in a primate model of sepsis (Creasey, Chang et al. 1993), but did not 
improve outcome in a large intervention trial of sepsis in humans (Herak, Antolic et 
al. 2009). It has not been investigated whether this drug has any effect on outcome 
in severe malaria.  
1.10.2 Antithrombin III  
AT III is a major endogenous anti-coagulant and anti-inflammatory agent (Roemisch, 
Gray et al. 2002). It is a circulating glycoprotein that can inhibit thrombin directly and 
via a number of upstream factors. AT III has poor anticoagulant activity until 
activated, principally by heparin sulphate. 
AT III plays an important role in the aetiology of sepsis with levels being negatively 
associated with severity and outcome (Baudo, Caimi et al. 1998). Infusion of AT III 
prevents mortality in an animal model of sepsis (Kessler, Tang et al. 1997) and has 
shown some success in placebo-controlled trials in humans with DIC and sepsis 
(Baudo, Caimi et al. 1998). 
Chapter 1: Introduction 
 55 
Levels of AT III antigen (Clemens, Pramoolsinsap et al. 1994; Mohanty, Ghosh et al. 
1997) and activity (Vogetseder, Ospelt et al. 2004) are decreased in severe P. 
falciparum infection. Levels correlate with severity and there is rapid recovery 
following antiparasitic treatment (Vogetseder, Ospelt et al. 2004). Low ATIII antigen 
levels are likely to be due to increased consumption from thrombin binding in 
thrombin-antithrombin (TAT) complexes as TAT complexes are significantly 
increased in severe malaria (Hemmer, Kern et al. 1991; Clemens, Pramoolsinsap et 
al. 1994); suggesting AT III is ‘mopping up’ excess thrombin. Decreased activity 
may reflect a decreased availability of ATIII antigen or may reflect compromised 
activation by heparin sulphate and indeed it has recently been shown that in vitro P. 
falciparum histidine rich protein II (HRPII) inhibits ATIII activation by heparin 
(Ndonwi, Burlingame et al. 2011).  
Since heparin can also disrupt rosette formation (Rogerson, Reeder et al. 1994) and 
inhibits parasite invasion and growth (Butcher, Parish et al. 1988; Kulane, Ekre et al. 
1992), heparin like drugs are potential therapies and in a simian model of malaria, 
treatment with heparin resulted in a decrease in mortality (Dennis and Conrad 1968). 
As discussed above the only studies to look at heparin treatment in humans 
(Hemmer, Kern et al. 1991; Rampengan 1991) were not powered to detect an 
improvement in outcome. A concern with heparin treatment is the danger of 
inducing bleeding and World Health Organization guidelines do not recommend the 
use of heparin in malaria because of this concern (2000). However heparinoids such 
as curdlan sulphate that disrupt iRBC binding but that have a lower risk of causing 
bleeding may represent an alternative. In two small studies, although not powered to 
show effect on mortality, curdlan sulphate decreased time until clearance of fever 
with no noted side effects and the beneficial effect was most noted in individuals 
with cerebral malaria (Havlik, Looareesuwan et al. 2005).   
 
Chapter 1: Introduction 
 56 
1.10.3 The Protein C Pathway  
The protein C pathway is essential for regulation of coagulation in healthy 
individuals, functioning at a critical intersection between coagulation, inflammation 
and protective endothelial processes (Esmon 2000; Mosnier, Zlokovic et al. 2007). 
Dysfunction of this pathway has been implicated in the coagulopathy of bacterial 
sepsis (Faust, Levin et al. 2001), dengue haemorrhagic fever (Cabello-Gutierrez, 
Manjarrez-Zavala et al. 2009) , asthma (Yuda, Adachi et al. 2004), rheumatoid 
arthritis (Xue, March et al. 2007; Xue, March et al. 2007), diabetic nephropathy 
(Isermann, Vinnikov et al. 2007) and inflammatory bowel disease (Scaldaferri, Sans 
et al. 2007).  
Protein C is activated through the receptors thrombomodulin and EPCR when 
thrombin binds thrombomodulin ((Esmon 2000)). Activated protein C (aPC) is 
anticoagulant both by inhibiting further thrombin production – through complex 
formation with factors Va and VIIIa and by increasing fibrinolysis by binding to 
plasminogen activator-1 (Esmon 2003). Through its receptor EPCR, aPC also 
mediates pleotropic anti-inflammatory (Esmon, Taylor et al. 1991) and 
cytoprotective (Mosnier, Zlokovic et al. 2007; Danese, Vetrano et al. 2010) effects, 
principally by modifying the response of the protease activated receptor-1 (PAR1). 
Specifically aPC is anti-inflammatory by downregulating monocyte cytokine 
production (Grey, Tsuchida et al. 1994) and by modifying endothelial cell gene 
expression profiles, reviewed in (Mosnier, Zlokovic et al. 2007), such as suppression 
of Nuclear transcription factor κB (NFκB) related upregulation of adhesion 
molecules and cytoprotective by blocking p53-mediated apoptosis ; inhibiting 
endothelial damage by binding to and preventing damage by intracellular histones 
(Xu, Zhang et al. 2009) and by maintaining endothelial barrier function (Feistritzer, 
Lenta et al. 2005; Niessen, Furlan-Freguia et al. 2009).  
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The two protein C receptors, thrombomodulin and EPCR, are constitutively 
expressed at lower levels in the brain than in the systemic circulation (Wong, 
Hofman et al. 1991; Laszik, Mitro et al. 1997) potentially making the brain vulnerable 
to a mechanism that caused dysfunction in this pathway. Evidence that the protein 
C pathway is implicated in cerebral specific pathology is also supported by fibrin 
deposits localized in the brain in a hypercoagulable mouse model with a partial 
thrombomodulin knockout (Maroney, Cooley et al. 2008); the finding that Factor V 
Leiden, a genetic defect in the protein C pathway, is a major risk factor for paediatric 
stroke (Herak, Antolic et al. 2009) and by protection by aPC against neuronal 
apoptosis in a murine model of ischaemic stroke (Cheng, Liu et al. 2003).  
 
 
 
Figure 1.6: Protein C activation. 
 1) The production of thrombin is initiated by the interaction between tissue factor and Factor VII; 2) 
Thrombin initiates the activation of protein c by altering the conformation of thrombomodulin (TM) so 
that it can bind protein C; 3) the thrombin-thrombomodulin complex is stabilized by the endothelial 
protein C receptor (EPCR); 4) Activated protein C (aPC), along with protein S (PS) form a complex with 
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factors Va and VIIIa (not shown) and inhibit further thrombin generation; 5) Through EPCR aPC 
initiates pleotropic anti-inflammatory and cytoprotective effects.  
 
There is evidence of involvement of the protein C pathway in malaria from limited 
previous research that relates to this pathway, although none has looked specifically 
in cerebral malaria. In vivo plasma protein C antigen and activity (Hemmer, Kern et 
al. 1991; Clemens, Pramoolsinsap et al. 1994; Vogetseder, Ospelt et al. 2004) are 
decreased in P. falciparum malaria infection. Levels show an inverse correlation 
with clinical severity (Vogetseder, Ospelt et al. 2004) and parasite density (Hemmer, 
Kern et al. 1991) and improve with treatment, correcting to within normal range in 
convalescence. Similarly protein S levels tend to be low in patients with severe but 
not mild P. falciparum infection and are lowest in patients with severe complications 
(Mohanty, Ghosh et al. 1997; Vogetseder, Ospelt et al. 2004).  
 
The concept that malaria might reduce endothelial expression of protein C receptors 
is supported by shedding of thrombomodulin from cultured endothelial cells by 
serum from patients with severe falciparum malaria (Hemmer, Bierhaus et al. 1994) 
and by increased soluble thrombomodulin in patient serum that correlated with 
disease severity in children from Mali with severe malaria [conference poster of 
unpublished work (Mita-Mendoza and Fairhurst 2011)]. It is also interesting to note 
that the chondroitin sulphate A side chain of thrombomodulin which increases its 
antithrombotic properties of 10 to 20 fold (Esmon 1995) is a potential binding site for 
iRBC (Rogerson and Brown 1997). 
 
The effectiveness of activated protein C as a treatment has not been investigated 
although there are anecdotal case reports of patients with severe P. falciparum 
malaria infection improving following treatment with activated protein C (Kendrick, 
Gray et al. 2006; Rankin and Austin 2007). 
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1.11 Vascular-bed specificity of the endothelium: why tissue 
culture and the measurement of soluble factors in vivo are 
not sufficient to understand the role of the endothelium in 
disease 
 
The endothelium interacts with circulating factors and blood cells through a 
repertoire of cell surface receptors. These can be significant for physical binding 
such as the binding of monocytes to endothelial receptors during the inflammatory 
response or of platelets during coagulation, and can also be important to transmit 
signals to the cell nucleus that facilitate adaptation under changing external 
conditions (Aird 2007). Both endothelial cell adhesion and cell-signalling are 
important in physiological responses but they can also contribute to pathology and 
are both considered contributory to cerebral malaria pathogenesis (Ockenhouse, 
Tegoshi et al. 1992; Berendt, Tumer et al. 1994; Jenkins, Wu et al. 2007). 
Endothelial cell receptor expression is highly variable. It varies between tissues, 
between types of blood vessels and even between different parts of the same blood 
vessel (Aird 2012). An example is variation in EPCR which is expressed at 
moderate or high levels in most organs including the heart, skin and kidney but at 
low levels in the brain; it is expressed at higher levels in large than in small blood 
vessels (Laszik, Mitro et al. 1997) and is expressed at higher levels on the sinus 
endothelium than on the valvular endothelium of a venous valve (Brooks, Trotman 
et al. 2009). Endothelial receptor expression is also highly variable in disease with 
the expression of some receptors increasing and others decreasing. The 
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phenomenon of endothelial activation in which a pro-inflammatory environment 
leads to increased expression of a number of receptors including ICAM-1, VCAM-1 
and E-selectin (Pober, Gimbrone et al. 1986) is implicated in the pathogenesis of a 
wide variety of inflammatory diseases including malaria (Ockenhouse, Tegoshi et al. 
1992; Chakravorty, Hughes et al. 2008). The same pro-inflammatory cytokine 
response can also lead to the decreased surface expression of other receptors 
including thrombomodulin and EPCR (Moore, Esmon et al. 1989; Fukudome and 
Esmon 1994). Levels in the plasma may correlate positively with endothelial levels 
in tissue - such as raised levels of sICAM-1 and E-selectin in plasma and in tissue in 
septic shock (Leone, Boutiere et al. 2002); negatively – such as raised soluble 
thrombomodulin (sTM) but reduced tissue thrombomodulin in meningococcal sepsis 
(Faust, Levin et al. 2001) or not at all – such as unchanged sEPCR levels compared 
to controls but reduced levels in tissue in meningococcal sepsis (Faust, Levin et al. 
2001) or unchanged sICAM-1 and sE-selectin compared with controls but increased 
levels in tissue in haemorrhagic shock patients (Leone, Boutiere et al. 2002).  
Most of the published literature exploring the effects of P. falciparum malaria – and 
indeed of other diseases – have explored changes to surface receptors in cultured 
endothelial cells (Aird 2012). This allows careful control of the environment, highly 
reproducible results and exploration in detail of the cellular mechanisms involved in 
any given effect such as in the highly informative studies: (Feistritzer and Riewald 
2005; Wu, Szestak et al. 2011). However the use of cultured cells to understand 
endothelial biology has important limitations, mRNA expression patterns of a variety 
of genes were markedly different between freshly isolated endothelial cells from 
healthy individuals and endothelial cells from the same source that have been 
cultured (Amatschek, Kriehuber et al. 2007) and a large proportion of vascular-bed 
specific differences in gene expression are lost after only a few passages in culture 
(Lacorre, Baekkevold et al. 2004; Burridge and Friedman 2010). Hence even if 
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tissue specific endothelial cells are used, failure to replicate critical parts of the in 
vivo environment may lead to the in vitro model being an imprecise representation 
of the true disease. Since in vitro models may be the only way to identify the exact 
molecular mechanism involved in an identified process, rather than excluding the 
use of tissue culture models this simply argues for the critical contribution of work in 
human tissue to inform the development of a relevant in vitro model.  
Two options to explore endothelial expression in human disease that have been 
used previously, both in malaria and in other diseases are staining of endothelial cell 
receptors on post-mortem tissue (Ockenhouse, Tegoshi et al. 1992; Turner, 
Morrison et al. 1994) and ex vivo staining of biopsies of accessible tissue (Turner, 
Ly et al. 1998; Faust, Levin et al. 2001). Table 1-3 summaries all the published post-
mortem studies in human cerebral malaria that have examined endothelial receptor 
expression. This shows that a wide variety of markers of adhesion receptors, 
angiogenic factors and receptors involved in cell immune response have been 
explored but that tissue factor is the only endothelial surface molecule that has been 
examined, and only in one study (Francischetti, Seydel et al. 2007). Table 1-4 
summaries studies that have examined endothelial expression in tissue ex vivo to 
investigate systemic endothelial events. We have excluded studies that have used 
biopsies to investigate organ specific disease (such as renal biopsies in kidney 
disease or skin biopsies in dermatological conditions) but we have included 2 
studies on IBD and a study on massive placental fibrin deposition because they 
have looked at the protein C pathway. It is important to note that the only study that 
examined endothelial expression of receptors ex vivo in malaria, in punch biopsies 
of dermis, while demonstrating endothelial activation in some vessels did not 
demonstrate a significant overall difference in any endothelial marker between 
uncomplicated and severe malaria although there was a significant difference in the 
level of soluble endothelial markers between these two syndromes. This was 
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probably because the endothelium in dermal vessels is associated with minimal 
sequestration and we have therefore used subcutaneous tissue with substantially 
higher levels of sequestration (See chapter 3).  
It is also of note that the 2 studies that looked at skin biopsies both detected 
endothelial specific changes in the skin biopsy that were not predicted accurately by 
changes in soluble receptors in the plasma in the same individuals (Faust, Levin et 
al. 2001; Leone, Boutiere et al. 2002). In the study by Faust et al. dermal biopsies 
from and adjacent to purpuric lesions in children with meningococcal sepsis showed 
loss of endothelial thrombomodulin and EPCR but while soluble thrombomodulin 
levels were increased in the meningococcal sepsis cases (indicative of increased 
thrombomodulin receptor shedding) soluble EPCR levels were not significantly 
different from controls. In the study by Leone et al. the inducible endothelial markers 
ICAM-1, VCAM-1 and E-selectin were increased in dermal biopsies of patients with 
both septic shock and traumatic shock patients but while soluble levels of ICAM-1, 
VCAM-1 and E-selectin were increased in septic shock they were no different from 
healthy controls in the traumatic shock group. The implication is that measurements 
of endothelial markers in the blood may not always be a good indicator of 
endothelial changes that occur in vascular-bed specific sites in the tissue, which 
may be heterogeneous, as was also supported by a detailed study of the 
endothelium in tissue in a murine model of sepsis (Shapiro, Yano et al. 2009).  
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Table 1-3: Post-mortem studies in cerebral malaria that examine endothelial receptor 
expression in the brain. 
Subjects Technique used Receptors examined Reference 
Asian adults (Myanmar) 
 
IHC - frozen CD36, TSP, ICAM-1, ELAM-1, VCAM-1 (Ockenhouse, Tegoshi 
et al. 1992) 
Asian adults (Thailand) IHC - frozen vWF, EN4ant, ICAM-1, ICAM2, CD36, 
TSP, E-selectin, VCAM-1, HLA, FcR 
(Turner, Morrison et al. 
1994) 
African children (Malawi) IHC - frozen ICAM-1 (Brown, Rogerson et 
al. 2001) 
African children (Malawi) IHC – FFPE Tissue factor (Francischetti, Seydel 
et al. 2007) 
African children (Ghana) IHC - frozen ICAM-1, VCAM-1, E-Selectin (Armah, Dodoo et al. 
2005) 
Asian adults (Vietnam) IHC - FFPE Flt-1, Flk-1, pKDR (Medana, Day et al. 
2010) 
Asian adults (Vietnam) IHC - FFPE EpoR, CD131 (Medana, Day et al. 
2009) 
IHC denotes Immunohistochemistry, FFPE denotes formalin-fixed paraffin-embedded; TSP denotes 
thrombospondin; ELAM-1 denotes endothelial leukocyte adhesion molecule-1; FcR denotes Fragment, 
crystallisable receptor; VCAM-1 denotes vascular cell adhesion molecule-1; EN4 denotes anti-
endothelial antibody; HLA denotes human leukocyte antigen; FcR denotes fragment crystallisable 
receptor; Flt-1 denotes Vascular endothelial growth factor (VEGF) receptor 1; Flk-1 denotes VEGF 
receptor 2; pKDR denotes the phosphorylated form of Flk-1; EpoR denotes erythropoietin receptor; 
vWF denotes von Willebrand Factor 
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Table 1-4: Human studies demonstrating endothelial expression ex vivo 
Disease Subjects Tissue used Numbers Technique used Receptor(s) 
examined 
Reference 
Malaria 
(severe & UM) 
Thai Adults Skin 10 severe 
10 UM 
IF – Fixed frozen  Tissue cytokines 
only 
(INFy, TNF, IL-1b, 
IL-2, IL-6, IL-10, 
GM-CSF, VIII) 
(Wilairatana
, Riganti et 
al. 2000) 
Severe malaria & 
sepsis 
Thai and 
European 
adults 
Dermis 
(p. biopsy) 
61 severe 
42 UM 
10 sepsis 
17 controls 
IHC - frozen ICAM-1, CD36, E-
selectin, P-
selectin, VCAM-1, 
TSP-1, vWF, HLA,  
(Turner, Ly 
et al. 1998) 
Sepsis 
(Meningococcal) 
European 
adults 
Dermis 
(p. biopsy) 
21 sepsis IHC - frozen EPCR, TM (Faust, 
Levin et al. 
2001) 
Sepsis & trauma European 
adults 
Skin 
(p. biopsy) 
26 sepsis 
13 trauma 
IHC - frozen E-selectin, ICAM-
1, VCAM-1, IgG2a 
(Leone, 
Boutiere et 
al. 2002) 
Atherosclerosis American 
adults 
Coronary 
arteries 
(Surgical) 
6 with ICMP 
12 controls 
IHC - FFPE  EPCR, TM (Laszik, 
Zhou et al. 
2001) 
MPFD American 
foetus' 
Placenta 
(Miscarriage) 
10 MFPD 
10 controls 
IHC - FFPE  EPCR, TM (Svensson, 
Waters et 
al. 2004) 
IBD European 
adults 
Bowel  
(e. biopsy) 
74 IBD  
70 controls 
IHC - FFPE & frozen EPCR, TM (Faioni, 
Ferrero et 
al. 2004) 
IBD European 
adults 
Colon  
(e. biopsy) 
29 IBD 
12 Controls 
IHC - FFPE  EPCR, TM (Scaldaferri, 
Sans et al. 
2007) 
MPFD denotes massive placental fibrin deposition; IBD denotes inflammatory bowel disease; p.biopsy 
denotes punch biopsy; e.biopsy denotes endoscopic biopsy; IHC denotes immunohistochemistry; 
FFPE denotes formalin-fixed paraffin embedded; TSP denotes thrombospondin; HLA denotes Human 
Leukocyte antigen; vWF denotes von Willebrand Factor; UM denotes uncomplicated malaria; TM 
denotes thrombomodulin; IgG denotes immunoglobulin gamma.   
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1.12 Summary of published literature on the role of coagulation in 
cerebral malaria pathogenesis 
 
Review of the literature reveals that that in vitro P. falciparum components can 
promote thrombin generation through tissue factor, stimulate the production of pro-
coagulant platelet and endothelial microparticles, inhibit antithrombin and cleave 
thrombomodulin. Data from malaria infection in humans has shown that there is a 
pro-coagulant state in malaria with dysregulation of a number of coagulation 
molecules but there is surprising paucity of literature on coagulation in cerebral 
malaria in adults or children or on coagulation in malaria of any severity in African 
children, with only study one small study on coagulation that showed no difference 
from uncomplicated malaria in clotting times. Although overt thrombosis or 
haemorrhage is rare in cerebral malaria in African children, detailed post mortem 
studies and examination of the retina in vivo have revealed that microvascular 
lesions are common. Their localization in neuroendothelium raises the possibility 
that understanding the mechanisms that underlie these lesions might also assist in 
understanding the reason for the dominant neurological involvement clinically in this 
condition.  
 
Because of the low constitutive expression of the receptors that regulate the protein 
C pathway we have identified it as a highly plausible mechanism to explain the 
haemorrhagic lesions in the brain – which we suspect are thrombi.  Because of its 
critical role in anticoagulation and a variety of endothelial homeostatic processes, 
dysfunction in this pathway also has the potential to link several of the other key 
pathological features of the disease including coagulation, inflammation and 
endothelial permeability. Despite this, there is a paucity of literature on the effects of 
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P. falciparum infection on the protein C pathway, and no literature on any 
component of the protein C pathway in cerebral malaria in adults or in children. We 
therefore set out to examine the coagulation profile and endothelial protein C 
pathway in tissue and blood from Malawian children with cerebral malaria compared 
with that of comatose and non-comatose controls. 
1.13 Objectives of the study 
The primary objective of this study is to test the hypothesis: 
Increased thrombin generation and disruption in the protein C pathway leads to 
fibrin deposition, particularly in the brain where constitutive expression of protein C 
pathway receptors is low. 
The secondary objective is to better characterise alterations to coagulation and to 
the endothelium in cerebral and uncomplicated malaria, to clarify possible roles in 
acute pathogenesis and to establish what happens to alterations after malaria 
parasites have been cleared. 
  
We propose the following specific aims: 
1) To assess whether haemorrhagic lesions in the brain post-mortem of 
children with fatal cerebral malaria are fibrin containing thrombi. 
2) To assess whether haemorrhagic lesions in the brain are associated with 
changes in endothelial phenotype, specifically loss of the protein C pathway 
anticoagulant receptors thrombomodulin and EPCR. 
3) To develop a method to examine endothelial phenotype ex vivo that can 
detect endothelial activation. 
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4) To perform a detailed assessment of coagulation in children with cerebral 
and uncomplicated malaria compared with febrile aparasitaemic and healthy 
Malawian paediatric controls.
  68 
 
 
 
2                                   
MATERIALS & METHODS
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2.1 Ethical approval 
The study was approved by ethical boards at the University of Malawi College of 
Medicine (no. P.02/10/860) and Liverpool School of Tropical Medicine in the United 
Kingdom (no. 09.74). Written informed consent was obtained from the parent or 
legal guardian of all the children enrolled (Copies of the documents submitted to the 
ethical committees, consent forms and the study protocol are in the appendix, 
Section A1-3). This study was a sub-study of a large cerebral malaria pathogenesis 
study. It was carried out in a unit with over 25 years experience of investigation into 
cerebral malaria and where great care is taken to adhere to Good Clinical Practice 
guidelines.  
2.2 Patient groups and enrolment criteria 
Participants for the plasma and subcutaneous tissue samples were recruited 
between January 2008 and June 2011 (Table 1). Although all the subcutaneous 
samples were recruited by the author, with regards to the blood samples the author 
participated as part of a team of 6 clinicians in the overarching cerebral malaria 
pathogenesis study. Healthy controls and patients with uncomplicated malaria and 
mild febrile illness were recruited by two nurses employed specifically for this study, 
who were supervised by the author. Five clinical groups were prospectively defined: 
retinopathy positive cerebral malaria, retinopathy negative cerebral malaria, 
uncomplicated malaria, mild aparasitaemic febrile illness and healthy controls.   
Cerebral malaria (WHO 2000)  
a. Age!between!1!and!12!years!!
b. Blantyre!Coma!Score!<!2!on!admission!
c. Peripheral!P.#falciparum!parasitaemia!(any!density)!
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d. No! improvement! in!Blantyre!Coma!Score! (to! a! score! above!2)! after! correction!of!
hypoglycaemia!(if!present)!
e. Informed!consent!from!the!parent!or!legal!guardian!
!!
Retinal examination by a specially trained ophthalmologist then classified patients 
into retinopathy positive cerebral malaria or retinopathy negative cerebral malaria 
according to the presence or absence of features of the cerebral malaria retina as 
described previously (Lewallen, Harding et al. 1999).  
Non-malarial coma 
a. Age!between!1!and!12!years!!
b. Blantyre!Coma!Score!<!2!on!admission!
c. Aparasitaemic!on!peripheral!blood!film!(thick)!
d. No! improvement! in!Blantyre!Coma!Score! (to! a! score! above!2)! after! correction!of!
hypoglycaemia!(if!present)!
e. Informed!consent!from!the!parent!or!legal!guardian!
!
Uncomplicated malaria 
a. Age!between!1!and!12!years!
b. Axillary!temperature!>37.5°c!
c. Blantyre!coma!score!5!
d. Peripheral!P.#falciparum!parasitaemia!(any!density)!
e. None!of:!
• Prostration!(unable!to!sit!unsupported)!
• History!of!convulsions!
• Jaundice!
• Respiratory!distress!
• Hypoglycaemia!
• Severe!anaemia!(Packed!cell!volume!<15%!or!Hb!<5g/dL)!
• Informed!consent!from!the!parent!or!legal!guardian!
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Mild aparasitaemic febrile illness 
a. Age!between!1!and!12!years!
b. Axillary!temperature!>37.5°c!
c. Blantyre!coma!score!5!
d. Negative!rapid!diagnostic!test!(First!Response;!Premier!Medical,!India)!
e. None!of:!
• Prostration!(unable!to!sit!unsupported)!
• History!of!convulsions!
• Jaundice!
• Respiratory!distress!
• Hypoglycaemia!
• Severe!anaemia!(Packed!cell!volume!<15%!or!Hb!<5g/dL)!
• Informed!consent!from!the!parent!or!legal!guardian!
Healthy controls 
a. Age!between!1!and!12!years!
b. Axillary!temperature!<37.5°c!
c. Scheduled!for!elective!surgical!procedure!under!general!anaesthetic!
d. No!complicating!medical!condition!(e.g.!diabetes,!malignancy,!inflammatory!bowel!
disease,!sickle!cell!disease)!
e. Negative!rapid!diagnostic!test!(First!Response;!Premier!Medical,!India)!
f. Informed!consent!from!the!parent!or!legal!guardian!
In all patient groups, children were excluded if they had clinical evidence of severe 
malnutrition (nutritional oedema, severe wasting, dermatitis or hair changes)(WHO 
1999), had World Health Organization (WHO) clinical stage 4 HIV infection (WHO 
2006) or were on antiretroviral therapy. In the cerebral malaria and non-malarial 
coma groups, patients were excluded if they had microbiological evidence of 
bacteraemia (pathogenic bacteria in culture media [Bactec; Becton Dickinson] after 
3 days incubation; N=2) or if they had evidence of meningitis (>10 leukocytes/ mL or 
pathogenic bacteria on gram stain or culture; N=8).   
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2.3 Determination of parasitaemia and count 
As detailed above uncomplicated malaria and mild febrile illness patients had the 
same enrolment criteria until the point of testing for parasitaemia. Parasitaemia was 
screened for using a combined P. falciparum Histidine rich protein and pan malarial 
Lactose dehydrogenase (pLDH) rapid diagnostic test kit (First response, Premier 
medical, India) and patients who had a positive rapid diagnostic test for pLDH had 
thick and thin smears. The presence or absence of parasitaemia in comatose 
children was screened for using Field’s stained thick blood films with smears 
repeated 6 hourly until resolution of coma or two consecutive negative smears. 
None of the non-malaria coma cases with negative films on admission had 
subsequent positive smears. Parasite counts for all groups were determined by 
Field’s stained thick and thin blood films and were expressed as asexual P. 
falciparum parasites per microliter. When there was sufficient parasite density the 
parasitaemia was counted on a thin film in 1000 RBC and converted to parasites per 
microliter using the red blood cell concentration from the full blood count. At low 
parasite densities the number of parasites was counted per 200 white blood cells on 
a thick film and converted to parasites per microliter using the white blood cell count 
from the full blood count. Patients who had a positive rapid diagnostic test and a 
negative smear or patients who had non-falciparum malaria species only were 
excluded from analysis.  
 
 
2.4 Collection of blood samples and preparation of plasma and 
serum  
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Blood was taken by venepuncture from a large vein from which blood was free 
flowing. From healthy control, uncomplicated malaria and mild febrile control 
patients this was generally from the brachial vein using a 23 gauge needle and from 
cerebral malaria and non-malarial comatose cases using a 21 gauge needle from 
the femoral vein. Blood was put immediately into blood tubes. Serum was prepared 
from blood collected into commercial serum tubes (S-Monovette, Sarstedt, 
Germany) containing a gel to promote rapid coagulation. Plasma for standard 
coagulation tests and soluble factors were prepared from blood collected into 
polypropylene tubes containing 3.2% sodium citrate (0.105M, adjusted to pH 5.4; 
Sigma, USA) in a 9:1 ratio of blood to anticoagulant. Plasma for activated protein C 
assays had sodium citrate as above plus benzamidine hydrochloride (20mM final 
concentration, adjusted to pH 5.4; Sigma); a protease inhibitor that prevents the 
breakdown of activated protein C by endogenous plasma proteases. To prevent 
bacterial contamination of the anticoagulants the solutions were prepared fresh 
monthly, sterile filtered and kept at 4°C. Anticoagulant tubes were prepared daily by 
adding anti-coagulant into blood tubes in a laminar flow hood. Plasma was 
separated by centrifugation at 1500g for 10 minutes. Serum was separated from 
clotted blood5 at 3000g for 10mins at 20°C. Samples were aliquoted as detailed in 
Figure 2.1 and frozen immediately at -80°C until used for assays. 
 
                                                
5 The commercial serum tubes used have a gel that promotes rapid clotting.  
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Figure 2.1: Preparation of aliquots of plasma and serum 
 
 
2.5 Coagulation tests and assays to measure soluble factors in 
the plasma 
 
2.5.1 Standard coagulation tests 
Prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen 
(Fibrinogen), Protein C activity and Antithrombin III activity were measured on an 
MDA180 analyser (Stago, France). As a these analysers were not available in 
Malawi these assays were performed in Liverpool at the Royal Liverpool Hospital 
haematology department according to standard protocols (Fareed, Messmore et al. 
1980; Toh, Samis et al. 2002). Samples were shipped to Liverpool frozen on dry ice.  
 
Blood from patient 
2ml Sodium citrate = BLUE 1ml Benzamide = GREEN 0.5ml serum  
Spin 1500g 10 mins 20°c and 
remove supernatant 
2x300µl 
Centrifuge 3000g 10mins 20°c 
and remove supernatant 
3x 150µl  2x150µl 
Spin 1500g 10 mins 20°c 
and remove supernatant 
4x150µl 
Pellet 
RNA later 
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2.5.2 Enzyme capture method for activated protein C (aPC) levels 
aPC was measured using an adapted protocol of an enzyme capture method for 
aPC detection developed by Liaw, Ferrell et al., (2003). The assay utilizes a highly 
specific monoclonal antibody raised against human aPC (clone 1555) to coat a 96 
well plate and bind the inactivated aPC antigen in benzamidine plasma samples. 
aPC is activated by washing off the benzamidine solution from the bound aPC and 
adding calcium. The quantity of bound aPC in each sample is determined using a 
specific chromogenic substrate (Spectrozyme PCa, American Diagnostica, USA) by 
measuring the amount of chromophore produced on a spectrophotometric plate 
reader at 405nm. When the substrate is in excess, there is a linear relationship 
between enzyme activity from aPC and the increase in absorbance detected from 
chromophore generation. The concentration of aPC in the samples can therefore be 
extrapolated with reference to a standard curve of dilutions of recombinant activated 
protein C of known concentration. As a control to ensure that another component of 
the samples was not effecting the chromogenic substrate excess antibody was 
added to the sample for a proportion of the samples. This in effect removes the aPC 
in the sample, and any chromogenic activity can be assumed to be cross-reactive 
activity due to an additional plasma component.  
 
2.5.2.1 General Protocol  
Plates were coated with 100µl per well of HAPC 1555 antibody at 5µg/ml in ‘basic 
buffer’ and incubated for either 2 hours at 37o C, or overnight at 4o C. Following 
incubation coating solution was removed and wells washed with 200µl ‘wash buffer’ 
for 5 minutes with gentle agitation on an automatic rotator (50 revolutions/ minute); 
for this and all wash procedures for the assay, only one row of wells was uncovered 
at a time to avoid wells drying out.  The plate was incubated for 1 hour at room 
Chapter 2: Materials & Methods 
 76 
temperature with 200µl per well ‘blocking buffer’ and washed twice for 5 min with 
gentle rotation. Wash buffer was aspirated and 100µl per well of diluted plasma 
samples mixed with ‘working cocktail’ or known standards (Table 2-1) were added to 
the plate, all samples were added in duplicate. In order to minimize the time to add 
all the solutions to the plate, a blank plate was used for dilution of the samples: 4.8ul 
‘working cocktail’ was added to 150µl of clinical sample mixed and 125µl of this was 
mixed with 125µl of dilution buffer in the blank plate. 100µl of this diluted solution 
was then added to the coated plate. Two additional wells containing diluted sample 
plus excess antibody (final concentration 50µg/ml) were added as a control for some 
samples. The plate was covered with an adhesive plate sealer and incubated for 1 
hour at room temperature. Following incubation the wells were washed twice for 10 
minutes with gentle rotation. Wash solution was aspirated and 100µl per well 0.5mM 
Spectrozyme PCa added. The plate was read on a plate reader at 405nm covered 
with an adhesive sealer and incubated overnight in the dark at 37o C in a humidified 
chamber and the plate read again at approximately 20 hours. 
 
2.5.2.2 Reagents for activated protein C assay 
Basic (coating) buffer 
 
• 20mM!NW2WHydroxyethylpiperazineWN'W2Wethanesulfonic!acid!(HEPES),!pH!7.5!
• 150mM!NaCl!
• 5mM!CaCl2!
• Adjust!to!pH!7.5!and!filter!sterilize!!
Blocking Buffer  
• Basic!buffer!plus!1%!BSA#
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Dilution Buffer  
• 20mM!HEPES,!pH!7.5!
• 150mM!NaCl!
• 10mM!CaCl2!!
• 0.1%!BSA!
• 2U/!ml!Heparin!(Sigma)!!
• 20mM!Benzamidine!
• Adjust!to!pH!7.5!
Wash Buffer  
• Basic!buffer!plus!0.05%!Tween!(Sigma)!
Working Cocktail  
• 1000µl!1M!HEPES,!pH!7.5!
• 10µl!10,000U/ml!Heparin!
• 500µl!1M!CaCl2 
 
 
Table 2-1: Preparation of standards for activated protein C assay 
Solution Add Of 
Dilution 
buffer Final Conc 
Initial 0.5µl 4.2mg/ml stock 500µl 4200ng/ml 
1 1.19µl Initial 500µl 10ng/ml 
2 250µl Solution 1 250µl 5ng/ml 
3 250µl Solution 2 250µl 2.5ng/ml 
4 240µl Solution 3 360µl 1ng/ml 
5 375µl Solution 4 125µl 0.75ng/ml 
6 267µl Solution 5 133µl 0.5ng/ml 
7 150µl Solution 6 150µl 0.25ng/ml 
Conc= concentration 
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Samples were determined in duplicate. The lower limit of detection was 0.5ng/ mL. 
For each diagnostic group (i.e. retinopathy positive cerebral malaria, uncomplicated 
malaria etc.) repeat determinations on a new aliquot were carried out for values that 
were either greater than double or less than half the median for that group.  
 
2.5.3 Measurement of soluble factors in plasma by enzyme linked 
immunosorbent assay 
Commercial enzyme linked immunosorbent assays were used to measure the 
factors as detailed in Table 2-2, following the manufacturers' instructions.  
Table 2-2: List of Commercial Enzyme linked immunosorbent assays used 
Antigen Manufacturer (country) Manufacturer’s reference 
sEPCR Stago (France) 0264 
sThrombomodulin R&D (USA) DY3947 
sICAM-1 R&D (USA) DY720 
sE-selectin R&D (USA) DY724 
Ang-2 R&D (USA) DY3947 
CRP R&D (USA) DY1707 
TAT Dade Behring (Germany)  Enzygnost TAT micro 
Prothrombin fragment 
(F1+2) Dade Behring (Germany)  Enzygnost F1+2 micro 
s= soluble; EPCR= Endothelial protein C receptor; ICAM-1; Intercellular adhesion molecule-1; Ang-2= 
Angiopoeitin 2; CRP= C-reactive protein; TAT= thrombin-anti-thrombin complexes 
 
For each antigen a selection of cases and controls was tested to find the optimum 
dilution to ensure the majority of samples fell within the standard curve at the 
chosen dilution. Samples below or above the limits of the standard curve were 
repeated with increased or decreased dilution as indicated. When neat samples 
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gave the same optical density as a plate blank they were reported as zero. The first 
1 or 2 plates for each antigen were carried out in duplicate to ensure consistency of 
the assay and thereafter in singlicate. For each plate a control sample (either an 
aliquoted standard, pooled plasma or a specific positive control when provided) was 
used to ensure internal consistency between plates. For each diagnostic group (i.e. 
retinopathy positive cerebral malaria, uncomplicated malaria etc.) repeat 
determinations on a new aliquot were carried out for values that were either greater 
than double or less than half the median for that group.  
 
 
2.6 Histology on post-mortem tissue 
 
2.6.1 Tri-chromic staining method to detect fibrin 
Fibrin was stained for using a method as described by Lendrum et al.(Lendrum, 
Fraser et al. 1962). This method is based on the affinity of the red stain, crystal 
ponceau, for fibrin. Red cells are preferentially stained by Martius yellow and 
connective tissue is stained light blue by methyl blue. Nuclei are discriminated as 
dark brown using Wergert’s haematoxylin. 
2.6.1.1 General method 
Tissue sections were de-paraffinised with two 5-minute emersions in 100% Xylene 
and rehydrated by 3 minutes successive emersions in: 95% ethanol, 90% ethanol, 
80% ethanol, 70% ethanol and dH2O. Sections were then incubated with Weigert's 
haematoxylin (Fisher scientific, USA) for 20 minutes, washed in dH2O for 1 minute 
and the stain differentiated in acid alcohol (1% hydrochloric acid in 70% alcohol) for 
5 seconds. The sections were then washed in dH2O for 5 minutes, rinsed in 95% 
Chapter 2: Materials & Methods 
 80 
ethanol and then stained in Martius yellow solution for 2 minutes. Martius yellow 
was rinsed and the sections stained in crystal ponceau solution 10 minutes. The 
section was then treated with 1% phosphotungstic acid (Sigma) for 5minutes and 
washed in dH2O for 30 seconds before staining with methyl blue solution for 2 
minutes. Sections were then dehydrated by 3 minute successive washes in each of: 
70% ethanol, 80% ethanol, 90% ethanol, 95% ethanol and then 100% xylene twice 
for 5 minutes before mounting with a cover slip using mounting solution (DPX, 
Sigma) 
 
2.6.1.2 Solutions for trichromic staining method 
Martius yellow solution  
0.2g Martius yellow (Sigma) 
100ml 95% alcohol  
2g phosphotungstic acid (Sigma).  
Dissolve the phosphotungstic acid in the alcohol before adding the Martius yellow.  
Crystal ponceau solution  
1% crystal ponceau (Sigma) in 2% acetic acid  
Methyl blue solution  
0.5% methyl blue (Sigma) in 1% acetic acid 
2.6.2 Staining for endothelial receptors using immunoperoxidase staining 
method 
All sections were incubated at 60°c for one hour before de-paraffinisation and re-
hydration in xylene and alcohol as described in the trichromic method above. In 
addition brain sections were first incubated at 40°c overnight. Heat induced antigen 
retrieval in citrate buffer (0.01M, pH 6.0, Sigma) was performed for 10 minutes prior 
Chapter 2: Materials & Methods 
 81 
to incubation with anti-Endothelial protein C receptor (EPCR) and anti-CD34 
antibodies and with EDTA buffer (0.65mM, pH 9.0, Sigma) prior to incubation with 
anti-CD31 antibody (Krenacs, Krenacs et al. 2010). The sections were then washed 
in dH2O and endogenous peroxidase activity blocked by incubating slides for 10 
minutes with 3% hydrogen peroxide. The slides were washed in PBS and incubated 
for 1 hour with mouse anti-human monoclonal antibodies recognising the following: 
thrombomodulin (clone 1009, 7.6 µg/ ml), EPCR (clone 1489, 92 µg/ ml brain, 15 
µg/ ml subcutaneous tissue and gut); ICAM-1 (clone 23G12, Leica; 1:25) CD31 
(clone JC70A, Dako, Denmark; 1:40 gut and skin; 1:10 brain) and CD34 (clone 
QBend10; Dako; 0.2 mg/ml). Thrombomodulin and EPCR antibodies were donated 
by the Esmon lab (Oklahoma, USA) (Laszik, Mitro et al. 1997). The sections were 
washed in PBS and incubated with labelled anti-mouse polymer-secondary antibody 
complex (Envision Plus kit, Dako) for 30 minutes. Staining was visualised with DAB 
solution (Envision Plus kit). Counterstaining was with haematoxylin (Sigma) for 1 
minute for gut and skin sections and 30 seconds for brain sections. Samples were 
rehydrated and mounted as described in the trichromatic method above. 
Optimisation was carried out for all the antibodies with and without antigen retrieval, 
use of EDTA and Citrate buffer and a variety of antibody concentrations to 
determine the conditions that gave the optimum staining as indicated by the 
maximum intensity of specific staining achieved with minimal background.  
 
2.6.3 Scoring of fibrin and Endothelial protein C staining in microvessels in 
post-mortem brain samples 
The degree of fibrin accumulation in cerebral microvessels was classified for each 
case in 50 vessels as greater than or equal to 50% of vessel containing fibrin, less 
than 50% of vessel containing fibrin or none. The intensity of immunostaining for 
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EPCR and thrombomodulin was graded as absent, weak, moderate or strong based 
on reference micrographs of vessels of each staining intensity. The degree of iRBC 
sequestration was assessed by counting the number of parasites, as indicated by 
malaria pigment, in a 10x100 µm area of each of 50 vessels per patient. Each 
vessel was scored as high [greater than 10 parasites], moderate [5 to10 parasites] 
or low [1 to 5 parasites]. Only good quality samples with minimal tissue damage 
were accepted for scoring: one case and one control were excluded from scoring in 
brain tissue stained for EPCR due to excessive tissue damage following antigen 
retrieval. The degree of fibrin accumulation and the staining intensity of EPCR were 
scored by the author and by three independent medical pathologists (based in 
Boston, USA) on the same slide set, which included positive and negative controls. 
The medical pathologists were unaware of study aims and blinded to diagnosis6. 
Reference micrographs of each staining intensity were provided to ensure 
consistency of scoring. Scoring was performed on a custom designed questionnaire 
sheet (appendix), which allowed scanning of the results into a computer database. 
The data was scanned and a data team in Malawi who were unaware of patient 
diagnosis or study aims checked the integrity of the data.  
 
Analysis of the scoring data was performed in consultation with a statistician, Brain 
Faragher at the Liverpool School of Tropical Medicine and with independent advice 
from a second statistician, Clarissa Valim at the School of Public Health, Harvard, 
Boston. To ensure validity to combine the scoring data for statistical analysis and 
consistency of reading we compared the data from the scorers for agreement by 
Bland-Altman plot (Bland and Altman 1986) and by correlation coefficients. There 
was good agreement (Figure 2.2) and correlation (Table 2-3) between the author 
                                                
6 True blinding of the author was not possible as the author was aware of the study hypotheses and 
that the presence of sequestered parasites defines retinopathy positive cerebral malaria 
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and all three independent scorers in scoring of fibrin although medical pathologist 3 
agreed the least well with the other scorers. For EPCR there was good agreement 
(Figure 2.3) and correlation (Table 2-4) between the author and two of the three 
independent medical pathologist but poor agreement and correlation between the 
third pathologist and the other scorers. Therefore for both variables (fibrin and 
EPCR) we combined the data from the three scorers with the highest scoring 
agreement (the author, pathologist 1 and pathologist 2): each scorer scored 50 
vessels per case and the results were combined, giving 150 vessels scored for each 
case for fibrin and 150 vessels scored per case for EPCR.  Statistical analysis was 
done on the combined scores, with a variable included in the ordinal regression 
model to adjust for any variation between scorers (see section 2.10). Micrographs 
were taken using a Leica DM1L microscope and a Micropublisher 3.3 RTV 
(QImaging) camera. 
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Figure 2.2: Bland-Altman plots to show inter-scorer agreement of Fibrin scoring in post-mortem 
brain sections.  
The mean score given by each scorer (author and each of 3 medical pathologists) for each case was 
calculated. Each graph is a comparison between 2 of the scorers with the X-axis showing the inter-
scorer mean for each case and the Y-axis showing the inter-scorer difference for each case.  
 
Table 2-3: Inter-scorer correlations for Fibrin scoring in post-mortem brain sections 
 Author Pathologist 1 Pathologist 2 Pathologist 3 
Author  0.85 (p=<0.001) 0.80 (p=<0.001) 0.75 (p=0.0012) 
Pathologist 1 0.85 (p=<0.001)  0.94 (p=<0.001) 0.83 (p=<0.001) 
Pathologist 2 0.80 (p=<0.001)  0.94 (p=<0.001)  0.69 (p=0.004) 
Pathologist 3 0.75 (p=0.0012) 0.83 (p=<0.001) 0.69 (p=0.004)  
Numbers are correlation coefficients with p values in brackets.  
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Figure 2.3: Bland-Altman plots to show inter-scorer agreement of EPCR scoring in post-mortem 
brain sections.  
The mean score given by each scorer (author and each of 3 medical pathologists) for each case was 
calculated. Each graph is a comparison between 2 of the scorers with the X-axis showing the inter-
scorer mean for each case and the Y-axis showing the inter-scorer difference for each case.  
 
Table 2-4: Inter-scorer correlations for EPCR scoring in post-mortem brain sections 
 Author Pathologist 1 Pathologist 2 Pathologist 3 
Author   0.86 (p=0.002) 0.83 (p=0.003) -0.058 (p=0.87) 
Pathologist 1 0.86 (p=0.002)   0.71 (p=0.02) -0.0018 (p=0.996) 
Pathologist 2 0.83 (p=0.003) 0.71 (p=0.02)   -0.0074 (p=0.98) 
Pathologist 3 -0.058 (p=0.87) -0.0018 (p=0.996) -0.0074 (p=0.98)   
Numbers are correlation coefficients with p values in brackets.  
 
2.6.4 Scoring of endothelial protein C and thrombomodulin in post-mortem 
subcutaneous tissue samples  
Because of the heterogeneous nature of the tissue and distribution of vessels it was 
not considered useful to score individual vessels in the gut and subcutaneous tissue. 
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Instead the intensity of immunostaining for EPCR and thrombomodulin was given an 
overall semi-quantitative score of absent (0), weak (1), moderate (2) or strong (3) 
based on reference micrographs of vessels of each staining intensity. Scoring was 
performed by the same scorers as in section 2.6.3 (author and 2 independent 
medical pathologists) and when different scores were given by scorers we used the 
mean of the 3 scores.  
 
2.7 Subcutaneous biopsies 
2.7.1 Biopsy technique  
Subcutaneous biopsies were taken from comatose retinopathy cerebral malaria and 
anaesthetised healthy controls (under general anaesthetic prior to their planned 
elective surgery).  Since comatose children with cerebral malaria might experience 
pain, a local anaesthetic cream (EMLA, APP Pharmaceuticals, USA) was applied to 
the skin 30 minutes prior to taking the biopsy. The biopsy was taken from the upper 
outer quadrant of the buttock using a 15-gauge hollow bore Menghini biopsy needle 
and syringe. The skin was first pierced with the trocar and the needle inserted at an 
acute angle just under the dermis and moved backwards and forwards while 
aspirating with the syringe. This technique produced a biopsy core of subcutaneous 
fat of approximately 2-3mm3, which were then smeared onto poly-lysine slides or 
used to make a single cell suspension or both. The biopsy was transported to the 
laboratory in cold serum free endothelial media (Iscove’s modified Dulbecco’s 
medium, Gibco, USA) 
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2.7.2 Immunofluorescence labelling of subcutaneous biopsy smears 
Samples of subcutaneous tissue were obtained by percutaneous biopsy from 
comatose cerebral malaria cases and anesthetized surgical controls using a needle 
and syringe as described previously (Wassmer, Moxon et al. 2011) and used for 
flow cytometry and for immunofluorescent staining. Fresh samples were smeared 
onto poly-lysine slides. A small amount of tissue was placed on the charged side of 
the slide and then a second slide was placed on top of the tissue again with the 
charged side facing the tissue. The tissue was then squeezed between the slides 
and, maintaining pressure, the slides were slid apart to smear the tissue across both 
Figure 2.4: Schematic for subcutaneous biopsy technique 
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slides. The tissue was then air-dried and fixed in ice-cold methanol before storing at 
-80°C. Non-specific binding was reduced by the application of blocking agent for 30 
minutes (Image iT, Invitrogen, USA) prior to immunolabeling with mouse anti-human 
primary antibody (all IgG1 monoclonal) for 1 hour, using one of: CD31 (clone 5.6E, 
Immunotech), ICAM-1 (clone 84H10, Immunotech) thrombomodulin (clone 1009; gift 
from Prof C. Esmon, Oklahoma Medical Research Centre), EPCR (clone 1462, 
gfrom C. Esmon). Non-specific mouse IgG (Sigma) was used as a control for all 
antibodies. Binding was revealed with Alexa fluor 488 goat anti-mouse (Invitrogen) 
and nuclei were stained with a 4', 6-diamidino-2-phenylindole (DAPI) containing 
mountant (Prolong Gold; Invitrogen). Micrographs were taken using a Leica DM1L 
microscope and Leica DFC300FX camera. 
2.7.3 Preparation of a single cell suspension, cell surface staining and 
analysis of endothelial cells by flow cytometry 
A single cell suspension was prepared using a method adapted from Wassmer, 
Moxon et al. (2011). The sample was placed in a C-tube (Miltenyi Biotec, Germany) 
containing collagenase digestion solution (3mg/ml type II; Gibco, USA; 1.5% bovine 
serum albumin, 25mM HEPES, 2mM glucose, 120mM sodium chloride, 50mM 
potassium chloride, 5mM calcium). The sample was gently minced with scissors and 
put through a cycle on a gentleMACSTM dissociator (Miltenyi Biotec, Germany) for 2 
minutes and then incubated at 37°c for 15 minutes at on a rotator; this was repeated 
with an additional 2 minute cycle on the dissociator. The digested material was 
filtered through a 100µm cell strainer and centrifuged at 500g washed in phosphate 
buffered saline (PBS) with 0.1% bovine serum albumin (BSA, Sigma). Cell numbers 
were determined on a haemocytometer and viability determined using trypan blue 
(0.4%, Invitrogen). Cell surface staining was performed for 30 minutes at 4°C using 
the antibodies and viability die as detailed in Table 2-5. Optimisation of antibody 
concentration was performed for all the antibodies used, selecting the concentration 
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that gave the greatest fold shift between cells stained with antibody and cells 
stained with the same concentration of a matched isotype control; when there were 
more than 1 million cells in a sample they were divided into tubes of not more than 1 
million cells for staining. Cells were examined using a CyAN ADP 9 colour flow 
cytometer (Beckman Coulter) and data analysed using FlowJo software (Treestar). 
 
Table 2-5: Antibody panel for flow cytometry on subcutaneous biopsies 
Laser  Filter Antigen/ target Clone Manufacturer Conjugate  
488nm 575/25 EPCR RCR-252 BD1 PE 
613/20 CD31 MEM-05 Exbio praha PEdynomics590 
680/30 ICAM-1 HCD54 Biolegend PEcy5 
405nm 530/40 Viability marker Live dead 
yellow 
Invitrogen N/A 
633nm 665/20 Thrombomodulin  501733 R&D APC 
750LP2 CD45 2D1 BD APCcy7 
1 Becton Dickinson; 2 LP= long pass 
 
 
2.8 Endothelial cell culture 
Primary human umbilical vein endothelial cells (HUVEC) at passage one (P1) were 
obtained from Promocell (Germany) and cultured according the manufacturer’s 
instructions using a commercial endothelial cell growth medium with 2% serum and 
added growth factors (Endothelial cell growth medium, Promocell). Briefly, cells 
were grown in sterile plastic tissue culture flasks (BD Falcon, USA) maintained at 
37°C and 5% carbon dioxide in a humidified tissue culture incubator. Medium was 
changed every 2-3 days and cells were passaged using 0.04% trypsin/ 0.03% 
ethylenediaminetetraacetic acid (EDTA [Promocell]) to detach the cells and trypsin 
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was neutralized with 0.05% trypsin inhibitor (1 to 1 ratio to trypsin/EDTA; Promocell) 
and seeded into 2 new culture flasks at 90-100% confluence. Cells used were 
between passage 4 and 6.  
To prepare cells for use for flow cytometry cells were washed with sterile PBS and 
detached using Accutase (Invitrogen, USA); a cell detachment solution that does not 
remove surface receptors, does not require neutralization and has minimal effect on 
cell viability. Surface staining was performed as described in section 2.7.3.  
2.8.1 Malaria parasite culture 
Malaria parasites used in this study were a lab adapted P. falciparum line, ItG. 
Parasite culture was performed according to the protocol used in the Craig 
laboratory (Adams, Turner et al. 2000). Parasites were grown in human red blood 
cell culture in complete RPMI-1640 medium supplemented with 10% pooled Human 
serum.  Cultures were maintained at 37°C in plastic tissue culture flasks which were 
filled with a gas mix of 1% oxygen, 3% carbon dioxide and 96% nitrogen prior to 
sealing. Medium was changed and parasitaemia checked every 2 days with smears 
taken to determine the stage and parasitaemia; parasitaemia was maintained below 
10% and new red cells were added to maintain a haematocrit of 1-2%.  
2.8.1.1 Parasite culture medium 
Under aseptic conditions in a laminar flow hood, mix: 
• 500mls!RPMIW1640!(Sigma,!USA)!
• 18.75ml!HEPES!(Sigma)!
• 5ml!20%!Glucose!solution!(7mM;!Sigma)!
• 3ml!1M!Sodium!Hydroxide!solution!(Sigma)!
• 1.25ml!Gentamicin!Sulphate!solution!(25ng/μl;!Sigma)!
• 5ml!200mM!Glutamine!solution!(Invitrogen)!
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Remove 100mls of this medium for washes. Add 40mls pooled human serum and 
sterile filter.  
 
 
2.9 Data entry 
The procedure was different for comatose patients recruited in the paediatric 
research ward (retinopathy positive cerebral malaria, retinopathy negative cerebral 
malaria, non-malarial coma) and for other patients (healthy controls, mild non-
malarial febrile illness, uncomplicated malaria). Comatose patients recruited on the 
research ward were recruited into a larger study on cerebral malaria pathogenesis 
of which this was one of several sub-studies. Patient information was recorded a 
standardized clinical research form (CRF) with additional details recorded in the 
patient notes. Data was double entered into a study database by a data entry team 
at the Blantyre Malaria Project. In contrast all other patients were recruited 
specifically for this study either in accident and emergency (uncomplicated malaria 
and mild non-malarial febrile illness) or in the paediatric surgical department prior to 
elective surgery (healthy controls). The recruiting nurses entered information from a 
standardized CRF onto laptop computers, using a custom designed MySQL7 based 
database. The database used simple drop down menus and required all information 
to be entered before it would allow submission. Backup was performed each day 
onto an encrypted hard drive. A paper version of the CRF was also completed as 
additional backup and the paper versions were compared against the electronic 
data each week at a team meeting by the author and the nurses to ensure accuracy. 
Information from the MySQL platform was then imported into spreadsheets for 
statistical analysis.  
                                                
7 An open source database management system: www.mysql.com 
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2.10 Statistical Analysis  
 
Statistical analysis was performed using Stata (version 11; StataCorp, USA) and 
Prism (version 5.0, GraphPad, USA) software. A conventional 5% alpha level was 
used throughout. 
 
2.10.1 Continuous data 
For the comparison of two groups a Student’s t-test was used to compare data that 
was normally distributed and the Mann-Whitney U test was used to compare groups 
for data that was not normally distributed. When multiple groups (3 or more) were 
compared, to adjust for multiple comparisons, the Tukey Honestly Significant 
Difference (HSD) test was used (Hsu 1996). Data was assumed to have either a 
normal or log normal distribution. All tests were two tailed. 
Correlation between two variables was assessed using a Pearson’s correlation 
coefficient (r) for normally distributed data or Spearman’s rank correlation coefficient 
for data that was non-normally distributed.  
Results of normally distributed data are reported as means and their 95% 
confidence intervals, of non-normally distributed data as medians and interquartile 
ranges and of log normal data as geometric means and their 95% confidence 
intervals.
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COAGULATION AT THE 
ENDOTHELIAL SURFACE IN POST-
MORTEM SAMPLES FROM 
MALAWIAN CHILDREN WITH 
CEREBRAL MALARIA 
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3.1 Introduction 
While coagulation is increasingly being proposed to be involved in cerebral malaria 
pathogenesis (van der Heyde, Nolan et al. 2006; Francischetti, Seydel et al. 2008; 
Milner 2010), evidence of dysregulation of coagulation in cerebral malaria is largely 
limited to data on coagulation in the peripheral circulation in non-immune adults 
(Clemens, Pramoolsinsap et al. 1994; Mohanty, Ghosh et al. 1997). These data 
show activation of coagulation (See Chapter 1) in cerebral malaria but this occurs in 
other severe malaria syndromes and, to a lesser extent, even in uncomplicated 
malaria, and is not specific to cerebral involvement.   
Haemorrhagic petechial lesions in the brain at autopsy (Figure 1.4; Chapter 1) have 
been described widely in pathological series in both adults and children (Dudgeon 
and Clarke 1917; Thomas 1971; MacPherson, Warrell et al. 1985; Walker, Salako et 
al. 1992; Taylor, Fu et al. 2004). These have been reported to be associated with 
thrombosis (Taylor, Fu et al. 2004; Dorovini-Zis, Schmidt et al. 2011) but the 
presence or absence of fibrin deposition in the vasculature in cerebral malaria has 
not been evaluated and the underlying mechanism for the haemorrhagic lesions 
remains unclear.  
A bank of post-mortem tissue from a comprehensive post-mortem study in 100 
Malawian children with cerebral malaria and other encephalopathic illnesses gave 
us access to a well-phenotyped tissue bank of cases and controls. To assess the 
presence or absence of thrombosis in the vasculature in cerebral malaria and to 
identify potential mechanisms we performed histology on post-mortem specimens 
from Malawian children with a post-mortem diagnosis of cerebral malaria and 
children who were parasitaemic and died with a clinical diagnosis of cerebral 
malaria but in whom another cause of death was identified at autopsy. We have 
used the autopsy classification definitions determined by previous work (Taylor, Fu 
et al. 2004), classifying children who had parasitaemia and who fulfilled clinical 
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criteria for cerebral malaria during life into three categories (which are described in 
detail in the introduction): 
CM1: Sequestration of iRBC in cerebral vessels and absence of haemorrhagic 
lesions on histology. 
CM2:  Sequestration of iRBC in cerebral vessels and presence of haemorrhagic 
lesions on histology 
CM3: Absence of iRBC sequestration in cerebral vessels on histology§§. 
 
3.2 Staining for fibrin 
3.2.1 Fibrin staining in the brain 
To assess for the presence of fibrin in vessels in the brain in cerebral malaria we 
used the tri-chromic histological staining method on post-mortem formalin-fixed 
paraffin-embedded samples [(Lendrum, Fraser et al. 1962) See description of 
method in Chapter 2]. Brain samples were stained from 7 CM2 cases, 3 CM1 cases 
and 6 CM3 non-CM controls (see Table 3-1 for details of diagnoses). The degree of 
fibrin deposition was assessed first by the author and then, to avoid bias, by 2 
medical pathologists who were blinded to patient diagnosis and unaware of study 
aims. Microvascular fibrin deposition in post-mortem brain samples was significantly 
more common in CM cases than in non-CM controls (Figure 3.1 and Figure 3.2; OR 
19.96, 95% CI 7.05-56.55; P=<0.001). Fibrin was detected in 76% of brain 
microvessels in CM cases compared to 14% of vessels in controls. Large fibrin 
                                                
§§ Identification of an alternative non-malarial cause of death in all CM3 cases in a detailed study (Taylor, Fu et 
al., 2004) is indicative that CM3 cases are not cerebral malaria and for the sake of simplicity we often refer to 
them as such in the chapter. 
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deposits, in which greater than 50% of the vessel lumen contained fibrin, were seen 
in 28% of microvessels in CM cases compared with 2% in controls. Fibrin deposits 
were associated with parasite sequestration (correlation coefficient= 0.60; 
P=<0.001) and frequently fibrin deposits were seen as a layer adjacent to 
endothelium, co-localized with iRBC as indicated by malaria pigment (Panel D; 
Figure 3.1). Microvascular haemorrhage was much less common than fibrin 
deposition occurring in 2.6% of vessels of CM1 and CM2 cases considered together. 
Consistent with their classification, microvascular haemorrhage was seen in only 
one vessel from a CM1 case (0.2%) compared with 3.7% of vessels in CM2 cases.  
Rare microvascular haemorrhage was also seen in the non-CM cases, in 0.7% of 
vessels. Adjacent fibrin deposition was seen in 76% of haemorrhages from CM2 
cases some of which were classical ring haemorrhages (Panel C; Figure 3.1), 
compared with 28% of haemorrhages associated with adjacent fibrin deposition in 
the controls.   
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Figure 3.1 Post-mortem brain specimens stained for fibrin (tri-chromic staining method) in 
cerebral malaria cases and non-cerebral malaria controls.  
In Panel A (x100) red arrows indicate vessels without visible fibrin in non-cerebral malaria control case. 
The arrow on the far right contains red blood cells, which stain yellow with this technique.  In panel B 
(x100) black arrows indicate vessels containing fibrin, which stains red. There are three haemorrhages 
with the one in the box detailed in Panel C and two others adjacent. Panel C (x400) is a detail of the 
box in Panel B with the black arrow indicating a fibrin-containing vessel at the centre of a ring 
haemorrhage. Panel D (x1000) shows red fibrin staining abutting endothelium at the edge of a vessel 
and co-localisation of malarial pigment (black dots shown by black arrow), indicative of iRBC adherent 
to the endothelial surface. 
A"
D"C"
B"
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Figure 3.2: Fibrin staining in blood vessels in cerebral malaria cases and non-cerebral malaria 
controls. 
The degree of fibrin accumulation was scored in 50 cerebral blood vessels from each of 10 cerebral 
malaria cases and 6 non-cerebral malaria controls as: none, less than 50% of the vessel lumen 
containing fibrin staining and greater than or equal to 50% of the vessel lumen containing fibrin. The 
left sided graph shows this as a scatter plot with data points indicating the percentage of vessels 
scored at each level in individual cases and horizontal lines the mean percentage of vessels scored at 
each level for the cerebral malaria or non-cerebral malaria group as a whole. The right-sided graph 
shows this same information but also includes scoring for the number of parasites in the vessels. The 
quantity of Plasmodium falciparum-infected red blood cell (iRBC) sequestration was scored semi-
quantitatively in each vessel as 0 [no parasites], 1 [1-5 parasites], 2 [5-10 parasites] or 3 [>10 
parasites]. The height of the bars indicates the proportion of vessels that were scored in each category 
for cerebral malaria cases (blue) and non-cerebral malaria controls (red) and the type of shading in the 
bars indicates the amount of iRBC sequestration in those vessels.  
 
 
 
  
0
20
40
60
80
100 Cerebral malaria 
 Controls
Fibrin staining in blood vessels
%
 B
lo
od
 v
es
se
ls
None <50% ≥50% 
0
20
40
60
80
100
0
1
2
3
Level of iRBC 
sequestrationCM
Controls
%
 B
lo
od
 v
es
se
ls
None !50% <50% 
% of blood vessel lumen containing fibrin  
Fibrin staining in blood vessels 
Chapter 3: Post-Mortem samples 
 99 
Case (Diagnosis) Haemorrhagic lesions*** 
% vessels 
containing 
fibrin††† 
EPCR   
Brain‡‡‡ 
CD34    
Brain§§§ TM SC.
**** 
Non CM 1 (Head trauma) No 15 Moderate Strong - 
Non CM 2 (Pneumonia) No 8 Moderate Moderate Strong 
Non CM 3 (Pneumonia) No 9 Weak - Moderate 
Non CM 4 (Pneumonia & Reye's syndrome) No 0 Moderate Weak Moderate 
Non CM 5 (Heart failure) No 3 Moderate Strong Moderate 
Non CM 6 (Ruptured AVM††††) No 44 - Strong Strong 
CM 1 Yes 52 Weak Moderate - 
CM 2 Yes 78 Weak Weak Weak 
CM 3 Yes 64 Weak Moderate Strong 
CM 4 Yes 85 Weak Moderate Moderate 
CM 5 Yes 34 Weak Strong Strong 
CM 6 Yes 46 - - - 
CM 7 Yes 76 - - - 
CM 8 No 80 - - Weak 
CM 9 No 76 - - - 
CM 10 No 53 - - - 
                                                
***Denotes whether or not perivascular hemorrhages were seen at histological examination 
†††  Denotes the overall percentage of vessels that contained fibrin staining using tri-chromic staining. 
‡‡‡ Denotes the overall staining intensity for EPCR in post mortem brain sections by immunostaining as scored by 
two independent scorers blinded to diagnosis. 
§§§ Denotes the overall staining intensity for CD34 in post mortem brain sections by immunostaining as scored by 
two independent scorers blinded to diagnosis. 
**** Denotes the overall staining intensity for thrombomodulin (TM) in postmortem subcutaneous (SC) sections 
by immunostaining as scored by two independent scorers blinded to diagnosis. 
††††  Cerebral arterio-venous malformation (AVM) 
-   Indicates that no suitable specimen was available for scoring due to limitations of samples and damage to 
small and delicate samples during antigen retrieval and staining.  
 
 
Table 3-1: Details of post-mortem cases 
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3.2.2 Fibrin staining in the Gut and Skin  
To assess whether fibrin accumulation was specific to the brain of children with 
cerebral malaria we performed tri-chromatic staining on post-mortem samples of the 
small intestine of the gut, an organ with levels of iRBC sequestration comparable 
with the brain (Seydel, Milner et al. 2006). iRBC sequestration in this organ was 
concentrated in the network of microvessels around, and in the tissue adjacent to, 
the intestinal villi (Figure 3.3, Panel B). Despite high levels of sequestration, fibrin 
deposition was rare, seen only in a few vessels per slide and was associated in most 
instances by visible malaria pigment indicating iRBC sequestration (Figure 3.3, 
Panel D). Adequate penetration of the stain into the tissue was demonstrated by 
staining of smooth muscle fibres, which stain red- orange with this technique  (Figure 
3.3, Panel D). 
 
Chapter 3: Post-Mortem samples 
 101 
 
Figure 3.3: Post-mortem gut samples from cerebral malaria cases stained for fibrin (tri-
chromatic method). 
Panel A (x100) is a micrograph showing a typical appearance in the gut in cerebral malaria cases with 
no fibrin deposits visible, the grey arrow indicates orange- red staining of a smooth muscle fibre. Panel 
B (x400) is a detail of the box in Panel A showing vessels with high iRBC sequestration, as indicated by 
malarial pigment [black dots] but no fibrin deposits. Panel C (x100) is a micrograph showing a vessel 
containing fibrin deposits [vessel in box]. Panel D (x400) is a detail of the area in the box; the black 
arrow shows a small fibrin deposit and the white arrows show iRBC sequestration seen by the presence 
of malarial pigment (the pigment by the lower arrow is only faintly visible). As previously some of the 
smooth muscle fibres stain orange- red (grey arrow). 
 
3.3 Endothelial protein C receptor staining 
3.3.1 Endothelial protein C receptor staining in the brain 
To assess whether thrombosis was associated with loss of endothelial anticoagulant 
function we performed immunoperoxidase staining using monoclonal antibodies 
A"
D"C"
B"
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against EPCR and thrombomodulin on post-mortem formalin-fixed paraffin-
embedded samples. In samples from the non-cerebral malaria (CM3) controls 
vessels exhibited consistent moderate- strong staining for EPCR. Staining in the 
cerebral malaria (CM2) cases was patchy with decreased or absent staining tending 
to occur in vessels with high iRBC sequestration often with moderate staining in 
parasite free vessels in close proximity (Figure 3.6). Scoring of the intensity of 
staining was performed by the author and then by two independent pathologists. 
EPCR staining in cerebral microvessels was weaker in the 5 cerebral malaria (CM2) 
cases than in the 5 non-cerebral controls (Figure 3.5; OR 0.048; 95% CI 0.012-0.20; 
p=<0.001). EPCR staining was weak in all 5 cerebral malaria cases and was 
moderate in 4 and weak in 1 non-CM case (Table 3-1). There was a negative 
association between EPCR staining and parasites (correlation coefficient= -0.57; 
P=<0.001); and this remained highly significant when considering CM2 cases alone 
(correlation coefficient= -0.24; p=<0.001). In a few vessels in which adjacent 
sections were available with tri-chromatic staining there was fibrin accumulation in 
areas where EPCR staining was absent (Figure 3.4). As other groups (Maruyama, 
Bell et al. 1985; Ishii, Salem et al. 1986; Laszik, Mitro et al. 1997), we did not detect 
thrombomodulin staining in cerebral microvessels using immunoperoxidase staining 
in cases or controls, with thrombomodulin staining seen only seen in choroid vessels 
(data not shown).   
 
Chapter 3: Post-Mortem samples 
 103 
 
Figure 3.4: Post-mortem brain specimens incubated with a monoclonal antibody against EPCR 
(immunoperoxidase method) or stained for fibrin (tri-chromic staining method).  
Panels A-C show immunostaining for endothelial protein C (EPCR) and panel D shows tri-chromic 
staining [fibrin stains red and red blood cells stain yellow]. Panel A (x100) shows vessels with strong 
staining for EPCR (arrows) in a control brain sample. Panel B (x100) shows vessels with absent 
staining for EPCR (arrows). Panel C (x400) is a detail of vessel in Panel B (box) showing sequestered 
parasites ([black dots], arrow). Panel D (x400) shows an adjacent tissue section stained with the tri-
chromic (M.S.P) method, demonstrating areas of fibrin accumulation (arrow, [red]). 
 
A"
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Figure 3.5: EPCR staining in blood vessels in the brain in cerebral malaria cases and non-
cerebral malaria controls.  
The intensity of EPCR staining was scored in 50 cerebral blood vessels from each of 5 cerebral malaria 
cases and 5 non-cerebral malaria controls as none, weak, moderate or strong based on reference 
micrographs. The left sided graph shows this as a scatter plot with data points indicating the percentage 
of vessels scored at each level in individual cases and horizontal lines the mean percentage of vessels 
scored at each level for the cerebral malaria or non-cerebral malaria group as a whole. The right-sided 
graph shows this same information but for the CM2 cases includes an indication of the amount of 
parasites in the vessels. The quantity of Plasmodium falciparum-infected red blood cell (iRBC) 
sequestration was also scored semi-quantitatively in each vessel as 0 [no parasites], 1 [1-5 parasites], 2 
[5-10 parasites] or 3 [>10 parasites]. The height of the bars indicates the proportion of vessels that 
stained each intensity for the cerebral malaria cases (blue) and non-cerebral malaria controls (red) and 
the shading in the bars indicates the amount of iRBC sequestration in those vessels.  
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Figure 3.6: Plasmodium falciparum-infected red blood cell sequestration is associated with low 
or absent staining for endothelial protein C receptor in cerebral vessels.  
Panels B, C, D and E are micrographs from post mortem tissue from four different fatal cerebral malaria 
cases (x400). Panel A is a low power view (x100) with Panel B (x400) a detail of the area in the box. 
Black arrows indicate regions of moderate or strong staining for EPCR in vessels (or regions of vessels) 
with low iRBC sequestration, red arrows indicate vessels with low or absent staining for EPCR in 
vessels containing high levels of iRBC sequestration (black dots).  
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3.3.2 CD34 staining in the brain 
To assess whether loss of EPCR and thrombomodulin was due to complete loss of 
the endothelial layer or to loss of all endothelial receptors we assessed the pattern of 
staining of a constitutive endothelial marker in vessels in the brain in cerebral malaria. 
We performed CD34 staining on post-mortem brain specimens from cerebral malaria 
cases and non-cerebral malaria controls. CD34 was chosen rather than CD31 as 
longer heat retrieval times were required for CD31 to achieve adequate staining, 
resulting in greater damage to the tissue. The pattern of CD31 staining was similar to 
that of CD34 (Figure 3.8). In non-cerebral malaria control (CM3) cases, vessels 
exhibited consistent moderate- strong staining for CD34. In cerebral malaria (CM2) 
cases the intensity of staining was similar but staining was patchy with moderate- 
strong CD34 staining in some vessels and faint or absent staining in others. Faint or 
absent staining was seen in vessels containing sequestered iRBC (Figure 3.7 Panels 
B and D) but also in iRBC free vessels (Figure 3.7 Panels B and C). To determine 
whether CD34 staining was decreased in cerebral malaria, the level of CD34 staining 
in microvessels in brain specimens from 5 cerebral malaria cases and 5 non-cerebral 
malaria controls was assessed first by the author and then by two medical 
pathologists blinded to patient diagnosis. In the non-cerebral malaria controls CD34 
staining was strong in 3 cases, moderate in 1 case and weak in 1 case and among 
the cerebral malaria cases CD34 staining was strong in 1 case, moderate in 3 cases 
and weak in one case (Table 3-1).   These data indicate that there may be some loss 
of a constitutive receptors other than EPCR in the brain but that the EPCR loss is not 
explained merely by loss of the endothelial layer.  
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Figure 3.7: Post-mortem brain specimens from cerebral malaria cases and non-cerebral controls 
incubated with a monoclonal antibody against CD34 (immunoperoxidase method).  
Panel A (x100) shows a micrograph from a non-cerebral malaria control in which vessels exhibit 
moderate- strong staining for CD34. Panel B (x100) shows a micrograph from a cerebral malaria case 
in which vessels exhibit variable degrees of CD34 staining. Red arrows show vessels containing 
sequestered iRBC, indicated by malarial pigment, some of which have low CD34 staining (top right 
arrow) and some moderate CD34 staining (middle and bottom left arrow). Panel C (x400) is a detail of 
the box in Panel B with the red arrow indicating a vessel containing sequestered iRBC with moderate 
CD34 staining and the black arrow indicating a vessel with minimal iRBC sequestration and low CD34 
staining. Panel D (x400) shows a micrograph from a cerebral malaria case; the red arrow indicates a 
vessel with iRBC sequestration and low CD34 staining and the black arrow indicates a iRBC free vessel 
with moderate- strong staining. White circles on the images are artefacts from air bubbles under the 
slide coverslip.  
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Figure 3.8: Comparison of immunohistochemical staining with antibodies against CD34 and 
CD31 in post-mortem brain specimens.  
Both panels are x100 and are samples from non-cerebral malaria controls (CM3).  
 
3.4 Thrombomodulin and EPCR staining in the Gut and in 
Subcutaneous tissue.  
To determine the pattern of thrombomodulin and EPCR expression in other 
tissues in which iRBC sequestration occurs we performed immunoperoxidase 
staining on post-mortem tissue samples of small intestine from the gut, a tissue with 
high iRBC sequestration and the subcutaneous adipose tissue layer of the skin, a 
tissue with moderate iRBC sequestration (Seydel, Milner et al. 2006). In samples 
from non-cerebral malaria cases (CM3) there was consistent thrombomodulin and 
EPCR scoring in both tissues. In contrast in cerebral malaria (CM2) cases, staining 
for both receptors was patchy and frequently areas of low or absent staining were 
associated with iRBC sequestration; vessels with iRBC sequestration and low 
staining were often observed in close proximity to iRBC free vessels with high 
staining (Figures 3.9-3.12). The overall intensity of thrombomodulin staining in 
subcutaneous specimens from 5 cerebral malaria (CM2) and 5 non-cerebral malaria 
(CM3) controls were assessed by the author and by 2 independent medical 
CD34 CD31 
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pathologists. Staining was moderate or strong in all the non-cerebral malaria controls 
whereas staining was weak in 2 of the cerebral malaria cases (Table 3-1). Scoring of 
gut samples was not attempted due to the difficulty in identifying individual 
microvessels given the morphology of the tissue.  
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Figure 3.9: Thrombomodulin staining in post-mortem gut specimens from cerebral malaria 
cases and non-cerebral malaria controls.  
Panel A is a micrograph (x100) from a non-cerebral malaria control and Panels B (X400) and C (x200) 
are from cerebral malaria cases. Black arrows indicate vessels with moderate to strong staining and red 
arrows indicate vessels containing iRBC, as indicated by malaria pigment (black dots), which have low 
thrombomodulin staining.   
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Figure 3.10: EPCR staining (immunoperoxidase method) in post-mortem gut specimens from 
cerebral malaria cases and non-cerebral malaria controls.  
Panel A is a micrograph (x100) from a non-cerebral malaria control showing consistent strong EPCR 
staining in the network of microvessels around the intestinal villi. Panel B (X100) is a micrograph from a 
cerebral malaria case showing patchy EPCR staining in the network of microvessels around the 
intestinal villi with areas of strong staining and areas of weak or absent staining. Panel C (x400) is a 
detail of the box in Panel B showing an area in which EPCR staining is weak. Red arrows indicate 
sequestered malaria infected red blood cells, visible by the presence of malaria pigment [black dots], in 
vessels with low EPCR staining.  
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Figure 3.11: Thrombomodulin staining in post-mortem subcutaneous tissue specimens from 
cerebral malaria cases and non-cerebral malaria controls.  
Panel A (x100) and Panel B (x400) are micrographs from non-cerebral malaria controls; Panel B is a 
detail of the box in Panel A (x100) showing vessels with high thrombomodulin staining, indicated by 
black arrows. Panels C to G are micrographs from cerebral malaria cases; Panel D (x400) is a detail of 
the box in Panel C (x100) and Panels F and G (x400) are details of the boxes in Panel E. Black arrows 
indicate moderate to high thrombomodulin staining in vessels without malaria infected red blood cells 
and red arrows indicate low thrombomodulin staining in vessels containing malaria infected red blood 
cells, as indicated by malarial pigment [black dots].  
A"
F"
D"C"
B"
E"
G"
Chapter 3: Post-Mortem samples 
 113 
 
 
Figure 3.12: EPCR staining in post-mortem subcutaneous tissue samples from cerebral cases 
and a non-cerebral malaria control.  
Panel A (x100) is a micrograph from a non-cerebral malaria control; black arrows indicate vessels with 
moderate-strong staining for EPCR. Panel B (x400) is a detail of the box in Panel A showing a vessel 
with moderate-strong EPCR staining. Panel C (x100) is a micrograph from a cerebral malaria case, red 
arrows indicate vessels with absent or low EPCR staining. Panel D (x400) is a detail of a vessel in the 
box in Panel C and Panel E is another detail view of a vessel from a cerebral malaria case both with 
minimal EPCR staining and iRBC sequestration indicated by malarial pigment [black dots].  
 
 
3.5 Discussion 
Cerebral malaria is associated with thrombosis in the microvasculature of the 
brain.  
The concept that haemorrhagic lesions seen in the brain in fatal cerebral malaria 
indicate intravascular coagulation is not new, having been proposed nearly 100 
years ago by Dudgeon and Clarke (Dudgeon and Clarke 1917). However although 
A"
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observed in other pathological series (MacPherson, Warrell et al. 1985; Silamut, Phu 
et al. 1999) there has been contention as to whether or not the lesions are indicative 
of coagulopathy with severe thrombi causing vessel damage and bleeding due to 
local consumption of clotting factors in the thrombus. An alternative explanation has 
been that haemorrhage is due to rupture of the vessels with extravasation of RBC as 
a result of increased intraluminal pressure secondary to obstruction by iRBC 
(Silamut, Phu et al. 1999). Thrombosis might then occur secondarily as a result of 
the vessel damage. In essence the two theories imply opposite directions of 
causality. This contention has previously been unresolved as surprisingly there have 
been no published studies in which a fibrin specific stain has been used. The 
availability of a bank of post- mortem tissue from a well-characterized cohort of 
children who have died from cerebral malaria and other encephalopathies (Taylor, 
Fu et al. 2004) allowed us to explore this question. Although the method used does 
not allow us to prove causality, the finding of marked fibrin accumulation in vessels 
with and without haemorrhagic lesions and the fact the presence of fibrin in the 
vessel outnumbers the presence of haemorrhage by over 10 times is strongly 
suggestive of a coagulopathic aetiology. In addition a coagulopathic origin is 
supported by the co-localisation of iRBC and fibrin (even in the absence of 
haemorrhage) and the presence of fibrin in the majority of vessels containing 
haemorrhage (76%) but with most fibrin containing vessels not being associated with 
haemorrhage. It is important to state that not every haemorrhage was seen to be 
associated with fibrin staining but considering the three dimension profile of most 
ring haemorrhages with a ring of haemorrhage occurring around a central thrombus 
this does not exclude that these haemorrhages are also caused by thrombosis, as 
observations were made on 4 µm slices of tissue and so the thrombus could be 
present in tissue immediately adjacent to the slice. Nonetheless, whether or not the 
haemorrhagic lesions are caused by thrombosis, the very high levels of fibrin present 
compared with a much lower level of haemorrhage shows that significant thrombosis 
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occurs in the microvessels of the brain in cerebral malaria and cannot be accounted 
for merely by clotting secondary to vessel rupture. 
 
Involvement of coagulation in cerebral malaria pathogenesis 
The observation of thrombosis in fatal disease does not itself demonstrate that 
coagulation is involved in cerebral pathogenesis in vivo. A limitation of dependence 
on data from post-mortem samples in this study is the possibility that the thrombosis 
observed has occurred in the agonal stages of illness. While it is not possible to 
observe the brain directly in vivo to detect haemorrhagic lesions and fibrin deposition, 
retinal vessel, which have the same embryological origin as cerebral vessels 
represent a ‘window into the brain’ (Beare, Taylor et al. 2006). The in vivo 
observation of similar microvascular lesions in retinal vessels and their high 
correlation to cerebral haemorrhages in fatal cerebral malaria cases (White, 
Lewallen et al. 2001) strongly suggests that coagulopathy and fibrin deposition 
occurs in non-fatal disease. In addition the extent of fibrin accumulation, with 65% of 
vessels containing visible fibrin when compared with only 13% in a control group that 
also died with an encephalopathic illness15, in conjunction with the lack of fibrin 
deposition in samples from the gut, indicate that this is not a non-specific agonal 
process.  
With respect to the involvement of coagulation in cerebral malaria pathogenesis, it 
has been proposed that coagulation is only important in a small number of 
individuals with very severe disease (Clemens, Pramoolsinsap et al. 1994). The 
evidence given to support this assertion was that mucosal bleeding, taken as a 
                                                
15 Although overall the CM3 controls had 13% of vessels containing visible fibrin, a large proportion of 
this is contributed by a single case that died of a ruptured arterio-venous malformation in which 44% of 
the vessels contained visible fibrin (non-CM 6, Table 3-1). That a case dying of cerebral hemorrhage 
has significant evidence of coagulation is unsurprising. 
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marker of disseminated intravascular coagulation, occurs in only 5% of severe 
malaria cases in southeast Asian adults. However that argument assumes that 
activation of coagulation is only important when systemic decompensation of the 
coagulation system occurs. The demonstration in this study that marked fibrin 
accumulation occurred in all 10 cerebral malaria cases, none of whom had 
significant mucosal bleeding and including the 3 CM1 cases, in which no 
haemorrhagic lesions were observed, implies that in African children intravascular 
thrombosis in the microvasculature can occur without progression to disseminated 
intravascular coagulation. In addition, advances in our understanding of the cross-
talk between coagulation and other key physiological mechanisms (Esmon, Taylor et 
al. 1991), particularly with regards to the protein C pathway implicated here, make it 
very likely that the extensive coagulation observed has wider implications for 
pathogenesis. Indeed the minimal thrombosis seen in the gut in this study and the 
focus of haemorrhagic lesions on the cerebral (and retinal) vessels observed in this 
and in other studies (Thomas 1971; Walker, Salako et al. 1992; Taylor, Fu et al. 
2004) implies that in African children with cerebral malaria coagulopathy may be 
largely restricted to the brain.  
 
Loss of protein C receptors explains microvascular thrombosis and cerebral 
specificity 
The association of fibrin deposition with iRBC sequestration and the frequent 
observation of fibrin deposits lining the endothelial surface (Figure 3.1) indicate the 
possibility of a defect in endothelial anticoagulant function. The absence of fibrin 
deposition in the gut despite high iRBC sequestration, and minimal haemorrhagic 
lesions noted in other organs in other post-mortem studies, contrasted with marked 
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fibrin deposition in the brain, indicates a process that more readily occurs in cerebral 
vessels. Loss of the protein C pathway receptors EPCR and thrombomodulin 
seemed a strong candidate because: (1) dysfunction of this pathway has been 
implicated in the coagulopathy of other conditions including bacterial sepsis (Faust, 
Levin et al. 2001), dengue haemorrhagic fever (Cabello-Gutierrez, Manjarrez-Zavala 
et al. 2009) and Crohn’s disease (Scaldaferri, Sans et al. 2007); (2) a 
hypercoagulable mouse model with a partial thrombomodulin knockout resulted in 
cerebral fibrin deposits (Maroney, Cooley et al. 2008) and (3) Factor V Leiden, a 
genetic defect in the protein C pathway, is a risk factor for paediatric stroke (Herak, 
Antolic et al. 2009). Furthermore two key endothelial receptors involved in regulation 
of the protein C pathway - thrombomodulin and EPCR - are constitutively expressed 
at lower levels in the brain than in the systemic circulation (Boffa, Jackman et al. 
1991; Wong, Hofman et al. 1991; Laszik, Mitro et al. 1997); suggesting that the brain 
might be more vulnerable to decompensation of this pathway than other organs.  
Therefore, to explore the hypothesis that iRBC sequestration was associated with 
dysfunction in the protein C pathway we used the immunoperoxidase staining 
method to detect EPCR and thrombomodulin expression on formalin-fixed and 
paraffin-embedded specimens from CM2 and CM3 cases. Confirming our hypothesis, 
in the brain EPCR staining was reduced in CM2 when compared with CM3 cases 
and loss was associated with the presence of iRBC. In the gut and subcutaneous 
tissue there was observed loss of both thrombomodulin and EPCR in vessels 
containing iRBC. Direct comparison of the relative expression between organs, to 
determine whether there was less EPCR in the brain than in the gut or subcutaneous 
tissue, was not possible because of variations in antigenicity of different tissues 
following fixation. However qualitatively it did appear that complete loss of EPCR 
staining was more common in the brain. Real time PCR might be a useful method to 
compare expression between tissues although it is also imperfect because it would 
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measure expression in a heterogenous piece of tissue containing both endothelial 
cells and other cells and the composition of cell types is different in different tissues. 
Laser microdissection of the endothelial layer might address this problem.  
A limitation of this study is that, as other groups (Maruyama, Bell et al. 1985; Ishii, 
Salem et al. 1986; Laszik, Mitro et al. 1997), we were unable to detect 
thrombomodulin in the brain and therefore could not demonstrate whether or not 
thrombomodulin is lost in the brain alongside EPCR. Very low levels of 
thrombomodulin expression have been demonstrated in cerebral microvessels of 
unfixed samples (Wong, Hofman et al. 1991) and by quantitative real time PCR 
(Tran, Wong et al. 1996; Wang, Tran et al. 1997); implying that failure to detect 
cerebral thrombomodulin in this study was due to lack of sensitivity to detect low-
level expression or corruption of the staining epitopes by fixation rather than 
complete absence. Frozen material for more sensitive immunofluorescence (Wong, 
Hofman et al. 1991) or RNA in-situ hybridization (Tran, Wong et al. 1996) were not 
available. Concurrent loss of thrombomodulin with EPCR in iRBC containing vessels 
in the brain in cerebral malaria is supported by loss of both receptors in 
subcutaneous tissue in this study (Figure 3.9, Figure 3.10), and by concurrent loss of 
these receptors in other diseases (Faust, Levin et al. 2001; Laszik, Zhou et al. 2001; 
Scaldaferri, Sans et al. 2007). 
As with the demonstration of fibrin a limitation of the demonstration of EPCR and 
thrombomodulin expression in post-mortem tissue is that it is possible that the loss of 
receptor expression occurred as a peri-morbid event. The pattern of staining, with 
moderate or strong staining frequently occurring in close proximity to the areas of 
faint or absent staining, and the consistent moderate- strong staining in the CM3 
controls make this explanation less likely. However it does not exclude that a 
complication specific to cerebral malaria causes this but only occurs in end stage 
disease. The macroscopic examination of vessels in the retina that provides strong 
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supportive evidence for the presence of fibrin in vivo is not applicable to observe 
receptor expression, which requires direct access to tissue. Since it is not possible to 
safely access cerebral or retinal endothelium in vivo, to assess whether or not EPCR 
and thrombomodulin are lost in cerebral malaria in non-fatal disease, we developed 
a model to examine the phenotype of subcutaneous endothelium ex vivo, which is 
discussed in Chapter 4.  
Possible causes for the loss of protein C receptor staining include: (1) cell death due 
to necrosis or apoptosis (2) receptor shedding and (3) downregulation. Although we 
cannot exclude cell death as the primary cause, it seems unlikely: firstly even in 
regions with complete receptor loss, cell nuclei were present, exhibited normal 
morphology and haematoxylin staining (Figure 3.4, Panel B); secondly we would 
expect cell death in such large areas of endothelium to be accompanied by vessel 
leak due to loss of endothelial integrity but, while leak in very focal areas of the brain 
and retinal vasculature is described, leak and oedema outside of the brain is not a 
prominent feature in cerebral malaria; thirdly, were the loss due to cell death we 
would expect all endothelial receptors to be lost equally and while the constitutive 
endothelial marker CD34 was also at times reduced at sites of iRBC sequestration, 
loss was not as consistent as for EPCR, and overall the staining for CD34 was little 
different in cases compared to controls. These observations make downregulation or 
receptor shedding seem more likely explanations and we have shown increased 
thrombomodulin shedding in cerebral malaria (Chapter 6) and this is associated with 
loss of receptor in ex vivo samples (See Chapter 4).  
Downregulation of thrombomodulin has been shown to occur in response to raised 
TNF levels and cerebral malaria is associated with raised TNF levels [(Grau, Taylor 
et al. 1989; Kwiatkowski, Hill et al. 1990); Chapter 6]. However against a TNF 
directed mechanism, similar levels of TNF have been shown in uncomplicated 
malaria compared to cerebral malaria (Lovegrove, Tangpukdee et al. 2009) and we 
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found a number of cerebral malaria cases with low levels of TNF (Chapter 6).  A 
mechanism that explains better the close localization of receptor loss with 
sequestered iRBC is iRBC receptor-ligand interactions with the endothelium. In 
support of this, changes in the expression of other receptors have been shown to be 
due to iRBC induction of endothelial signalling pathways (Tripathi, Sullivan et al. 
2006; Chakravorty, Carret et al. 2007; Jenkins, Wu et al. 2007) and indeed a contact 
dependent mechanism has been shown to induce tissue factor expression on the 
endothelial surface (Francischetti, Seydel et al. 2007). Receptor cleavage occurs in a 
number of inflammatory conditions (Blobel 2002) and increased thrombomodulin 
shedding from cultured endothelium in vitro is induced by serum from patients with 
severe P. falciparum malaria (Hemmer, Bierhaus et al. 1994). Possible candidates 
for this are matrix metaloproteases (MMP), neutrophil elastase and parasite (Gillrie, 
Lee et al. 2012) or human (Xu, Zhang et al. 2009) histones.  
It is important to state that the proposed link between iRBC sequestration, fibrin 
thrombi and loss of protein C pathway receptors is inferred by an observed 
association and does not prove a causal link. It is possible that our observations do 
not represent a specific process or processes linked to iRBC sequestration but rather 
a non-specific ‘storm’ of events that simply causes disruption in a number of 
endothelial pathways. While the CM3 non-cerebral malaria controls who also died, 
provide good evidence that these processes do not occur simply because these 
children were very sick, it remains possible that both fibrin production and loss of 
protein C receptors are caused by another primary event that causes a non-specific 
endothelial insult. This is addressed partially through the use of an ex vivo technique 
described in chapter 4 but further work to investigate the underlying mechanism for 
this defect could be explored through use of an in vitro endothelial model in which 
causality can be directly demonstrated. However the localized pattern of protein C 
loss and fibrin deposition and the cerebral specificity of fibrin deposition indicate 
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against such a non-specific event. Furthermore while it is plausible that loss of 
protein C receptors is not the primary event in cerebral malaria pathogenesis, 
identification of involvement of this pathway is important because of the wide ranging 
effects it has on inflammation and endothelial homeostasis, and because there are a 
range of potential therapeutic agents to target this pathway.  Indeed while not shown 
to be the primary event in the pathogenesis of bacterial sepsis, identification of 
defects in the protein C pathway and the use of therapies directed at this pathway 
led to the first adjunctive therapy to demonstrate improvements of outcome in sepsis 
(Bernard, Vincent et al. 2001) with greater success than therapies directed at any 
other pathway. 
Summary: loss of protein C receptors links iRBC sequestration to coagulation 
and inflammation 
 We have demonstrated that in cerebral malaria marked fibrin deposition occurs in 
the microvasculature of the brain at sites of iRBC sequestration but not in other 
organs. We have also shown that iRBC sequestration is associated with localized 
loss of endothelial anti-coagulant function in a key endothelial homeostatic 
mechanism, as indicated by the loss of the protein C pathway receptors EPCR and 
thrombomodulin. Because the protein C pathway regulates coagulation (Esmon 
2001), inflammation (Esmon, Taylor et al. 1991) and endothelial permeability 
(Niessen, Furlan-Freguia et al. 2009) and is a critical protection against neuronal 
damage (Zlokovic and Griffin 2011), this localized defect can potentially link major 
pathogenic components of the disease. To further explore whether this same effect 
occurs and is important in vivo we developed a novel ex vivo technique to look at 
biopsies of subcutaneous tissue (Chapter 4).  
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4.1 Introduction 
To confirm that endothelial changes observed post-mortem occurred in non-fatal 
disease we required an ex vivo method to examine endothelial phenotype. Since it 
is clearly not ethically feasible to sample tissue from the brain in vivo we needed to 
identify an accessible tissue that could be safely and easily sampled to give 
information about events that occur in the brain. Dermal biopsies have been used in 
children with meningococcal septicaemia (Faust, Levin et al. 2001) and in Thai 
adults with severe malaria (Turner, Ly et al. 1998) and neither reported adverse 
events. However while significant changes were seen associated in the 
characteristic skin lesions of meningococcal disease, significant changes were not 
seen in dermal vessels in malaria where there is no clinically obvious skin pathology 
(see section 4.4). Since the changes of interest to us in the protein C pathway 
receptors occurred at sites of iRBC sequestration in post-mortem tissue (see 
chapter 3), we wanted to use a tissue that has significant iRBC sequestration. iRBC 
is low in the dermis so this was not a good choice of tissue. For this reason 
subcutaneous tissue seemed more appropriate as significant iRBC sequestration 
has been observed in that tissue in Malawian children with cerebral malaria (Seydel, 
Milner et al. 2006). Additional supportive factors were that focal accumulation of 
cytokines has been demonstrated in subcutaneous tissue in severe malaria 
(Wilairatana, Riganti et al. 2000) and because we had demonstrated some 
phenotypic similarity between subcutaneous fat endothelium and cerebral 
endothelium (Wassmer, Moxon et al. 2011). However while in our previous work we 
had used subcutaneous fat endothelium to examine endothelial cells in culture and 
another group (Wilairatana, Riganti et al. 2000) had stained the fatty layer of punch 
biopsies, a specific quantitative method to examine and compare endothelial 
receptor expression in this tissue had not been previously described.  
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4.2 Tissue smears on slides 
General methods and details of enrolment and informed consent are detailed in 
chapter 2. Since there was no published data on the use of subcutaneous tissue to 
look at microvascular endothelial phenotype in any disease we first needed to 
determine: (1) whether microvessels could be reliably isolated from subcutaneous 
fat; (2) whether the expression of the endothelial receptors could be visualised and 
compared between individuals; (3) whether sufficient endothelium could be reliably 
isolated from the limited amount of tissue in a biopsy using a procedure that would 
be acceptable in comatose children; (4) whether activation occurs in the 
endothelium in subcutaneous biopsies in cerebral malaria indicating that disease 
specific changes can be detected in this tissue. 
4.2.1 Optimisation of the biopsy procedure 
To explore the first question we initially used subcutaneous fat from the incision site 
obtained from elective surgical procedures.  Tissue was smeared onto poly-lysine 
slides, fixed and stained with the optimised protocol described in chapter 2 (see 
section 2.7.2). Optimal antibody concentrations, blocking conditions and incubation 
times were determined using cultured endothelial cells (using a HUVEC derived cell 
line: EAhy926). Variations tested included different antibody clones, different 
primary and secondary antibody concentrations (3 to 5 different dilutions per clone, 
typically: no antibody; 1 in 10; 1 in 50; 1 in 100 and 1 in 1000 dilutions of the stock 
concentration); different blocking agents (5% BSA, Sigma; Image iT, Invitrogen) and 
different incubation times of the primary antibody (1 hour room temperature; 
overnight at 4°C). Variations tested during optimization of preparation of the fat 
smears included: different fixation agents (paraformaldehyde, formaldehyde and 
methanol) and inclusion or not of a permeabilisation step with Triton X100 (Sigma). 
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Regardless of other variations in the protocol, DAPI gave reliable staining of cell 
nuclei and enabled visualisation of the structure of the tissue and of the typical 
elliptical nuclei of endothelial cells (Figure 4.1). Optimisation of the smearing 
technique was critical to achieve optimal density of cells and to increase the chance 
that vessels were spread across the slide and not clumped. Vessels were detected 
and stained for endothelial receptors using this method but were infrequent with the 
majority of cells being adipocytes, fibroblasts and keratinocytes and it was 
necessary to view several slides to find one clearly visible vessel. 
Rather than use a punch biopsy, which may require a stitch and often leaves a scar, 
we elected to use needle biopsies. Optimisation of biopsy technique using three 
different needles (19 gauge biopsy needle, 16 gauge venepuncture cannula, 15 
gauge Tru-Cut and 16 gauge Menghini biopsy needle) was performed on samples 
taken during elective surgery. The 19 gauge biopsy needle and 16 gauge cannula 
both resulted in very small amounts of tissue; only able to cover 3 or 4 slides. The 
Tru-Cut and Menghini needles isolated larger amounts of tissue and the Menghini 
was chosen because it sampled more tissue despite having a smaller needle gauge. 
Using this technique we were able to isolate samples and demonstrate endothelial 
staining of the 4 major receptors of interest (Figure 4.1, Panels A-D).  
4.2.2 Tolerability of the needle biopsy procedure 
Since the procedure was used on small children it was essential that it was 
minimally invasive and resulted in minimal inconvenience to the child. Although we 
were unable to isolate sufficient amount of tissue from the smaller biopsy needle, 
subcutaneous tissue is superficial and so the needle was only inserted just below 
the skin; making the likelihood of affecting any important structures such as nerves 
or larger blood vessels very small. The location from which we took the biopsy, the 
upper outer quadrant of the buttock, also assists in minimising this risk. A small 
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amount of bleeding was usual after taking the biopsy however in all cases this was 
easily stopped by the application of pressure to the wound site for 2-3 minutes. A 
card (Appendix) with contact details was given to the parents of all children who had 
a biopsy taken and parents were asked by the Malawian study nurse to contact the 
study team in the event of any concerns including the development of redness 
suggesting infection, delayed healing or the development of a scar. In addition all 
but 3 of the cerebral malaria patients came back to at least one follow up visit, to 
check on their clinical recovery, and had the biopsy site checked and most came 
back for several visits. In all the cases the biopsy sites were either no longer visible 
or healing well.  
Since all of the children in this study were comatose or under general anaesthetic, 
we were not able to assess whether the procedure, with use of an anaesthetic 
cream, would be acceptable on children who were conscious.  
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Figure 4.1: Microvessels in subcutaneous biopsies stained for endothelial receptors ex vivo 
Panels A-D (x400) show samples from healthy control children and Panels E and F (x400) 
show samples from children with cerebral malaria. Nuclei stained with 4',6-diamidino-2-
phenylindole (DAPI) appear in blue and endothelial receptors appear in green in the 
following order: CD31 (Panel A); ICAM-1 (Panel B); thrombomodulin (TM, Panel C and E); 
and endothelial protein C receptor (EPCR, Panel D). In samples from a cerebral malaria 
patient, iRBC sequestration (arrows) is associated with low thrombomodulin staining (Panel 
E) and low EPCR staining (Panel F).  
 
4.2.3 Examination of immunofluorescence staining in subcutaneous tissue 
microvessels of cerebral malaria cases and healthy controls 
To explore the possibility of using immunofluorescence labelling of slide smears to 
distinguish differences in endothelial expression we examined a marker of 
endothelial activation which is one of the principle receptors for iRBC cytoadherence, 
ICAM-1 and the protein C pathway receptor, thrombomodulin; both have been 
shown to be altered in cerebral malaria by immunohistochemical staining on post-
mortem tissue ((Turner, Morrison et al. 1994); chapter 3). Vessels were examined 
from 5 healthy Malawian children attending elective surgery and 4 children with 
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cerebral malaria. From the biopsy for each case positive (CD31; a constitutive 
endothelial marker) and negative control (secondary antibody only) analyses were 
performed and half the remaining slides were used for each receptor. The intensity 
of fluorescence staining was scored by the author in an ordinal fashion with the 
following categories: none; weak; moderate or strong. ICAM-1 staining was similar 
between groups Figure 4.2. Although there was a slightly higher proportion of 
moderately stained vessels in CM than in controls, this was not significant (OR 0.75; 
95% CI 0.37 to 1.56; p = 0.45).  
 
Figure 4.2: ICAM-1 scoring in blood vessels in immunofluorescence stained biopsies of 
subcutaneous tissue.  
The author scored vessels from 5 healthy control patients and 4 cerebral malaria cases. 
Immunofluorescence staining intensity for ICAM-1 in each vessel seen was scored as: none, weak, 
moderate or strong. The bar graph depicts the percentage of vessels that were scored for each 
staining intensity in the two different groups.  CM denotes cerebral malaria. 
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In contrast thrombomodulin staining was weaker in the cerebral malaria cases than 
in the controls ( Figure 4.3) and this was statistically significant (OR 0.28; 95% CI 
0.13 to 0.64; P=0.002). Because of the small numbers in this exploratory data, 
comparison was between all vessels in cerebral malaria and all vessels in controls. 
It should be stated that this is statistically liberal approach, strictly we should include 
a variable to cluster by case and thereby control for inter-individual effects but this 
would give us insufficient power to detect a difference with such a small number of 
cases.   
 
 Figure 4.3: Thrombomodulin scoring in blood vessels in immunofluorescence labelled biopsies 
of subcutaneous tissue.  
The author scored vessels from 5 healthy control patients and 4 cerebral malaria cases. 
Immunofluorescence staining intensity for thrombomodulin in each vessel seen was scored as: none, 
weak, moderate or strong. The bar graph depicts a summary of the percentage of vessels that were 
scored for each staining intensity in the two different patient groups. CM denotes cerebral malaria 
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4.3 Quantitative examination of endothelial expression in 
subcutaneous fat by flow cytometry 
 
To develop a more consistent and objective quantitative method of assessing 
endothelial phenotype we used flow cytometry on subcutaneous tissue, which had 
first been digested to make a single cell suspension by adapting a method 
developed by (Hutley, Herington et al. 2001) and refined in (Wassmer, Moxon et al. 
2011) 
 
4.3.1 Preparation of a single cell suspension and assessment of different 
collagenases 
To perform flow cytometry it was necessary to prepare a single cell suspension from 
the piece of subcutaneous tissue obtained at biopsy. This required a digestion 
process to remove the connective tissue in the extracellular matrix.  However since 
the objective was assessment of endothelial phenotype it was critical that this 
process had minimal effect on endothelial receptors. Two different collagenases 
were assessed based on their enzymatic properties and successful use for creating 
cell suspensions in previous work: type IV collagenase (Haniffa, Ginhoux et al. 
2009) and type II collagenase (Wassmer, Moxon et al. 2011). The two preparations 
were assessed on the degree of physical separation achieved and on the degree of 
cleavage of endothelial receptors. We had already established in previous work that 
good separation of cells in subcutaneous tissue was achieved with Type II 
collagenase at a concentration of 3mg/ mL (Wassmer, Moxon et al. 2011) Another 
group had shown separation of cells in the dermis using 0.8mg mg/ mL of type IV 
collagenase (Haniffa, Ginhoux et al. 2009) but had not looked at separation of 
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subcutaneous tissue. To ensure fair comparison of the two preparations we tested 
the type IV collagenase at 0.8mg/ mL and 3mg/ mL. To assist digestion we gently 
minced the tissue with scissors first and used a GentleMACS tissue dissociator; a 
device that agitates the cells, designed to assist in the preparation of single cell 
suspensions. The protocol used is described in section 2.5.3 of the methods section.  
Over the 35-minute digestion protocol, type II collagenase yielded approximately 
twice the number of single cells as 3mg/ mL of type IV from similar tissue volumes 
and resulted in near complete dissociation of the cells in the tissue with no visible 
lumps of tissue remaining. 0.8mg/ mL of type IV collagenase yielded slightly fewer 
cells than 3mg/ mL of type IV and visible lumps of tissue were apparent in both. A 
prolonged incubation of cultured HUVEC for 2 hours at 37°C resulted in only subtle 
alteration of endothelial phenotype with minimal differences between the different 
collagenases (Figure 4.4) and the cytometric separation of cells types by receptor 
expression on dissociated tissue between 3mg/mL of type II when compared with 
3mg/mL of type IV collagenase was also similar (Figure 4.5). Since the effects on 
endothelial receptor expression were minimal and due to the superior dissociation of 
the tissue of interest we elected to use Type II collagenase (3mg/mL).  
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Figure 4.4: Comparison of endothelial receptor expression in HUVEC after 2 hours incubation 
with collagenase solutions.  
Cultured endothelial cells were lifted to make a single cell suspension using Accutase and put into 
either endothelial media (no treatment), 3mg/ mL collagenase II, 3mg/ mL of collagenase IV or 0.8mg/ 
mL of collagenase IV. The cells were incubated on a rotator at 37°C for 2 hours before performing 
surface staining for different endothelial receptors and were then examined for endothelial expression 
by flow cytometry. Panels A to C show treatment with both type II and type IV collagenase compared to 
no treatment whereas Panel D shows treatment with type II collagenase compared to no treatment 
only.  
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Figure 4.5: Comparison of cytometric separation of cell types from subcutaneous tissue after 
incubation with Type II and Type IV collagenase.  
Samples of subcutaneous fat obtained during elective surgical procedures were minced and 
dissociated to make a single cell suspension using digestion with either 3mg/ mL of type IV 
collagenase or 3mg/ mL of type II collagenase. Cell surface staining and staining with a viability marker 
was performed and the cells were analysed by flow cytometry using the gating strategy described 
above.  
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4.3.2 Gating strategy 
A rigorous gating strategy was used throughout to separate the population of single, 
live, CD45-, CD31+ cells.  
 
 
Figure 4.6: Gating strategy for cytometric separation of human umbilical vein endothelial cells.  
Panel A: Forward scatter (FSC) and side scatter (SSC) gating is used to exclude very small events and 
events with low SSC such as cellular debris and red blood cells. Panel B: FSC-Height (FSC-H) against 
FSC-Area (FSC-Area) gating was used to include only single cells. Panel C: Live/ dead gating using a 
viability marker was used to exclude events dead cells (see Figure 4.7). Panel D: CD31 gating was 
used to select CD31+CD45- endothelial cells (see Figure 4.8) 
 
 
Live/dead (viability) gating was optimized first on cultured endothelial cells (HUVEC) 
to ensure correct gating on the endothelial cell population. Live/ Dead Fixable 
Yellow dead cell staining kit (Invitrogen) was used and gave clear separation 
between a highly staining population of dead endothelial cells which exhibited low 
FSC and high SSC properties (Figure 4.7, Panel A) whereas the population of low 
staining cells exhibited the typical FSC and SSC signature of viable endothelial cells 
(Figure 4.7, Panel B). Once this gating position was established on HUVEC only 
small adjustments were needed to adjust the gating for endothelial cells in the ex 
vivo biopsies.  
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Figure 4.7: Viability gating on cultured endothelial cells.  
Cultured human umbilical vein endothelial cells (HUVEC) were made into a suspension using Accutase 
but without a wash step prior to lifting so that the dead, non-adherent cells were retained. Cells were 
stained with Live/dead fixable stain for 30 minutes at room temperature prior to examination by flow 
cytometry. (A) Dead cells are much more permeable to the dye and therefore have high signal. (B) Live 
intact cells have low permeability to the dye and have low signal.  
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Figure 4.8: CD31/ CD45 gating to distinguish endothelial cells from other cell types in 
subcutaneous samples.  
Following gating on forward and side scatter, exclusion of doublets and viability gating a 
heterogeneous population of cells remains. Endothelial cells are distinguished from other cells on the 
basis of expression of CD31 and lack of expression of CD45.  
 
Although CD31 is regarded as a endothelial marker (Liu and Shi 2012), it is also 
expressed by a proportion of leukocytes and gating of CD31 against CD45, a 
generic leukocyte marker, was used to separate CD45+CD31+ leukocytes from 
CD45-CD31+ endothelial cells (Figure 4.8). Consistent with the heterogeneity and 
sample variation when the tissue was viewed on smears, there was considerable 
variation in the relative proportions of the different cell groups; particularly in the 
proportion of endothelial cells. In order to ensure the quality of data a prospective 
minimum of 200 live CD31+CD45- events was set for the study with the intention to 
exclude patients for whom this minimum number of endothelial events was not 
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captured (however we included all recorded events in the analysis, not only the 
minimum 200).  
Isotype controls from the same manufacturer as the conjugated primary antibody 
were used: (a) to verify CD31 gating was appropriate and that positivity was not due 
to autofluorescence or non-specific binding (Figure 4.9, Panel A) and (b) to 
determine the background for each of the receptors of interest to enable 
determination of expression level either by positive event gating (Figure 4.9, Panels 
B and C) or by subtraction of the mean fluorescence intensity (MFI) of the isotype 
control from that of the stained population.  
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Figure 4.9: Isotype controls in antibody panels and gating to determine positive events.  
In dissociated subcutaneous samples gated according to the optimised strategy described above three 
antibody panels are used for each sample. The first antibody panel contains viability stain and CD45 
antibody but an isotype control instead of CD31 antibody and confirms true CD31 positivity (A). A 
second panel of antibodies containing CD31 antibody but with isotype controls for the other endothelial 
receptors (ICAM-1, EPCR and thrombomodulin) enables gating on endothelium and reveals 
background signal for these receptors (B). The third panel contains antibodies for all the receptors, 
enabling either determination of positive events by positioning a gate above the isotype control (C) or 
determination of mean fluorescence intensity (MFI) for a receptor by subtracting the background MFI 
from the MFI for the stained population.  
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4.3.3 Identification of malaria infected red blood cells  
To optimally assess the effect of malaria on endothelial expression from 
subcutaneous biopsies using flow cytometry we wanted to develop a method to 
quantify infected red blood cells (iRBC) in the sample. No data was available on 
methods for separation of iRBC by flow cytometry in a heterogeneous cell 
population. Published data did exist on the characterization of the iRBC through the 
parasite life cycle using flow cytometry (Rosenfeld and Campbell 2011). This was 
based on changes in the amount of DNA in iRBC through the asexual parasite life 
cycle using the nuclear stain Hoechst. Since uninfected RBC (except for 
reticulocytes) do not have nuclear material we hypothesized that Hoechst could be 
used to distinguish uRBC from iRBC (as well as early from late stages) with RBC 
being distinguished from other cells types using a constitutive RBC surface protein; 
glycophorin A (CD235a). Hoechst 34850 staining distinguished cultured 
Plasmodium falciparum iRBC from uRBC (Fig. 4.10) and Hoechst and 235a staining 
allowed clear separation of cultured endothelial cells (EAhy926), iRBC and uRBC 
(Fig 4.11). However in three successive experiments we were unable to distinguish 
iRBC in samples of subcutaneous fat spiked with cultured iRBC. A likely explanation 
is that there was a very large spectral overlap between Hoechst 34850 and the 
yellow fluorescent Live/Dead stains, which had similar excitation spectra and were 
both excited by the violet laser. Although theoretically the emission spectra should 
be different for these two fluorochromes on our setup they were very similar; 
resulting in complete loss of Hoechst signal when colour compensation was 
performed. Although it does appear that addition of iRBC quantification would be 
possible with further optimization, due to time constraints we elected to perform the 
study to explore endothelial expression in children with cerebral malaria with the 
optimized endothelial panel only. 
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Figure 4.10: Hoechst staining on infected and uninfected red blood cells.  
In red blood cells cultured with a lab adapted parasite line (ITG, 10% parasitaemia) Hoechst staining 
demonstrates a positive population (7%)  not present when no staining is used or in uninfected red 
blood cells (uRBC).  
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Figure 4.11: Separation of endothelial cells from iRBC and uRBC using glycophorin A (CD235a) 
and Hoechst staining.  
(A) Red blood cells cultured with malaria parasites (ITG, 50% parasitaemia) mixed with Human 
Umbilical Endothelial Cells; (B) uninfected red blood cells only or (C) Human Umbilical Endothelial cells 
only were stained with Glycophorin A (CD235a), CD31 (a constitutive endothelial marker) and Hoechst 
34850 and were examined by flow cytometry. In (A) gating on Hoechst and 235a showed a population 
of 235a+, Hoechst+ events which constituted approximately 50% of the 235a+ population, had the 
Forward Scatter (FS) and side scatter (SS) signature of red blood cells, were CD31- (not shown) and 
were not present in (B) uninfected red cells or (C) endothelial cells: indicating that they were iRBC. 
Hoechst+CD235a- events in (A) exhibited the typical FS and SS signature of endothelial cells and were 
CD31 positive: indicating that they were endothelial cells.  
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4.3.4 Endothelial phenotype in cerebral malaria 
We used the optimized flow cytometry technique for the determination of endothelial 
phenotype by flow cytometry in biopsies of subcutaneous tissue to compare 
endothelial expression of the receptors ICAM-1, EPCR and thrombomodulin in 
microvessels between 20 cerebral malaria cases and 17 healthy controls. Levels of 
the cleaved soluble receptors were measured in plasma in parallel (described in 
1.3.5). Mean cell viability was similar between the two groups: healthy controls 
80.8% (95% CI 77.6 to 84%); cerebral malaria 74.6% (95% CI 70.6 to 78.6). For 
ICAM-1 and thrombomodulin there was minimal overlap between positive events 
and the isotype control, whereas for EPCR there was significant overlap with the 
isotype control (Panel B). For this reason expression was determined by mean 
fluorescence intensity for ICAM-1 and thrombomodulin and by percentage positive 
events for EPCR. 
Endothelial ICAM-1 expression was increased in cerebral malaria (Figure 4.12, 
Panel C; geometric mean, 449 mean fluorescence intensity [MFI]; 95% CI 374 to 
540) when compared with healthy controls (205 MFI; 95% CI 177 to 237; P=<0.001). 
In contrast endothelial thrombomodulin was decreased in cerebral malaria cases 
(geometric mean, 136 MFI; 95% CI 98 to 188) when compared with healthy controls 
(247 MFI; 95% CI 173 to 350; P=0.01). EPCR was also decreased in cerebral 
malaria (geometric mean 9.07 % positive; 95% CI 6.16 to 12.0) when compared with 
controls (16.0 % positive; 95% CI 10.9 to 23.4; P=0.004).  
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Figure 4.12: Flow cytometric analysis of endothelial receptor levels in subcutaneous biopsies 
from healthy children and children with cerebral malaria.  
Samples from subcutaneous biopsies were gently digested to make a single cell suspension, labelled 
by immunofluorescence and then analysed by flow cytometer to examine the receptor expression of 
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endothelial cells from microvessels in the sample. Panel A shows the flow cytometric gating strategy 
for samples to distinguish endothelial cells as single, live, CD31+CD45- cells. Panel B shows 
histograms for 3 different endothelial receptors: Intracellular adhesion molecule-1 (ICAM-1), 
thrombomodulin and endothelial protein C receptor (EPCR). These show representative plots from a 
single case for cerebral malaria (cerebral malaria, blue), healthy control (HC, red) and isotype control 
(IC, grey). ICAM-1 and thrombomodulin staining show low overlap with the isotype control and receptor 
expression was determined by mean fluorescence intensity (MFI), whereas EPCR staining overlapped 
considerably with the isotype control and expression was determined by percentage positive events 
(Panel B). Panel C shows scatterplots for the endothelial expression levels of ICAM-1, thrombomodulin 
and EPCR as determined by flow cytometry in 17 cerebral malaria cases and 20 healthy controls.  
Panel D shows scatterplots for levels of soluble ICAM-1 (sICAM-1), sThrombomodulin and sEPCR as 
determined by enzyme linked immunosorbent assay in plasma samples paired with the subcutaneous 
samples from Panel C. Horizontal lines indicate geometric means and bars 95% confidence intervals.  
 
 
4.3.5 Considering age and sex as determinants of receptor expression 
The ages of children were similar in the cerebral malaria group (median = 4.6 years; 
Interquartile range [IQR]) 2.9 to 6.1 years) and control groups (median = 4 years; 
IQR 2.8 to 5.5 years p=0.48). There was a lower proportion of females in the healthy 
control group (25% female) than in the cerebral malaria group (52% female) 
although this was not statistically significant (p=0.101). Endothelial expression levels 
were not statistically different between sexes for any of the three receptors in 
healthy controls alone (ICAM-1 p=0.60; thrombomodulin p=0.32; EPCR p=0.23); 
cerebral malaria alone (ICAM-1 p=0.54; thrombomodulin p=0.37; EPCR p=0.89) or 
considering both groups combined (ICAM-1 p=0.31; thrombomodulin p=0.18; EPCR 
p=0.21). There was no statistical association between age and receptor level 
(ICAM-1 p=0.56; thrombomodulin p=0.99; EPCR p=0.29).  
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4.3.6 Soluble endothelial receptors in plasma 
Soluble ICAM-1 (sICAM-1) levels from children who had undergone subcutaneous 
sampling were raised in 15 retinopathy positive CM cases (Figure 4.12; geometric 
mean, 742 ng/ mL; 95% CI 534 to 1032 ng/ mL) when compared with 17 healthy 
controls (204 ng/ mL; 95% CI, 164 to 253 ng/ mL; P=<0.001). Soluble 
thrombomodulin (sThrombomodulin) levels were also raised in cerebral malaria 
(geometric mean 9.06, 95% CI, 7.33 to 11.2 pg/ mL) when compared with healthy 
controls (4.29 pg/ mL, 95% CI, 3.67 to 5.02 pg/ mL; P=<0.001) but soluble EPCR 
(sEPCR) levels were similar between the two groups: CM (geometric mean, 96.3 
ng/ mL; 95% CI, 67.1 to 138.1 ng/ mL); controls (123.1 ng/ mL; 95% CI, 104.8 to 
144.6 ng/ mL). To explore whether there was a correlation between levels of shed 
receptors and levels of receptors in the microvasculature of subcutaneous tissue we 
compared levels of soluble receptors in plasma with endothelial expression levels in 
the biopsies as measured by flow cytometry (Figure 4.13). Raised soluble ICAM-1 
(sICAM-1) levels in plasma were associated with raised levels on the vascular 
endothelium in the subcutaneous biopsies (p=<0.001; r= 0.74). In contrast for 
thrombomodulin there was trend towards a negative association, although not 
significant, raised soluble thrombomodulin (sTM) in plasma was associated with a 
trend towards decreased levels on the vascular endothelium in the subcutaneous 
biopsies (p=0.066; R= -0.32). For EPCR there was no statistical association 
between plasma levels and endothelial levels of receptor (p=0.42; r = -0.14). When 
the association was examined for ICAM-1 or thrombomodulin within the cerebral 
malaria or healthy control groups only the associations were not statistically 
significant.  
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Figure 4.13: Comparison of receptor levels between endothelium and plasma.  
The X-axis indicates expression levels of ICAM-1, thrombomodulin and EPCR on the endothelium of 
subcutaneous biopsies as measured by flow cytometry. For ICAM-1 and thrombomodulin this is 
measured as mean fluorescence intensity units (MFI) and for EPCR as percentage positive events. 
The Y-axis shows the levels of soluble receptor in a paired plasma sample (taken from the patient at 
the same time as the biopsy) as measured by enzyme linked immunosorbent assay (ELISA). The first 
column shows comparison of the different endothelial and soluble levels in 17 healthy controls, the 
second column in 15 cerebral malaria cases and the third in both healthy controls and cerebral malaria 
cases (n=32). Associations in the first two columns for all the factors are non-significant.   
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4.4 Discussion 
We have developed an original quantitative method to determine endothelial 
phenotype ex vivo. The technique was well tolerated and because serial samples 
could be taken from the same patient the method could be used to follow endothelial 
changes during disease progression or recovery. Using immunofluorescence 
stained smears we showed that needle biopsies of subcutaneous tissue could be 
used to isolate microvessels. In patients with cerebral malaria we used DAPI 
staining to demonstrate the presence of iRBC within vessels. As in post-mortem 
samples, the presence of iRBC sequestration in microvessels was associated 
qualitatively with loss of the receptors thrombomodulin and EPCR from the 
endothelial surface. Using immunofluorescence staining of biopsy smears, in a pilot 
study of 4 cerebral malaria patients and 5 healthy controls we showed a reduction in 
thrombomodulin in cerebral malaria compared to healthy controls although levels of 
ICAM-1 were similar between cerebral malaria and controls. In contrast, using the 
flow cytometry method a clear decrease in thrombomodulin and EPCR expression 
and also a clear increase in endothelial ICAM-1 expression was demonstrated in 17 
cerebral malaria cases when compared with 20 healthy controls.  
Both the use of immunofluorescence staining on whole tissue smears and the use of 
flow cytometry on single cell digests had advantages and disadvantages. The 
smears had the advantage of preserving some of the structure of the tissue, 
allowing iRBC to be seen within the vessels and enabled observation of the pattern 
of receptor staining with respect to the vessel itself and in relation to iRBC. Since 
the cells are mixed randomly in a single cell suspension this is not possible using 
the flow cytometry method. However a major limitation of the smear method was the 
large variability of many parts of the method. Correct smear thickness, good 
antibody penetration and the spreading of a vessel along the surface of the slide to 
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avoid clumps all needed to occur to allow the endothelial receptors to be adequately 
stained and viewed. Each vessel then had to be summarised by a single score 
category with the limitations of bias and subjectivity. In contrast the quantitative 
nature of flow cytometry and the impressive recovery of endothelial events (because 
the method looks at all of the cells individually) gave a more objective and sensitive 
way of comparing endothelial expression between individuals. The importance of 
this sensitivity is illustrated by the clear detection of increased ICAM-1 expression in 
subcutaneous tissue in cerebral malaria cases by flow cytometry but not by scoring 
of immunostaining. In addition flow cytometry allowed comparison of multiple 
parameters on the same sample, including the use of a viability marker. A potential 
criticism of the flow cytometry technique is the digestion process. The longer the 
tissue is ex vivo before endothelial expression is examined the greater the chance 
that ex vivo alterations will occur in the tissue. However tests on cultured cells in the 
optimisation phase showed minimal interference with endothelial phenotype. This 
was over 2 hours rather than the 35 minutes used on the biopsies and the cultured 
cells lacked the protective effect of the serum present in natural tissue. In addition a 
rapid turnaround time of 2 hours from patient to analysis was employed and since 
cases were compared with samples from controls that have undergone the same 
procedure it seems likely that differences seen in the cerebral malaria cases are due 
to events that occurred in vivo.  
Using the optimised flow cytometry technique we were able to demonstrate that in 
cerebral malaria there is increased ICAM-1 in subcutaneous tissue microvessels, 
indicating endothelial activation in this tissue and to demonstrate loss of the protein 
C receptors EPCR and thrombomodulin occurs in vivo and is present at the time of 
admission to hospital. This both supports the post-mortem data presented in chapter 
3 but also demonstrates utility of this ex vivo method to demonstrate endothelial 
changes in this disease, informative of changes that occur in the brain (seen post-
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mortem). Endothelial phenotype has previously been examined ex vivo using 
immunostaining on dermal biopsies but while this demonstrated endothelial changes 
in a study of children with meningococcal sepsis (Faust, Levin et al. 2001) no signs 
of endothelial activation were detected in a study using dermal samples from Thai 
adults with severe malaria (Turner, Ly et al. 1998) despite evidence of endothelial 
activation in the plasma. Explanations for detection of endothelial activation in 
malaria in this study in subcutaneous tissue by flow cytometry but not in dermal 
samples in the study by Turner, Ly et al. are: (1) increased sensitivity to detect 
changes using flow cytometry compared with using a subjective scoring method; (2) 
higher sequestration of iRBC in subcutaneous tissue when compared with dermal 
vessels (Seydel, Milner et al. 2006) resulting in more pronounced changes in the 
vessels in subcutaneous tissue when compared with dermal vessels; (3) changes 
are more pronounced or are specific to cerebral malaria (since the Turner, Ly et al. 
study included individuals with other severe malaria syndromes); (4) changes are 
more pronounced in African children than in adults in south East Asia. It seems 
likely that a combination of these explanations is implicated and examination of 
subcutaneous biopsies in Thai adults using the flow cytometry method described 
here would be an interesting topic for future research. 
While we need to be cautious about over interpreting the results, the comparison of 
soluble and endothelial receptors is interesting. People have often assumed a 
correlation between soluble receptor levels and endothelial receptors levels but the 
implication of this data, for the microvasculature at least, is that assuming a positive 
correlation between soluble and endothelial receptor levels would be incorrect. This 
is in keeping with a lack of correlation between endothelial expression in skin 
biopsies and soluble factors in a study of septic and traumatic shock in human 
adults (Leone, Boutiere et al. 2002) and a lack of correlation between endothelial 
findings in different organs in a mouse model of sepsis (Shapiro, Yano et al. 2009) 
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and which was attributed to vascular bed heterogeneity. Different pictures are seen 
in this study for the three different receptors: (1) endothelial ICAM-1 expression is 
increased in cerebral malaria, sICAM-1 is also increased and overall there is a 
positive association between endothelial ICAM-1 and sICAM-1 levels (Figure 4.13); 
in contrast endothelial thrombomodulin is decreased in cerebral malaria but there is 
increased sTM in plasma and there is a negative association between endothelial 
receptor thrombomodulin and sTM levels; endothelial EPCR is decreased in 
cerebral malaria but sEPCR is unchanged and there is no correlation between 
endothelial receptor and sEPCR levels. These discrepancies are biologically 
plausible when considering that soluble receptors in plasma: (1) are a pooled 
measure of events throughout the vasculature and not just in the microvasculature 
and (2) must be shed from the endothelium to be detected in plasma. Since ICAM-1 
and thrombomodulin are expressed constitutively predominantly in the 
microvasculature whereas EPCR is expressed predominately in larger vessels the 
most plausible explanation for a lack of increased sEPCR is that the disease 
process in cerebral malaria leads to increased receptor shedding in the 
microvasculature but not in larger vessels. This is consistent with endothelial 
pathology occurring focally at sites of iRBC sequestration, as iRBC is restricted to 
the microvasculature (Ponsford, Medana et al. 2012). Whether this is the correct 
explanation or not for the different patterns of correlation between endothelial and 
soluble levels for the three different receptors the implication of the data here as in 
the human (Leone, Boutiere et al. 2002) and murine sepsis (Shapiro, Yano et al. 
2009) studies is that soluble endothelial markers are an imperfect indicator of the 
state of the microvascular endothelium. Although for two of the three receptors 
examined (ICAM-1 and thrombomodulin) the soluble levels of receptors are 
informative of events in the microvasculature, they are only correctly interpreted 
having examined the microvascular itself.  
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The demonstration of a microvascular coagulopathy as demonstrated by fibrin 
deposition in chapter 3 and of an alteration in a critical anticoagulant pathway in 
chapter 3 and in this chapter might be expected to alter the state of haemostasis in 
the systemic circulation. However given the importance of vascular heterogeneity 
we cannot necessarily predict the status of coagulation in venous blood from the 
endothelial phenotype in the microcirculation, yet the state of coagulation in the 
circulation is important to understand in order to consider therapeutic options. In the 
next chapter we therefore examined in detail a number of coagulation indices and 
their association with cerebral malaria and with outcome.   
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5                               
COAGULATION FACTORS IN 
THE BLOOD OF MALAWIAN 
CHILDREN WITH 
UNCOMPLICATED AND 
CEREBRAL MALARIA 
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5.1 Introduction 
 
While multiple groups have published data on coagulation levels in the blood in non-
immune adults (Hemmer, Kern et al. 1991; Clemens, Pramoolsinsap et al. 1994; 
Mohanty, Ghosh et al. 1997; Vogetseder, Ospelt et al. 2004), only one study has 
looked at coagulation in children with cerebral malaria (Akingbola, Shokunbi et al. 
2006). That study showed no difference in functional coagulation results 
(prothrombin time [PT], activated partial thromboplastin time [aPTT], total clotting 
time and fibrinogen) between 35 children with cerebral malaria and 30 children with 
uncomplicated malaria and 30 healthy controls. These results are in keeping with 
the observation that in children with cerebral malaria clinically overt coagulopathy 
(thrombosis or bleeding) is rare (Marsh, Forster et al. 1995). Indeed, this lack of 
evidence of clinical or laboratory coagulopathy has been interpreted as indicating 
that coagulation is not an important component of cerebral malaria pathogenesis in 
African children. However our finding of marked fibrin deposition in the brain post-
mortem (Chapter 3) and the thrombosis and haemorrhage observed in retinal 
vessels in vivo (Taylor, Fu et al. 2004) suggest otherwise. Therefore to better 
understand the effects of endothelial pathology on haemostasis and to examine why 
loss of protein C pathway receptors is not associated with overt disseminated 
intravascular coagulation we measured a panel of coagulation indices. 
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5.2 Measures of thrombin generation: Thrombin-anti-thrombin 
complexes and Prothrombin fragment F1+2 
Since free thrombin is rapidly metabolized in the blood it cannot be measured 
directly in plasma samples (See Chapter 1, section 1.10). It is therefore measured 
ex vivo by several surrogate markers. One method is by measuring a complex 
produced when thrombin binds to the thrombin inhibitor antithrombin (AT); termed 
thrombin-anti-thrombin (TAT) complexes (Lau and Rosenberg 1980). Another 
method is by measuring levels of the fragment from prothrombin (F1+2), which is 
cleaved off when the active thrombin portion is released from its zymogen, 
prothrombin (Aronson, Stevan et al. 1977). Both of these were measured using 
commercial ELISA kits (see Chapter 2 for details of the method)  
Plasma samples were recruited on admission from children with retinopathy positive 
and negative cerebral malaria, aparasitaemic coma and from children attending 
hospital with uncomplicated malaria and uncomplicated aparasitaemic febrile illness 
(See Chapter 2 for details on enrolment and preparation of plasma). Plasma TAT 
levels were raised in 67 children with retinopathy positive CM (geometric mean16, 
26.7µg/ mL; 95% CI, 20.5 to 34.8µg/ mL) when compared with 19 healthy children 
(geometric mean, 7.8µg/ mL; 95% CI, 4.7 to 12.9µg/ mL; P=<0.001), 30 children 
with non-malarial mild febrile illness (geometric mean, 12.3µg/ mL; 95% CI, 7.4 to 
20.3µg/ mL; P=<0.01) and 30 children with uncomplicated malaria (geometric mean, 
10.6µg/ mL; 95% CI, 7.6 to 14.8µg/ mL; P=<0.01; Figure 5.1 panel A). Levels were 
also higher in 19 children with retinopathy negative cerebral malaria than in healthy 
children (geometric mean, 21.9µg/ mL; 95% CI, 12.1 to 39.5µg/ mL; P=<0.05) but 
there was not a statistically significant difference between retinopathy negative CM 
and retinopathy positive CM or with the other control groups. F1+2 levels were 
                                                
16 Geometric mean is used for log-normal data to enable statistical adjustment for multiple comparison 
(see Chapter 2).  
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higher in 72 children with retinopathy positive cerebral malaria (geometric mean 524 
ng/ mL; 95% CI 389 to 706) when compared with 33 healthy children (geometric 
mean 176 ng/ mL; 95% CI 140 to 220 ng/ mL; p=<0.001) and with 85 children with 
mild non-malarial febrile illness (geometric mean 142 ng/ mL; 95% CI 120 to 167 ng/ 
mL; p=<0.001) but there was not a significant difference with any of the other groups 
(Figure 5.1, Panel B). 
 
Figure 5.1: Plasma levels of thrombin anti-thrombin complexes (TAT) and Prothrombin 
fragment F1+2 in Malawian children grouped according to diagnosis and outcome.  
Panel A shows plasma TAT levels taken on admission in children with (from right to left) retinopathy 
positive cerebral malaria (Ret pos cerebral malaria, n=67), retinopathy negative cerebral malaria (Ret 
neg cerebral malaria, n=19), non-malarial coma (n=11), uncomplicated malaria (n=30), mild non-
malarial febrile illness (n=30) and healthy controls (n=19). Panel B shows Prothrombin fragment (F1+2) 
levels on admission in (from right to left) retinopathy positive cerebral malaria (Ret pos cerebral 
malaria, n=72), retinopathy negative cerebral malaria (Ret neg cerebral malaria, n=22), non-malarial 
coma (n=4), uncomplicated malaria (n=30), mild non-malarial febrile illness (n=85) and healthy controls 
(n=33). Horizontal lines are geometric means. Asterisks indicate significant differences in comparison 
with the retinopathy positive cerebral malaria group using the Tukey honestly significant difference test 
for multiple comparisons: * p=<0.05; ** p=<0.01; *** p=<0.001.  
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Among children with retinopathy positive cerebral malaria, mean TAT levels at 
admission were higher in the 16 children who went on to die (geometric mean, 
45.6µg/ mL; 95% CI, 24.7 to 84.1µg/ mL) than in those who survived (geometric 
mean, 22.5µg/ mL; 95% CI, 16.9 to 29.9µg/ mL; P=0.02, Figure 5.2).  
 
Figure 5.2: Thrombin-anti-thrombin complexes in fatal and non-fatal cerebral malaria.  
Thrombin anti-thrombin (TAT) levels taken on admission in patients with retinopathy positive cerebral 
malaria grouped according to outcome: those who went on to die (fatal (n=15) and those who survived 
(non-fatal (n=51). Horizontal lines indicate geometric means. 
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time (PT), which is an indicator of the status of the tissue factor or extrinsic pathway 
and activated partial thromboplastin time (aPTT), which is an indicator off the status 
of the intrinsic and common pathways and we also measured fibrinogen, the 
zymogen for fibrin. These factors were measured using an automated coagulation 
analyser on plasma samples recruited and prepared as described in the methods 
chapter (sections 2.1-2.3).  
PT was prolonged in 68 children with retinopathy positive cerebral malaria (Figure 
5.3; geometric mean, 16.9 seconds; 95% CI 16.1 to 17.8 sec; P=<0.01) and in 23 
children with retinopathy negative cerebral malaria (geometric mean, 17.6 seconds; 
95% CI 15.3 to 20.2; P=<0.01) when compared with 30 healthy children but not 
when compared with 21 children with uncomplicated malaria (geometric mean 15.5 
seconds; 95% CI, 14.6 to 16.5 seconds) or 23 children with mild aparasitaemic 
febrile illness (geometric mean 15.6 seconds; 95% CI, 14.8 to 16.4 seconds; ). 
Among children with retinopathy positive cerebral malaria PT on admission showed 
a trend towards being longer in children who went on to die (fatal cerebral malaria; 
Figure 5.3 Panel B; geometric mean 18.9 sec; 95% CI 16.2 to 22.0 sec) compared 
with those children who survived to be discharged from hospital but this was not 
statistically significant (geometric mean 16.7 sec; 95% CI 15.8 to 17.5; p=0.0503). In 
contrast aPTT was not significantly different between retinopathy cerebral malaria 
cases and the other diagnostic groups although there was a significant difference 
between healthy controls (geometric mean 30.1 sec; 95% CI 28.8 to 31.5 sec; 
p=<0.05).  
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Figure 5.3: Prothrombin time in Malawian children grouped according to diagnosis and 
outcome: 
 Panel A shows Prothrombin time (PT) in seconds (sec) on admission in children with (from right to left) 
retinopathy positive cerebral malaria (Ret pos cerebral malaria, n=68), retinopathy negative cerebral 
malaria (Ret neg cerebral malaria, n=23), non-malarial coma (n=10), uncomplicated malaria (n=21), 
mild non-malarial febrile illness (n=23) and healthy controls (n=30). Panel B shows PT at admission in 
patients with retinopathy positive cerebral malaria grouped according to outcome: those who went on 
to die (fatal (n=11) and those who survived (non-fatal (n=57). Horizontal lines indicate geometric 
means. Asterisks in panel A indicate significant differences in comparison with the retinopathy positive 
cerebral malaria group using the Tukey honestly significant difference test for multiple comparisons: * 
p=<0.05; ** p=<0.01; *** p=<0.001.  
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Figure 5.4: Activated partial thromboplastin time in Malawian children:  
Activated partial thromboplastin time (aPTT) in seconds (sec) on admission in children with (from right 
to left) retinopathy positive cerebral malaria (Ret pos cerebral malaria, n=68), retinopathy negative 
cerebral malaria (Ret neg cerebral malaria, n=23), non-malarial coma (n=10), uncomplicated malaria 
(n=20), mild non-malarial febrile illness (n=20) and healthy controls (n=30). Asterisks indicate 
significant differences in comparison with the retinopathy positive cerebral malaria group using the 
Tukey honestly significant difference test for multiple comparisons: * p=<0.05; ** p=<0.01; *** 
p=<0.001.  
 
 
Fibrinogen levels in plasma on admission were not significantly different between 
children with retinopathy positive cerebral malaria (geometric mean 3.9 g/ L; 95% CI 
3.1 to 4.4 g/ L) and 30 healthy children (2.7 g/ L; 95% CI 2.4 to 2.9 g/ L; p=>0.05) or 
any of the other diagnostic groups (Figure 5.5, Panel A; p=>0.05). Compared with 
the healthy controls, fibrinogen levels were higher in 20 children with uncomplicated 
malaria (geometric mean 4.8 g/ L; 95% CI 4.2 to 5.6 g/ L; p=<0.01) and 21 children 
with retinopathy negative cerebral malaria (geometric mean 4.6 g/ L; 95% CI 3.9 to 
5.4 g/ L). Among children with retinopathy positive cerebral malaria there was a 
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negative association between fibrinogen levels and TAT levels (Spearman r = -0.69; 
p=<0.001). However against localized activation of coagulation from venepuncture 
trauma or coagulation occurring ex vivo 17, fibrinogen was detectible in all the 
samples and several of the samples with high TAT levels also had high fibrinogens 
(Figure 5.5, Panel B). 
 
Figure 5.5: Fibrinogen levels in Malawian children and association between fibrinogen and 
thrombin-anti-thrombin levels: 
 Panel A shows fibrinogen levels (Claus method) in Malawian children with (from right to left) 
retinopathy positive cerebral malaria (Ret pos cerebral malaria, n=68), retinopathy negative cerebral 
malaria (Ret neg cerebral malaria, n=21), non-malarial coma (n=11), uncomplicated malaria (n=20), 
mild non-malarial febrile illness (n=23) and healthy controls (n=30). Panel B shows the association 
between fibrinogen and thrombin-anti-thrombin levels in 58 children with retinopathy positive cerebral 
malaria for whom paired values were available. Asterisks in panel A indicate significant differences in 
comparison with the retinopathy positive cerebral malaria group using the Tukey honestly significant 
difference test for multiple comparisons: * p=<0.05; ** p=<0.01; *** p=<0.001.  
 
                                                
17 When fibrin formation occurs from venipuncture trauma or ex vivo, fibrin is formed from consumption of the 
fibrinogen in the sample or around the site of venipuncture and there is limited time (during venipuncture) or no 
possibility (ex vivo) for fibrinogen to be replenished by the circulating pool. In contrast when coagulation occurs in 
the circulation there is a large pool of circulating fibrinogen and in additional new fibrinogen can be made. A pro-
coagulant state can be associated with both low and high fibrinogen levels.  
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5.4 Anticoagulant function in cerebral malaria: Antithrombin, 
protein C, protein S and activated protein C 
 
5.4.1 Anti-thrombin III and Protein C levels  
 Anti-thrombin III (ATIII) activity was measured in plasma levels taken at admission 
and compared against a standard pooled plasma from United Kingdom adults used 
by many routine diagnostic laboratories (see Chapter 2). ATIII activity was lower in 
69 children with retinopathy positive cerebral malaria (Fig 5.6; geometric mean 
74.6%; 95% CI 71.1 to 78.3%) than in 29 healthy control children (geometric mean 
115.3%; 95% CI 110.9 to 120.0%; p=<0.001), 13 children with mild aparasitaemic 
febrile illness (geometric mean 100.6%; 95% CI 86.2 to 117.4%) and 19 children 
with uncomplicated malaria (geometric mean 103%; 95% CI 95.7 to 110.8%). 
Compared with 19 children with retinopathy negative cerebral malaria (geometric 
mean 78.1%; 95% CI 76.0 to 96.9%) activity was significantly lower in the 
retinopathy positive cerebral malaria group when comparing the groups directly 
(p=0.02), but this was not significant when adjusting for multiple comparisons 
(p=>0.05). Levels in the retinopathy negative group were significantly different from 
the healthy control children (p=<0.001). Among children with retinopathy positive 
cerebral malaria there was not a significant difference between the 11 children who 
died (n=11; p=0.08) and the 52 children who survived to be discharged from hospital 
(n=57). However when expressing ATIII as a ratio with thrombin-anti-thrombin levels, 
to give an indication of the relative levels of available ATIII compared with the levels 
that have already been used to inactivate thrombin, ATIII-to-TAT ratio was 
significantly higher in patients who survived than those who went on to die 
(p=<0.01). 
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A similar pattern between diagnostic groups was demonstrated for protein C activity, 
also compared against a standard of pooled plasma from UK adults. Protein C 
activity is a method of detecting levels of protein C antigen, enabled by ex vivo 
activation of protein C and detection of the aPC levels in the converted plasma18. 
Protein C activity was markedly decreased in 68 children with retinopathy positive 
cerebral malaria (geometric mean 28.1%; 95% CI  24.0 to 33.1%) compared to 30 
healthy control children (geometric mean 79.3%; 95% CI 73.6 to 85.6%; p=<0.001), 
18 children with mild aparasitaemic febrile illness (geometric mean 52.6%; 95% CI 
42.3 to 65.5; p=<0.001), 20 children with uncomplicated malaria (geometric mean 
42.3%; 95% CI 35.9 to 49.8%; p=<0.05) and 11 children with non-malarial coma 
(geometric mean 49.8%; 95% CI 32.8 to 75.7%; p=<0.05). Among children with 
retinopathy positive cerebral malaria protein C activity at admission trended towards 
but was not significantly different in the 11 children who died (geometric mean 
20.1%; 95% CI 9.4 to 43%) from the 56 children who survived (geometric mean 
30.2%; 95% CI 26.7 to 34.3%; p=0.053). 
 
  
 
                                                
18 While it is possible to measure protein C antigen directly by ELISA, protein C activity is now more commonly 
used in UK laboratories.  
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Figure 5.6: Anti-thrombin and protein C activity in Malawian children grouped according to 
diagnosis and outcome:  
Panel A shows antithrombin III (ATIII) activity as a percentage (compared with United Kingdom adult 
plasma standards) at admission in children with (from right to left) retinopathy positive cerebral malaria 
(Ret pos cerebral malaria, n=69), retinopathy negative cerebral malaria (Ret neg cerebral malaria, 
n=19), non-malarial coma (n=11), uncomplicated malaria (n=19), mild non-malarial febrile illness 
(n=13) and healthy controls (n=29). Panel B shows ATIII activity at admission in patients with 
retinopathy positive cerebral malaria grouped according to outcome: those who went on to die (fatal 
(n=12) and those who survived (non-fatal; n=57). Panel C shows a ratio of ATIII to thrombin-anti-
thrombin complexes in fatal (n=11) and non-fatal (n=51) retinopathy positive cerebral malaria. 
Horizontal lines indicate geometric means. Panel D shows Protein C activity at admission in children 
with (from right to left) retinopathy positive cerebral malaria (Ret pos cerebral malaria, N=69), 
retinopathy negative cerebral malaria (Ret neg cerebral malaria, n=19), non-malarial coma (n=11), 
uncomplicated malaria (n=19), mild non-malarial febrile illness (n=18) and healthy controls (n=29). 
Panel E shows Protein C activity at admission in patients with retinopathy positive cerebral malaria 
grouped according to outcome: those who went on to die (fatal (n=11) and those who survived (non-
fatal; n=57). Asterisks indicate significant differences between groups, in panel A with a Tukey HSD 
and in panel C with simple regression: * p=<0.05; ** p=<0.01; *** p=<0.001.  
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5.5 Activated protein C levels and Prothrombin fragment-to-
activated protein C ratio in cerebral malaria.  
 
As discussed in Chapter 1, activated protein C is a principle plasma anticoagulant 
(Esmon 2000). Protein C activation is initiated by the presence of thrombin (Chapter 
1, Figure 1.6) and occurs on the endothelial receptors thrombomodulin and EPCR. 
We have shown that endothelial thrombomodulin and EPCR are decreased in the 
microvasculature at sites of iRBC sequestration in the brain, subcutaneous tissue 
and gut in cerebral malaria (Chapters 3 and 4). Expression of these receptors did 
not seem to be affected in larger vessels in which there is no iRBC sequestration. 
While the complete loss of thrombomodulin and EPCR in some areas in the 
microvasculature will lead to local impairment of protein C generation in those 
locations, it is important to establish how the mixed pattern of protein C receptor 
expression seen in cerebral malaria affects global aPC production.  In addition we 
have shown that thrombin generation is markedly increased in cerebral malaria 
(Figure 5.1) and also that protein C antigen levels are reduced. A possible 
explanation for this is that there has been rapid activation of protein C, resulting in 
consumption of protein C antigen outstripping production. To assess the balance of 
protein C activation to thrombin generation we measured aPC levels in benzamidine 
citrate plasma using an enzyme capture method (See Chapter 2, Section 2.3.2) and 
compared the ratio of thrombin generation, as determined by plasma F1+2 levels, to 
aPC levels between children with cerebral malaria and children with other acute 
febrile illnesses (Fig 5.7). 
The lowest level to which we could reliably detect aPC was 0.5ng/ mL; aPC levels 
were significantly higher in 92 children with retinopathy positive cerebral malaria (Fig 
5.7A; geometric mean 2.05 ng/mL; 95% CI 1.76 to 2.37 ng/ mL) than in 21 healthy 
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controls (geometric mean 0.88 ng/ mL; 95% CI 0.72 to 1.09 ng/ mL; p=<0.001); 25 
children with mild aparasitaemic febrile illness (geometric mean 1.17 ng/ mL; 95% 
CI 0.89 to 1.55 ng/ mL; p=<0.05) and 24 children with uncomplicated malaria 
(geometric mean 0.99 ng/ mL; 95% CI 0.71 to 1.38 ng/ mL; p=<0.05). There was not 
a significant difference in aPC levels between children with retinopathy positive 
cerebral malaria and those with retinopathy negative cerebral malaria (geometric 
mean 1.98 ng/ mL; 95% CI 1.58 to 2.47) or 5 children with non-malarial coma 
(geometric mean 1.43 ng/ mL; 95% CI 0.61 to 3.38 ng/ mL). F1+2-to-aPC ratio was 
similar between the different diagnostic groups (Figure 5.7, Panel C). 
Among children with retinopathy positive cerebral malaria there was not a significant 
difference in plasma aPC levels or in F1+2-to-aPC ratio on admission between the 
16 children who went on to die (Fig 5.7B; [aPC levels] geometric mean 2.09 ng/ mL; 
95% CI 1.35 to 3.23 ng/ mL; Fig 5.7 D; [F1+2 to aPC ratio] geometric mean 2.87; 
95% CI 1.21 to 6.80 ng/ mL) and those who survived ([aPC levels]: geometric mean 
2.04 ng/ mL; 95% CI 1.73 to 2.41 ng/ mL; p=0.91; [F1+2-to-aPC ratio]: geometric 
mean 1.45; 95% CI 0.89 to 2.38; p=0.2).  
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Figure 5.7: Plasma levels of activated protein C and of prothrombin fragment-to-activated 
protein C ratio on admission in Malawian children grouped according to diagnosis and outcome.   
Panel A shows activated protein C (aPC) levels in plasma taken on admission in children with (from 
right to left) retinopathy positive cerebral malaria (Ret pos cerebral malaria, n=92), retinopathy negative 
cerebral malaria (Ret neg cerebral malaria, n=22), non-malarial coma (n=5), uncomplicated malaria 
(n=24), mild non-malarial febrile illness (n=25) and healthy controls (n=21). Panel B shows plasma 
aPC levels in retinopathy positive children who went on to die (fatal, n=16) and those who survived 
(non-fatal, n=76). Panels C shows prothrombin fragment (F1+2)-to-aPC ratio in the same patients as 
Panel A and panel D in fatal and non-fatal retinopathy positive cerebral malaria. Horizontal lines 
indicate geometric means.  
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5.6 Activated partial thromboplastin time waveform in cerebral 
malaria 
The aPTT biphasic waveform is derived from an alteration that occurs to the light 
absorption pattern during measurement of aPTT (Downey, Kazmi et al. 1997). This 
process has been found to be a sensitive indicator of a procoagulant state (Toh 
2002) and has been incorporated into guidelines for recognizing compensated DIC 
(Toh and Downey 2005). It has been shown to be superior to C-reactive protein 
(CRP) in predicting outcome in severe sepsis (Toh, Ticknor et al. 2003) and superior 
to D-dimers for predicting DIC (Downey, Kazmi et al. 1998). It is measured on a 
MDA180 analyser, which displays and is capable of measuring the initial slope and 
not just the rapid change that is indicative of clotting. Initially noted to occur in 
patients with severe sepsis (Downey, Kazmi et al. 1997) a biphasic aPTT waveform 
has been found to be due to the calcium dependent formation of a complex between 
CRP and very low density lipoprotein (VLDL; (Toh and Giles 2002), although the 
reason that this occurs is not well understood. A value of 100% indicates that the 
light absorbance slope follows a typical pattern of healthy control plasma, which 
does not form CRP-VLDL complexes. Values less than 100% indicate deviation 
from this slope (a biphasic wave) and the lower the value the greater the deviation; 
indicating CRP-VLDL complex formation. From previous studies a value of less than 
95% has been determined as a cut-off to define a waveform that is strongly 
abnormal and definitely indicative of the presence of CRP-VLDL complex; values of 
less than 98% have been determined to generally be associated with complex 
formation and are considered borderline abnormal (Toh 2002). 
Compared with the healthy control children (median 99.6%) median waveform was 
lower in 72 children with retinopathy positive cerebral malaria (96.7%, p=<0.001) 
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and 20 children with uncomplicated malaria (98.5%; p=<0.05; Figure 5.8, Table 5-1). 
After correction for multiple comparisons none of the other groups were significantly 
different from the healthy controls (Figure 5.8, Table 5-1). Among children with 
retinopathy positive cerebral malaria median waveform was significantly lower in 
children who went on to die (90.5%) than in those who survived (97.4%; p=<0.05; 
Figure 5.8).  
 
 
Figure 5.8: Activated partial thromboplastin time waveform.  
Panel A shows aPTT waveform on admission in children with (from right to left) retinopathy positive 
cerebral malaria (Ret pos cerebral malaria, N=72), retinopathy negative cerebral malaria (Ret neg 
cerebral malaria, n=23), non-malarial coma (n=12), uncomplicated malaria (n=20), mild non-malarial 
febrile illness (n=16) and healthy controls (n=30). Panel B shows aPTT waveform at admission in 
patients with retinopathy positive cerebral malaria grouped according to outcome: those who went on 
to die (fatal (n=12) and those who survived (non-fatal (n=60). Solid horizontal lines indicate medians. 
Asterisks indicate significant differences between groups using a Mann-Whitney U test with adjustment 
for multiple comparisons in Panel A: * p=<0.05; ** p=<0.01; *** p=<0.001. Values below the black line 
(98%) are considered ‘borderline positive’, values below the red line (95%) are ‘strongly positive’.  
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Table 5-1: Activated partial thromboplastin time waveform in Malawian children 
 Healthy 
controls 
Mild 
febrile 
illness 
Uncomp. 
Malaria1 
Coma No 
Malaria 
Ret. 
Negative 
CM1 
Ret. Pos. 
Cerebral 
Malaria 
(All)2 
Ret. Pos. 
Cerebral 
Malaria 
(Non-
fatal) 
Ret. Pos. 
Cerebral 
Malaria 
(Fatal) 
Number of 
children 
30 16 20 12 23 72 60 12 
Median 99.59 99.35 98.54 99.34 98.95 96.66 97.42 90.51 
25% 
Percentile 
99.33 98.51 96.29 98.7 96.35 92.26 93.66 79.32 
75% 
Percentile 
99.79 99.95 99.29 99.7 99.47 98.96 99.01 97.25 
Borderline or 
strongly 
positive - no. 
(%) 
1 (3) 3 (18%) 8 (40%) 1  (8%) 7 (30%) 44 (61%) 34 (57%) 10 (83%) 
Strongly 
positive - no. 
(%) 
1 (3) 1 (6%) 3!(16%)! 0 5 (22%) 28 (39%) 21 (35%) 7 (58.3%) 
1Uncomp. malaria denotes uncomplicated malaria 
2Ret. denotes retinopathy 
3Pos. denoted positive  
 
5.7 Discussion 
5.7.1 Coagulation is activated but compensated in the systemic circulation 
in African children with cerebral malaria 
In Malawian children with cerebral malaria we found evidence of increased thrombin 
generation (Figure 5.1), a high rate of positive aPTT waveforms (Figure 5.8) and 
decreased protein C antigen and ATIII (Figure 5.6) indicating activation of 
coagulation. However tests of functional coagulation were only moderately 
deranged (PT was moderately prolonged and aPTT was not different from controls) 
and aPC was increased to maintain a F1+2-to-aPC ratio similar to controls. These 
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data indicate that although coagulation is activated, in the systemic circulation it is 
generally adequately compensated and that the coagulopathy with marked fibrin 
deposition demonstrated in cerebral microvessels does not occur throughout the 
systemic vasculature. It fits with the observation that loss of thrombomodulin and 
EPCR was localized to sites of iRBC sequestration and that decompensation is 
mainly restricted to the brain where constitutive levels of these receptors are low. It 
is also in keeping with data presented here (Chapter 4) and by others that indicate 
that malaria is a microvascular disease with pathology localized to the small vessels 
where iRBC sequester (Turner, Morrison et al. 1994; Dorovini-Zis, Schmidt et al. 
2011; Ponsford, Medana et al. 2012).  
Activation of coagulation has been demonstrated previously in adults with severe 
and uncomplicated malaria and might therefore be expected in African children with 
cerebral malaria. Yet because the phenotype of severe and cerebral malaria in 
African children is different from that in adults (see Chapter 1) and specifically overt 
thrombosis and mucosal bleeding occur less frequently in children, data cannot be 
extrapolated from adult studies. While one small study investigated PT and aPTT in 
cerebral malaria in African children, the data presented here represent the first study 
to systematically investigate coagulation in African children with malaria infection.  
5.7.2 Is a compensated activation of coagulation important? 
These data demonstrate marked activation of coagulation in the systemic circulation 
in cerebral malaria as indicated by raised TAT complexes. This activation is 
accompanied by consumption of the anti-coagulant factors protein C and ATIII. 
However this does not cause overt coagulopathy in the systemic circulation; there is 
an appropriate increase in aPC production – as indicated by the F1+2-to-aPC ratio, 
aPTT is normal and PT is only moderately increased.   
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A potential interpretation of these data might be that since coagulation in peripheral 
blood is compensated, coagulation is not an important contributor to cerebral 
malaria pathogenesis. While the demonstration of marked fibrin deposition in 
cerebral vessels is a clear demonstration that the activation of coagulation is not 
benign, the data on coagulation in peripheral blood also provides additional 
information about cerebral malaria pathogenesis when interpreted in the context of 
the contribution of coagulation to physiology and our understanding of the role of 
coagulation in the pathology of other diseases (reviewed in Chapter 1). In particular 
it is now widely recognized that a subclinical state of activation of coagulation, 
termed compensated disseminated intravascular coagulation (DIC) in a consensus 
report by the International Society of Thrombosis and Hemostasis (ISTH; (Taylor, 
Toh et al. 2001), is important in the disease process and in contributing to mortality 
even when it does not develop into overt DIC (Taylor, Toh et al. 2001; Toh and 
Downey 2005). The importance of such a state of activation of coagulation is 
thought to be through cross-talk with inflammatory pathways (Esmon, Taylor et al. 
1991) and by affecting endothelial function (Coughlin 2000; Mosnier, Zlokovic et al. 
2007) and we discuss the specific implications of these in a combined model of 
pathogenesis in Chapter 7.  
 
5.7.3 Increased thrombin generation and elevated prothrombin time but not 
activated partial thromboplastin time support activation of coagulation 
through the tissue factor pathway 
A striking finding here is the clear increase in thrombin generation in cerebral 
malaria as indicated by both increased TAT complexes and increased F1+2 (Figure 
5.1). Traditionally the activation of coagulation and production of thrombin was 
considered to occur by two pathways; the intrinsic pathway and the extrinsic 
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pathway (also known as the tissue factor pathway). While their separation is 
somewhat simplistic as there is overlap between them in vivo, independent 
consideration of these different pathways can help with understanding the 
mechanism of coagulation. PT is an indicator of the function of the extrinsic pathway 
and aPTT is an indicator of the function of the intrinsic and common pathways. 
While interpreting these with caution, the significant prolongation of PT but not aPTT 
would tend to indicate that there has been consumption of the factors specific to the 
extrinsic pathway, indicating that coagulation has been activated through tissue 
factor. This is in keeping with the findings in a previous study demonstrating that 
iRBC contact with the endothelium can induce endothelial tissue factor expression 
and that also showed tissue factor expression post-mortem in vessels in Malawian 
children who died of cerebral malaria (Francischetti, Seydel et al. 2007). Activation 
via the tissue factor pathway might also occur through the focal endothelial damage 
in the brain microvasculature (Dorovini-Zis, Schmidt et al. 2011) and through the 
platelet microparticles generated in cerebral malaria (Combes, Taylor et al. 2004). 
However evidence of activation through the tissue factor pathway in African children 
with cerebral malaria is in contrast to a study in non-immune Asian adults with 
severe and cerebral malaria in which the profile of coagulation factors indicated 
activation through the intrinsic pathway (Clemens, Pramoolsinsap et al. 1994). While 
the mechanisms for this activation through the intrinsic pathway are less apparent, 
different mechanisms of activation might in part explain why the clinical phenotype 
of coagulopathy is different in adults and children. 
 
5.7.4 Protein C activation is not impaired globally 
Despite the marked loss of the receptors EPCR and thrombomodulin in the 
microvasculature where iRBC sequester, we found no evidence of global 
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impairment in protein C activation in African children with cerebral malaria (Figure 
5.6). Total aPC levels were significantly raised in cerebral malaria when compared 
with healthy controls. The similar F1+2-to-aPC ratio in cerebral malaria when 
compared to healthy controls and the other diagnostic groups indicates that this 
increase was physiologically appropriate to meet the increased thrombin generation. 
This was the case even in children who went on to die (Figure 5.6, Panel D) 
although there was a slight but non-significant trend towards a higher F1+2-to-aPC 
ratio in fatal CM. This is in contrast to severe sepsis where global impairment in 
protein C activation is indicated by significantly increased F1+2-to-aPC ratio and in 
which fatal sepsis was associated with a significantly higher ratio (Liaw, Esmon et al. 
2004). This appropriate protein C activation, despite the loss of receptors essential 
in the process, might initially seem a contradiction. However it is important to 
consider that the aPC levels measured here are in peripheral blood whereas the 
loss of receptors was demonstrated in localized areas in the microvasculature. As 
discussed in Chapter 3 during the consideration of paired soluble and endothelial 
samples, a peripheral blood sample represents a pool that is contributed to by 
multiple organ beds and does not allow discrimination of the contribution of its 
component parts. Hence adequate protein C activation in vessels in which there is 
no iRBC sequestration and normal thrombomodulin and EPCR expression might 
mask failure of protein C activation at sites of where these receptors are lost. Indeed 
rather than a contradiction this asymmetrical picture in which the protein C pathway 
is impaired at very specific sites but not globally, in contrast to the more systemic 
protein C pathway impairment in sepsis, fits with the clinical pictures in the two 
syndromes; with evidence of global dysregulation in coagulation and endothelial 
function in sepsis in contrast to highly localized impairment in coagulation and 
endothelial function in cerebral malaria (discussed further in Chapter 7). 
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5.7.5 Potential limitations 
A potential limitation of these data is that coagulation assays and particularly assays 
of thrombin generation can be unreliable as they are very sensitive to iatrogenic 
coagulation created by localized activation of coagulation when venepuncture is 
traumatic. On the one hand it must be accepted that venepuncture in children is 
difficult and that it is likely that some of the data is explained by artefact (for example 
there are 2 healthy control children with TAT levels >50 µg/ mL that seem more 
likely due to artefact than natural variations in TAT levels). However, we made every 
effort to minimize trauma during venepuncture, which was performed by a small 
group of experienced clinicians and nurses. In addition the use of multiple control 
groups and the physiological consistency between different coagulation results goes 
against the trends in the data being due to artefact. Specifically high fibrinogen 
levels in several of the samples with the highest TAT levels (Figure 5.5, Panel B), 
the high number of biphasic waveforms (a test little affected by venepuncture and 
handling) and also the only subtle changes in functional coagulation indicate against 
coagulation artefact.  
Another potential limitation is that the dysregulated coagulation levels presented in 
this chapter are simply a bystander effect. A large number of factors have been 
shown to be elevated or decreased in malaria (see Chapter 1) and it might be 
argued that a further dysregulated pathway merely suggests that individuals with 
cerebral malaria are sick and that normal physiological process are likely to be 
disrupted as part of an inflammatory ‘storm’. While these are important questions to 
consider, the exploration of coagulation here was conducted with a view to better 
understand the physiology associated with a specific pathologic process – namely 
the coagulopathy that results in deposition of fibrin in a localized fashion at sites of 
iRBC sequestration in the cerebral microvasculature – and not just to detect blindly 
whether another pathway was dysregulated. The fibrinogen levels indicate further 
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evidence that the dysregulation of coagulation in the circulation is not merely 
elevated secondary to an inflammatory response. Plasma fibrinogen is consumed in 
the clotting process since fibrinogen is cleaved to produce fibrin, in contrast 
fibrinogen is raised during inflammation as part of the acute phase response. That 
fibrinogen levels are raised in retinopathy negative cerebral malaria but not in 
retinopathy positive cerebral malaria (Figure 5.5, Panel A) and further that fibrinogen 
level tend to be lower in sicker patients with higher TAT levels (Figure 5.5, Panel B) 
indicate that activation of coagulation is not merely occurring as part of a systemic 
inflammatory process. Yet, while disputing that the dysregulation in coagulation 
presented here can be dismissed purely as a bystander to inflammation, this is not 
to disregard that there is a link between the two processes. Indeed the crosstalk 
between coagulation, inflammation and endothelial function (Esmon, Taylor et al. 
1991; Levi, ten Cate et al. 2002) provides a further argument for understanding 
better the physiology of coagulation in this disease as it has the potential to link key 
pathogenic components frequently regarded as disparate entities. In addition 
biphasic waveforms in children with cerebral malaria and to a lesser extent with 
uncomplicated malaria indicate dysregulated lipid metabolism. Therefore before 
considering a combined model of disease that incorporates this novel data (in 
Chapter 7) we sought to better understand the endothelial processes in the disease 
acutely and during convalescence by examining soluble endothelial markers in the 
peripheral blood (Chapter 6).  
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6                                           
SOLUBLE FACTORS IN THE 
BLOOD IN UNCOMPLICATED 
AND CEREBRAL MALARIA
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6.1 Introduction 
Examination of soluble factors in blood enables analysis of patterns in large 
numbers of patients. The samples are more readily obtained than biopsies, and 
enabled us to examine levels at multiple time points.  
In this chapter we describe data in which we have examined soluble factors to 
expand our understanding in two specific areas: 
1) Acute changes in soluble factors in the blood in uncomplicated and 
cerebral malaria: we sought to better understand endothelial events in acute 
diseases and particularly the endothelial processes recognized by examination of 
endothelial expression in chapters 3 and 4; sTM, sEPCR and sICAM-1. sTM has 
been measured in one previous study in adults with uncomplicated and severe 
malaria (Hemmer, Bierhaus et al. 1994) but not in  children with cerebral malaria. 
sEPCR has not been previously measured in uncomplicated malaria or cerebral 
malaria in adults or children. sICAM-1 has been measured in four previous studies 
of children with cerebral malaria (Jakobsen, McKay et al. 1994; McGuire, Hill et al. 
1996; Roca-Feltrer, Kwizombe et al. 2012; Roca-Feltrer, Lalloo et al. 2012) but was 
measured again in our specific cohort for comparison with the other markers.  
2) Changes in soluble factors in the blood in uncomplicated and cerebral 
malaria over time and into convalescence: In this cohort we measured a panel of 
endothelial and inflammatory markers to better understand what happens to the 
endothelium and to inflammatory markers in the period after infection. This was to 
explore whether endothelial dysfunction persists beyond clearance of the infection, 
which might have important consequences for subsequent infections and for long-
term health (see Chapter 1).  
Methods for this chapter are described in Chapter 2.  
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6.2 Soluble thrombomodulin, Endothelial Protein C and 
Intercellular Adhesion Molecule-1 in cerebral malaria cases 
and controls 
In Chapter 4 we showed that endothelial thrombomodulin and EPCR expression is 
decreased in the microvasculature in cerebral malaria and that this was associated 
with increased levels of soluble thrombomodulin but not of EPCR in the blood in 
paired plasma samples. To further explore this process and whether it was specific 
to malaria we measured levels of soluble thrombomodulin and EPCR in plasma 
samples from a larger cohort of children with cerebral malaria. We compared levels 
in retinopathy positive cerebral malaria to those from other children with acute 
illness (enrolment criteria detailed in chapter 2): retinopathy negative cerebral 
malaria; aparasitaemic children with a non-malarial cause of coma; children with 
uncomplicated malaria; aparasitaemic children with mild febrile illness and healthy 
controls. Soluble thrombomodulin levels were higher in 72 children with retinopathy 
positive cerebral malaria (Figure 6.1; geometric mean [geo mean]= 9.3 µg/ mL; 95% 
CI 7.6-11.3 µg/ mL; p=<0.001) and in 95 children with uncomplicated malaria (geo 
mean= 5.9 µg/ mL; 95% CI 5.4-6.4 p=<0.01) than 36 healthy control children (geo 
mean= 4.7µg/ mL; 95% CI 4.7-5.2). In contrast there was not a significant difference 
between healthy controls and 23 children with retinopathy negative cerebral malaria 
(geo mean= 5.9 µg/ mL; 95% CI 4.3- 8.2; p=0.22); 10 children with non-malarial 
coma (geo mean= 3.8 µg/ mL; 95% CI 2.2-6.6 µg/ mL; p=0.55) or 103 children with 
mild febrile illness (geo mean = 4.5; 95% CI 4.1-4.9µg/ mL; p=0.55). Using the 
Tukey Honestly Significant Difference test (HSD; see Chapter 2, section 2.10) to 
statistically adjust for multiple comparisons only retinopathy positive cerebral 
malaria remained statistically significantly different from healthy controls (p=<0.001) 
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and retinopathy positive cerebral malaria was also significantly different from all the 
other groups (p=<0.05 for retinopathy negative cerebral malaria; p=<0.001 for mild 
febrile illness, uncomplicated malaria and non-malarial coma). Among patients with 
retinopathy positive cerebral malaria, soluble thrombomodulin levels on admission 
were significantly higher in children who went on to die (geo mean= 14.5 µg/ mL; 
95% CI 9.5 – 22.1 µg/ mL; p=0.013) than in those who survived (geo mean= 8.2 µg/ 
mL; 95% CI 6.6 – 10.1 µg/ mL). 
sEPCR was measured in the same cohort but, due to limited availability of samples 
was measured in a smaller number of children. sEPCR levels were increased in 47 
children with uncomplicated malaria (geometric mean 98.6ng/ mL; 95% CI 88.2 to 
110.1ng/ mL; p=<0.001) and 17 children with retinopathy negative cerebral malaria 
(geometric mean= 110.0ng/ mL; 95% CI 86.9 to 139.4 ng/ mL) when compared to 
35 healthy control children (geometric mean 62.5 ng/mL; 95% CI 54.9 to 71.1 
ng/mL). In contrast levels in 32 children with retinopathy positive cerebral malaria 
were not significantly different from the controls (Fig. 6.2).  
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Figure 6.1: Plasma soluble thrombomodulin levels in Malawian children grouped according to 
diagnosis and outcome.  
Graph on left shows plasma soluble thrombomodulin (sTM) levels taken on admission in children with 
(from right to left) retinopathy positive cerebral malaria (Ret pos cerebral malaria, n=72), retinopathy 
negative cerebral malaria (Ret neg cerebral malaria, n=23), non-malarial coma (N=10), uncomplicated 
malaria (N=103), mild non-malarial febrile illness (n=95) and healthy controls (n=19). Graph on right 
shows plasma sTM levels taken on admission in patients with retinopathy positive cerebral malaria 
cases grouped according to outcome: those who went on to die  (n=16) and those who survived 
(n=56). Bars are geometric means with 95% confidence interval.  
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Figure 6.2: Soluble Endothelial protein C receptor levels in Malawian children grouped 
according to diagnosis.  
Levels of soluble endothelial protein C receptor (sEPCR) were measured in plasma taken on 
admission in children with (from right to left) retinopathy positive cerebral malaria (Ret pos cerebral 
malaria, n=32), retinopathy negative cerebral malaria (Ret neg cerebral malaria, n=17), uncomplicated 
malaria (N=47), mild non-malarial febrile illness (n=47) and healthy controls (n=35). Asterisks indicate 
groups with significant differences from the healthy controls after adjusting for multiple comparison: * 
p=<0.05; **p=<0.01; *** p=<0.001.  
 
Using the Tukey HSD to adjust for multiple comparison sICAM-1 levels were 
significantly higher in 102 children with retinopathy positive cerebral malaria (Figure 
6.3; geo mean= 566 pg/ mL; 95% CI 494-648 pg/ mL; p=<0.001), 29 children with 
retinopathy negative cerebral malaria (geo mean 364; 95% CI 258-514 pg/ mL; 
p=<0.01) and 47 children with uncomplicated malaria (geo mean 476 pg/ mL; 95% CI 
413-549 pg/ mL; p=<0.001) than in 36 healthy control children (geo mean= 203 pg/ 
mL; 95% CI 178-232). Levels in 46 children with mild non-malaria febrile illness were 
not significantly different from controls (geo mean=290 pg/ mL; 95% CI 264-318). 
Levels in children with retinopathy positive cerebral malaria were also significantly 
higher than children with retinopathy negative cerebral malaria (p=<0.01) and mild 
febrile illness (p=<0.001) but were not significantly different from children with 
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uncomplicated malaria. Among patients with retinopathy positive cerebral malaria, 
sICAM-1 levels from plasma at admission were not significantly different between 
patients who went on to die (geo mean=655 pg/ mL; 95% CI 429-1002; p=0.5) and 
those who survived (geo mean 561 pg/ mL; 95% CI 485-650 pg/ mL).  
 
 
Figure 6.3: Plasma soluble ICAM-1 levels in Malawian children grouped according to diagnosis 
and outcome.  
Graph on left shows plasma soluble ICAM-1 (sICAM) levels taken on admission in children with (from 
right to left) retinopathy positive cerebral malaria (Ret pos cerebral malaria, n=102), retinopathy 
negative cerebral malaria (Ret neg cerebral malaria, n=29), uncomplicated malaria (n=47), mild non-
malarial febrile illness (n=46) and healthy controls (n=36). Graph on right shows plasma sTM levels 
taken on admission in patients with retinopathy positive cerebral malaria cases grouped according to 
outcome: those who went on to die  (n=9) and those who survived (n=91). 
 
 
To assess whether in cerebral malaria raised endothelial markers were associated 
with a systemic inflammatory response we compared levels of soluble 
thrombomodulin and ICAM-1 to TNF levels in the same patients, a cytokine that has 
been frequently implicated in cerebral malaria pathogenesis (Grau, Taylor et al. 
He
alt
hy
 co
ntr
ols
Mi
ld 
feb
rile
 illn
es
s
Un
co
mp
lica
ted
 M
ala
ria
Re
t N
eg
ati
ve
 C
M
Re
t P
os
itiv
e C
M
50.0
158.1
500.0
1581.1
**
***
sI
C
AM
 p
g/
 m
l
LO
G
***
Die
d
Su
rvi
ve
d
50.0
158.1
500.0
1581.1
sI
C
AM
 p
g/
m
l
LO
G
Chapter 6: Soluble factors in the blood  
 183 
1989; Kwiatkowski, Hill et al. 1990; Walther, De Caul et al. 2012). Due to limitations 
in sample volumes paired soluble thrombomodulin levels and TNF were done on 
samples recruited in 2008 and soluble ICAM-1 and TNF levels from samples 
recruited in 2010 and 2011. When TNF concentrations were plotted against soluble 
thrombomodulin concentrations in 71 children with retinopathy positive cerebral 
malaria for whom we had paired values, using a Spearman’s rank correlation there 
was a significant association (Figure 6.4; r=0.31; p=0.01). In contrast there was not 
a significant (Spearman’s rank) correlation between TNF and ICAM-1 
concentrations in the 96 children with retinopathy positive cerebral malaria for whom 
we had paired values  (Figure 6.4; r=0.04; p=>0.05). 
 
Figure 6.4: Association between TNF levels and Thrombomodulin and ICAM-1 levels.  
Left hand graph shows the concentration the comparison of TNF and soluble thrombomodulin (TM) 
levels in paired samples from 71 children with retinopathy positive cerebral malaria and right hand plot 
the comparison of TNF with soluble ICAM-1 levels in 96 children with cerebral malaria. 
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6.3 Tumour necrosis factor: inflammation and cerebral malaria 
pathogenesis 
6.3.1 Lack of association between TNF levels and mortality in cerebral 
malaria 
High TNF levels have in previous studies been shown to be associated with fatal 
outcome in Malawian children with severe malaria (Grau, Taylor et al. 1989) and 
Gambian children with cerebral malaria (Kwiatkowski, Hill et al. 1990). More recently 
however a study in Ugandan children found no difference in TNF levels between 
uncomplicated and cerebral malaria (Lovegrove, Tangpukdee et al. 2009) and a 
study in Indonesian adults found higher levels of TNF in P. vivax than in P. 
falciparum malaria (Yeo, Lampah et al. 2010). TNF levels in the cohort of children 
recruited in 2008 levels were raised in children with retinopathy negative (Fig 6.5; 
median 71.5 pg/ mL; Interquartile range [IQR] 11.7 pg/ mL to 250 pg/ mL) and 
retinopathy positive cerebral malaria (median 77.5 pg/ mL; IQR  34.3 pg/ mL to 420 
pg/ mL) when considering that TNF is generally not detectible in healthy children 
(Lovegrove, Tangpukdee et al. 2009). However there was no difference between the 
two groups (p=0.33) and among children with retinopathy positive cerebral malaria, 
TNF levels on admission were not significantly different between children who 
survived (median 102.3 pg/ mL; IQR  35.8 pg/ mL to 484 pg/ mL) and children who 
went on to die (median 62.4 pg/ mL; IQR  13.8 pg/ mL to 236 pg/ mL; p=0.22). 
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Figure 6.5: TNF levels in Malawian children with cerebral malaria recruited in 2008.  
Graph on the left shows TNF concentrations in plasma taken at admission in 19 children with 
retinopathy negative (ret neg) cerebral malaria) and 66 children with retinopathy positive (ret pos) 
cerebral malaria. Graph on right shows admission plasma TNF concentrations in children with 
retinopathy positive cerebral malaria in the 51 children who survived to discharge (non-fatal) and 15 
children who died (fatal). Horizontal lines indicate medians.  
 
6.3.2 Effect of HIV status on TNF levels 
In considering possible reasons for the lack of association between TNF 
concentration and mortality here and the lack of difference between levels in 
uncomplicated and severe malaria in the recent Ugandan study (Lovegrove, 
Tangpukdee et al. 2009) when compared with the two earlier studies that showed 
associations between higher levels and outcome (Grau, Taylor et al. 1989; 
Kwiatkowski, Hill et al. 1990) we considered significant epidemiological changes that 
might plausibly effect cytokine response. One major change that has occurred in 
Africa over the last 20 years is a significant rise in the prevalence of HIV. Therefore 
in the data from our 2008 cohort we compared TNF concentrations by HIV status. 
HIV status was available for 45 of the 66 patients retinopathy positive cerebral 
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malaria patients; the other 21 did not have an HIV test either because the parent or 
guardian didn’t give informed consent or because the child died before counselling 
and testing could be performed. Among the 45 children with retinopathy positive 
cerebral malaria for whom HIV status was known, although not significant (p=0.16) 
median TNF levels were more than twice as high in the 39 children who were HIV 
negative (median 102 pg/ mL; IQR  40.9 pg/ mL to 725 pg/ mL) than the 6 children 
who were HIV positive (median 43.5 pg/ mL; IQR 23.4 pg/ mL to 217 pg/ mL; Figure 
6.6). With only 6 HIV positive children this analysis was underpowered and while the 
post-hoc nature of this analysis, the small numbers and the lack of statistical 
significance did not allow us to draw any confident conclusions from this data we 
thought that this pattern might potentially be biologically significant. We therefore 
measured levels of TNF in patients recruited in 2010 and 2011 with the prospective 
hypothesis that HIV infection might affect levels of TNF during cerebral malaria such 
that TNF levels are lower in HIV positive than HIV negative children with cerebral 
malaria.  
Suitable blood samples were available for 162 children with retinopathy positive 
cerebral malaria for the two years. As in 2008 there was not a significant difference 
in TNF levels on admission between the 127 children who survived to discharge 
(median 20.6 pg/ mL; IQR 7.3 pg/ mL to 42.5 pg/ mL) and the 19 children who died 
(median 47.6 pg/ mL; IQR 7.7 pg/ mL to 91.8 pg/ mL, p=0.12; Figure 6.7) although 
in contrast to 2008 there was a trend toward higher levels in fatal disease. There 
was also not a significant difference in TNF levels in the 15 children who had severe 
neurological sequelae19 (median 16.5 pg/ mL; IQR 4.9 pg/ mL to 44.6 pg/ mL; Figure 
6.7); in whom the trend was towards lower TNF levels than in survivors without 
sequelae. From the 162 children with retinopathy positive cerebral malaria recruited 
in 2010 and 2011, 132 children were HIV negative, 13 children were HIV positive 
                                                
19 Defined as a motor deficit, such as weakness in a limb or of facial muscles, sensory deficit such as hearing or 
vision loss (partial or complete), development of epilepsy or regression in developmental milestones.  
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and HIV results were not available for 17 children.  Plasma TNF levels on admission 
in the 13 HIV infected children (median 6.5 pg/ mL; IQR 4.9 pg/ mL to 13.4 pg/ mL) 
were significantly lower than levels in the 132 HIV negative uninfected children 
(median 24.6 pg/ mL; IQR 7.8 pg/ mL to 48.1 pg/ mL; p= <0.008; Figure 6.7).  
 
 
Figure 6.6: TNF levels in Malawian children with retinopathy positive cerebral malaria recruited 
in 2008, grouped by HIV status.  
Plasma TNF levels on admission in 39 HIV negative (HIV -) children, 6 HIV positive children (HIV +) 
and 21 children for whom HIV results were not available (not tested). Horizontal lines indicate medians. 
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Figure 6.7: TNF levels in Malawian children with cerebral malaria recruited in 2010 and 2011; 
grouped by outcome, HIV status and retinal findings.  
Panel A shows plasma TNF levels on admission in children with retinopathy positive cerebral malaria 
grouped by outcome into the 127 children who survived to discharge without long-term sequelae (non-
fatal), 15 children who survived to discharge but had severe neurological symptoms (sequelae) still 
present at one month follow up and 19 children who died before discharge (fatal). Panel B shows 
admission plasma TNF levels in 132 children with retinopathy positive cerebral malaria who were HIV 
negative and 13 children who were HIV positive. Panel C shows children with cerebral malaria grouped 
by HIV status and retinal findings into: 132 children who were HIV negative and retinopathy positive 
(HIV – RET +), 43 children who were HIV negative and retinopathy negative (HIV – RET -), 13 children 
who were HIV positive and retinopathy positive (HIV + RET +) and 3 children who were HIV negative 
and retinopathy negative (HIV + RET -). Horizontal lines indicate the medians and where shown bars 
indicate the interquartile range. Comparison between non-fatal and fatal cases in Panel A and HIV 
negative and HIV positive retinopathy positive cerebral malaria cases in Panel B and C were 
performed using a Mann-Whitney U test.  
 
 
6.3.3 Effect of HIV on plasma IL-10 levels and TNF-to-IL-10 ratio in children 
with cerebral malaria 
While the lack of TNF production in HIV positive children with cerebral malaria may 
reflect decreased inflammatory response due to impairment in either T-helper-1 
(Th1) or monocyte/ macrophages function it may also reflect a change in the 
balance of pro-inflammatory and anti-inflammatory cytokines. The predominately 
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anti-inflammatory cytokine, IL-10 can decrease TNF secretion and has been 
implicated in cytokine perturbation in HIV in other aspects of HIV pathology (Ji, 
Sahu et al. 2005; Patel, Swan et al. 2009; Kwon, Angin et al. 2012). We therefore 
measured IL-10 levels in plasma of children with retinopathy positive cerebral 
malaria and compared absolute IL-10 levels and IL-10 levels as a ratio with TNF 
levels to look at the balance between these Th1 and Th2 related cytokines in HIV 
positive and negative children. IL-10 levels were significantly higher in the 120 HIV 
negative children with retinopathy positive cerebral malaria (Fig 6.8; median 0.43 
pg/ mL; IQR 0.27 pg/ mL to 0.96 pg/ mL) than in the 13 HIV positive children with 
retinopathy positive cerebral malaria (median 0.94 pg/ mL; IQR 0.48 pg/ mL to 2.7 
pg/ mL; p=0.046; Figure 6.8). However TNF-to-IL-10 ratio was not significantly 
different between children who were HIV negative (median 31.9; IQR 12.8 to 72.5) 
and HIV positive (median 16.1; IQR 6.4 to 56.5). 
 
 
Figure 6.8: IL-10 and TNF-to-IL-10 ratio in Malawian children with retinopathy positive cerebral 
malaria.  
Graph on left shows plasma IL-10 levels on admission in 120 HIV negative children (HIV - ) and 13 HIV 
positive children (HIV +). Graph on right shows TNF-to-IL-10 ratio on admission in the same children. 
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Horizontal lines indicate medians and statistical comparison between groups is with a Mann-Whitney U 
test.     
 
6.3.4 Effect of HIV status on soluble ICAM-1 levels in children with cerebral 
malaria 
Since the generation of Th1 type cytokines and particularly TNF has been linked to 
the upregulation of adhesion molecules on the surface of endothelial cells and 
thereby in augmenting iRBC cytoadherence and sequestration we examined 
whether there was reduced shedding of soluble ICAM-1 into the plasma in HIV 
positive children with cerebral malaria compared with HIV negative children. We 
therefore compared soluble ICAM-1 levels by HIV status in children with retinopathy 
positive cerebral malaria in the 2010 and 2011 cohorts. There was available sample 
for 107 HIV negative children and 12 HIV positive children. sICAM levels were 
significantly higher in the HIV negative children (median 563 pg/ mL; IQR 330 to 841 
pg/ mL) than in the HIV positive children (median 350 pg/ mL; IQR 289 to 437pg/ 
mL; p=0.041; Figure 6.9). When looking at sICAM-1 levels by HIV status and 
retinopathy the trend roughly mirrored that of TNF levels (compare Figure 6.7, Panel 
C with Figure 6.9, right Panel) 
 
Chapter 6: Soluble factors in the blood  
 191 
 
Figure 6.9: Soluble ICAM-1 levels in Malawian children with cerebral malaria grouped by HIV 
status.  
Graph on left side shows ICAM-1 levels in plasma on admission in children with retinopathy positive 
cerebral malaria 76 of whom were HIV negative (HIV -) and 9 of whom were HIV positive (HIV+). 
Graph on right shows admission plasma levels of soluble ICAM-1 in children with cerebral malaria 
grouped according to retinopathy and HIV status (from left to right): HIV negative and retinopathy 
positive (n=76); HIV negative retinopathy positive (n=20); HIV positive retinopathy positive (n=9); HIV 
positive retinopathy negative (n=3). Horizontal lines indicate medians and (in the left graph) bars 
indicate interquartile range. Statistical comparisons are with a Mann-Whitney U test. 
 
6.3.5 Differences in TNF levels by year 
In analysing the TNF data it became clear that the median TNF levels in 2008 were 
higher than those in the combined 2010 and 2011 cohort (p=<0.001) and when 
further subdivided it became apparent that the median levels were different for all 
three years (Figure 6.10; Table 6-1). There might be a number of causes for this 
variation which we will consider in the following categories: (1) systematic artefact of 
sample collection, processing or storage (2) systematic artefact of TNF 
measurement or (3) biological variations.  
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Firstly considering the sample collection preparation and storage. Although sample 
collection method has not changed over that period there were some differences in 
the method of plasma preparation and storage between 2008 and the combined 
2010 and 2011 cohort (2010/11). A technician was employed in 2010/11 to process 
the blood samples and plasma was therefore likely on average to have separated 
and frozen more rapidly in 2010/11 than in 2008. Since TNF is secreted by 
monocytes it is possible that the slower time to separation of plasma from whole 
blood resulted in greater ex vivo production of TNF in the 2008 samples. In addition 
plasma was aliquoted before freezing in 2010/11 but not in 2008. As a result all TNF 
measurements in 2008 were done on samples that had been freeze thawed at least 
once whereas the majority of 2010/11 samples had not been freeze/ thawed. 
Although it seems more likely that this would reduce measured TNF levels due to 
freeze-thaw degradation it is remotely possible that cryoprecipitation or evaporation 
of water from the samples resulted in artefactual concentration of TNF in the 2008 
samples.  
Considering sample measurement, samples from all three years were measured 
using a commercial ELISA antibody pair kit (Diaclone). However the 2008 cohort 
was measured with a different batch of antibodies and standards than 2010/11 and 
it is possible that some variation was contributed by the different batches.  
While plausible that these methodological differences in plasma preparation and 
storage and in TNF measurement explain some of the differences in TNF by year it 
is important to state that the methodological differences are between the 2008 and 
2010/11 cohorts. However while it is important to consider the reasons for 
differences between these cohorts, since we have examined each cohort 
independently, these methodological differences do not undermine the validity of the 
2010/11 data.  
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Considering biological reasons for the variation, clinical and laboratory indices that 
might be associated with variation in TNF levels were considered (Table 6-1).   
Multiple logistic regression was performed to find a best-fit model to explain the 
variation in TNF levels between the years, firstly between all three years (Table 6-2; 
r=0.201; p=0.0497) and secondly between 2010 and 2011 (Table 6-3; r=0.268; 
p=0.0401). The best- fit model for all three years indicated that significant 
independent associations with TNF were gender (sex; males tended to have higher 
TNF levels); prior treatment with any antimalarials (hxantima; children with prior anti-
malarial treatment tended to have lower TNF levels), prior treatment with 
lumefantrine-artemeter (hxla; children with prior lumefantrine-artemether treatment 
tended to have lower TNF levels) and HIV status (HIV positive children tended to 
have lower TNF levels than HIV negative children). Between 2010 and 2011 the 
best-fit model indicated that independent associations with TNF were sex, prior 
antimalarial treatment, blood lactate and HIV status.  
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Figure 6.10: TNF levels in Malawian children with retinopathy positive cerebral malaria grouped 
by year.  
Graph shows plasma TNF levels on admission in 105 children recruited in 2008, 2010 
children recruited in 2010 and 78 children recruited in 2011.  
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Table 6-1: Characteristics of children with retinopathy positive cerebral malaria by year 
 
2008 2010 2011 
Number of children 72 101 62 
TNF - pg/ mL median (IQR) 77.5 (35.2-403) 45.9 (15.7-83.1) 20.0 (6.6-48.8) 
Age – months (IQR) 43 (31-67) 45 (31-66) 50.5 
Female sex – (%) 45 (64.1) 48 (47.5) 33 (53.2) 
Parasitaemia – parasites 
x103/ ul (IQR) 86.5 (9.6-288) 74.7 (12.8-285) 71.4 (11.8- 332) 
Fatal outcome – (%) 15 (20.8) 14 (13.9) 7 (11.3) 
Prior ACT's - no. (%) 13 (18.1) 17 (16.8) 17 (27.4) 
Prior Antimalarials- no. (%) 35 (48.6) 51 (50.5) 25 (40.3) 
HIV - no. (%) 6 (8.3) 5 (5) 8 (13.1) 
Blood glucose - mmol/ L 
median (IQR) 5.9 (4.7-7.4) 6.8 (5.5-8.9) 5.9 (4.9-7.1) 
Blood lactate - mmol/ L 
median (IQR) 6.1 (3.2-10.3) 7.2 (4.1-12.2) 4.1 (3.0-8.1) 
Haemoglobin - g/ dL – median 
(IQR) 6.4 (5.2-7.6) 6.5 (5.3-8) 6.4 (5.1-7.5) 
Coma resolution - hours 
median (IQR) 34 (18-54) 34 (16-48) 44 (22-62) 
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Table 6-2: Output from Stata statistical software of best fit multiple logistic regression model for 
the prediction on TNF from clinical and laboratory data; 2008, 2010 and 2011.  
Sex denotes gender, hxantima denotes a history of prior treatment with at least one dose of an oral or 
parenteral anti-malarial drug prior to presentation to hospital, hxla denotes a history of prior treatment 
with at least one dose of oral lumefantrine-artemether prior to presentation to hospital 
 
 
Table 6-3: Output from Stata statistical software of best fit multiple logistic regression model for 
the prediction on TNF from clinical and laboratory data; 2010 and 2011 only.  
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6.4 Do soluble markers remain persistently elevated after 
parasites have been cleared?  
6.4.1 Profile of markers of endothelial activation - soluble ICAM-1, soluble E-
selectin and soluble Angiopoetin-2 – during acute malarial and non-
malarial illness and during recovery.  
Blood samples were obtained from 88 children with MF, 84 children with UM, 18 
children with CM and 36 healthy control children. Approximately 50% of these were 
followed up to day 28: 47 MF (53%), 41 UM (49%), 9 CM (50%). Reasons for failure 
to follow up were: patient died (CM n=2; UM n=2), did not attend follow up visits (CM 
n=4; MF n=33; UM n=31), parasitaemia or fever on follow up (CM group n=1; MF 
group n=2; UM group n=4), or a suitable blood sample was not obtained (technical 
difficulty or declined by child or guardian; CM group n=2; MF group n=6; UM group 
n=6).  
At enrolment sICAM-1, sE-selectin and Ang-2 were markedly raised in all febrile 
groups when compared with healthy controls (Figure 6.11; Table 6-4; p = < 0.001).  
At 7 days post-enrolment Ang-2 and sICAM-1 levels remained raised in all groups 
when compared with the healthy controls (Figure 6.11;Table 6-4); although there 
was not a significant difference between sICAM-1 levels in children with 
aparasitaemic mild febrile illness and the controls once we had adjusted for multiple 
comparisons. In contrast sE-selectin levels were only significantly raised in cerebral 
malaria at day 7 when compared with the controls. 
At 28 days post-enrolment Ang-2 and sICAM-1 levels remained significantly 
different from the controls in both uncomplicated malaria and aparasitaemic mild 
febrile illness (Figure 6.11; Table 6-4). Geometric mean levels in cerebral malaria 
were similar to uncomplicated malaria and aparasitaemic febrile illness and for 
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sICAM-1 were significantly higher than those in healthy controls using a simple non-
parametric comparison (p=0.04; Mann-Whitney U) but were not significantly different 
from the controls after adjusting for multiple comparisons (p=>0.05; Tukey HSD). At 
28 days post-enrolment E-selectin levels were not statistically different from the 
controls in any of the groups.  
In cerebral malaria patients, blood samples were also taken at 24 hours and 48 
hours and sICAM-1 levels were measured at these additional time points to show a 
more complete evolution of levels (Figure 6.12). This shows substantial reduction in 
sICAM-1 levels over the first 48 hours (geometric mean 757 pg/ mL at admission; 
609 pg/ mL at 24 hours and 477 pg/ mL at 48 hours; p=0.02) but levels were similar 
between 48 hours and 7 days; still remaining significantly different from levels in 
healthy controls (p=<0.001). Levels reduced between 7 and 28 days; with 28 day 
levels no longer being significantly different from controls.  
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Figure 6.11: Soluble ICAM-1, E selectin and Angiopoetin-2 levels in plasma during acute febrile 
illness and one week and one month later.  
Plasma levels of soluble Intercellular Adhesion Molecule (sICAM-1; top row) and E-selectin (middle 
row) and Angiopoietin-2 (Ang-2; bottom row) were measured at enrolment (Day 0) and at one week 
(Day 7) and one month (Day 28) follow up visits in: 84 children with uncomplicated malaria (UM); 88 
children with mild aparasitaemic febrile illness (MF) and 18 children with cerebral malaria (CM). 
Comparison is made with levels in 36 healthy control children (HC). Horizontal lines indicate geometric 
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means and bars 95% confidence intervals. Asterisks (*) indicate a statistically significant difference in 
comparison with the healthy controls and the number of stars the level of significance: * P = < .05; ** P 
= < .01 *** P = < .001. Where no asterisk is shown there is not a significant difference from the healthy 
controls  
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Table 6-4: Soluble markers in plasma at enrolment and at follow up visits.  
 Healthy controls  
(N=36) 
Mild febrile 
illness  
(N=87) 
P2 Uncomplicated 
malaria 
(N=84) 
P Ret Pos CM 
(N=18) 
P  
sICAM-1 pg/ mL 
enrolment  
198 (160-247)1 316 (295-339) < .001 464 (295-505) < .001 624 (377-1033) < .001 
sICAM-1 pg/ mL day 7 258 (235-282) ns 343 (299-394) < .001 478 (364-626) < .001 
sICAM-1 pg/ mL day 28 269 (242-299)  .05 277 (251-304) .01 291 (201-421) ns 
sE-selectin pg/ mL 
enrolment 
68 (57-82) 122 (105-142) < .001 147 (130-160) < .001 205 (158-266) < .001 
sE-selectin pg/ mL day 7 76 (66-87) ns 79 (68-91) ns 109 (77-154) .05 
sE-selectin pg/ mL day 28 79 (68-92) ns 82 (74-91) ns 93 (64-135) ns 
Ang-2 pg/ mL enrolment 232 (207-261) 382 (339-431) < .001 579 (523-641) <.001 1536 (1190-1982) <.001 
Ang-2 pg/ mL day 7  383 (333-440) < .001 442 (389-502) < .001 548 (401-749) < .001 
Ang-2 pg/ mL day 28  311 (275-350) < .01 320 (285-359) < .01 307 (213-443) ns 
sTM pg/ mL enrolment 4.7 (4.2-5.2) 4.5 (4.2-4.9) ns 6.0 (5.4-6.5) .05 9.1 (7.5-11.1) < .001 
sTM pg/ mL day 7 4.7 (4.3-5.1) ns 5.0 (4.4-5.6) ns 5.6 (4.3-7.2) ns 
sTM pg/ mL day 28 5.2 (4.8-5.6) ns 4.6 (4.1-5.3) ns 4.1 (3.4-5.1) ns 
CRP mg/ mL enrolment 0.41 (0.23-0.74) 26.7 (20-35) < .001 75 (61-92) < .001 149 (111-199) < .001 
CRP mg/ mL day 7 3.0 (2.0-4.4) < .001 5.3 (4.2-6.7) < .001 16.0 (8.3-32) < .001 
CRP mg/ mL day 28 0.62 (0.37-1.0) ns 0.73 (0.48-1.1) ns 12.7 (3.1-52) ns 
F1+2 pg/ mL day 
enrolment 
176 (140-220) 142 (120-167) ns 219 (180-268) ns 376 (245-577) .05 
F1+2 pg/ mL day 7 176 (135-229) ns 220 (186-260) ns 500 (279-898) ns 
  ns 142 (111-182) ns 180 (105-310) ns 
1All values are geometric means with 95% confidence intervals in brackets  
2P values are from statistical comparison with the healthy controls by Tukey honestly significant 
differences test to adjust for multiple comparisons. ns denotes not significant 
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Figure 6.12: Soluble Intercellular Adhesion Molecule levels in plasma during acute illness and 
during follow up in cerebral malaria compared with levels in healthy controls.  
In patients with retinopathy positive cerebral malaria soluble ICAM-1 levels were measured at 
admission (0hrs) and at 4 other time points during acute illness and recovery (the 0, 24 and 48 hour 
data is the same as that in Fig 6.11). Horizontal lines indicate geometric means and bars the 95% 
confidence intervals. Comparison is made with levels in 36 healthy controls children; solid green line 
indicates the geometric mean in healthy controls and dashed lines indicate 95% confidence intervals.   
 
 
6.4.2 Profile of C-reactive protein, soluble thrombomodulin and prothrombin 
fragment F1+2 during acute malarial and non-malarial illness and during 
recovery.  
Alongside markers of endothelial activation we measured CRP, sTM and F1+2 in 
the same cohort of patients. At enrolment CRP levels were raised in all acute illness 
groups when compared with the healthy controls (Figure 6.12; Table 6-4; all 
p=<0.001); sTM was raised in uncomplicated malaria and aparasitaemic febrile 
illness and F1+2 was raised in cerebral malaria only (p=<0.05). 
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At 7 days post-enrolment CRP levels were lower than at admission in all acute 
illness groups but remained significantly raised in all groups compared to the 
healthy controls (p=<0.001 for all groups). sTM levels in the acute illness groups 
were similar to the controls in all groups and F1+2 was raised in CM only (p=<0.001). 
At 28 days CRP levels in aparasitaemic mild febrile illness and uncomplicated 
malaria had further reduced and were no long significantly different from the controls. 
In contrast in cerebral malaria, while levels were lower at 28 days post-enrolment 
(geometric mean 12.7 mg/ mL) than at Day 7 (16.0 mg/ mL), they remained 
significantly different from controls (0.41 mg/ mL; p=<0.001). sTM and F1+2 levels 
were similar to the controls.  
As with sICAM-1, because blood samples were taken at 24 and 48 hours in patients 
with cerebral malaria we were able to examine more completely the evolution of 
CRP in cerebral malaria (Figure 6.14). The trend of CRP levels shows a different 
pattern than sICAM-1. Geometric mean levels were similar at admission (149mg/ 
mL; 95% CI 111 to 199) and 24 hours (177mg/ mL; 95% CI 124 to 254; p=0.4) and 
there were significant reductions between 24 and 48 hours (88 mg/ mL; 95% CI 49 
to 160mg/ mL; p=0.03) and 48 hours and 7 days (16.2; 95% CI 8.3 to 32 mg/ mL; 
p=<0.001).  
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Figure 6.13: Soluble Thrombomodulin and Prothrombin fragment F1+2 in plasma during acute 
febrile illness and one week and one month later.  
Plasma levels of soluble thrombomodulin (sTM) and Prothrombin fragment (F1+2) were measured at 
enrolment (Day 0) and at one week (Day 7) and one month (Day 28) follow up visits in: 84 children with 
uncomplicated malaria (UM); 88 children with mild aparasitaemic febrile illness (MF) and 18 children 
with cerebral malaria (CM). Comparison is made with levels in 36 healthy control children (HC). 
Horizontal lines indicate geometric means and bars 95% confidence intervals. * P = < .05; ** P = < .01 
*** P = < .001. 
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Figure 6.14: C-reactive protein levels in plasma during acute illness and during follow up in 
cerebral malaria cases.  
In patients with retinopathy positive cerebral malaria C-reactive protein (CRP) levels were measured at 
admission (0hrs) and at 4 other time points during acute illness and recovery. Horizontal lines indicate 
geometric means and bars the 95% confidence intervals. The solid green line indicates the geometric 
mean in healthy controls and dashed lines their 95% confidence intervals.  Asterisks indicate 
differences between adjacent time points that are statistically significant; adjacent time points without 
asterisks indicate that they were not significantly different.  
 
6.5 Discussion 
6.5.1 What do soluble receptors levels tell us about cerebral malaria 
pathogenesis? 
In previous chapters we have demonstrated that in cerebral malaria there is a 
change in the phenotype of the microvascular endothelium. The endothelium is 
activated as demonstrated by increased ICAM-1 expression on the endothelium in 
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subcutaneous biopsies (Chapter 4) and there is decreased expression of the 
receptors EPCR and thrombomodulin, as demonstrated in subcutaneous biopsies 
and in post-mortem subcutaneous and brain samples (Chapter 3). One possible 
mechanism for the decreased EPCR and thrombomodulin is cleavage of these 
receptors from the endothelial surface. In support of this mechanism, in plasma 
samples paired with the subcutaneous biopsies, we showed that sTM was markedly 
higher in the plasma in cerebral malaria cases than in healthy controls. However,  
reflecting its low relative expression in the microvasculature, plasma levels of 
sEPCR were not significantly different between cerebral malaria and controls. 
Because uncomplicated malaria is rarely fatal and because, while developing a 
novel method, we preferred to only take biopsies from comatose or anaesthetized 
children this data lacked an uncomplicated malaria group. This meant that we were 
unable to demonstrate whether these effects are specific to cerebral malaria or 
occur in all malaria infections. Notwithstanding the limitations discussed in 
interpreting levels of cleaved soluble receptors to infer information about the 
microvasculature, blood samples are far more readily obtained than biopsies. 
Therefore examining soluble factors enabled inclusion of more patients and groups 
with uncomplicated malarial and aparasitaemic febrile illness. It also allowed us to 
explore the association between levels of cleaved soluble receptors and outcome in 
a larger cohort of retinopathy positive cerebral malaria cases.   
The relative levels of all three receptors in retinopathy positive cerebral malaria were 
similar to those demonstrated in the small cohort in chapter 4, with increased 
sICAM-1 and sTM compared with healthy controls but no significant difference in 
sEPCR levels. sICAM-1 levels were also significantly raised in uncomplicated 
malaria and retinopathy negative cerebral malaria although to a lesser degree than 
in retinopathy positive cerebral malaria and a similar trend was true for sTM 
although with an even clearer differentiation between retinopathy positive cerebral 
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malaria and the other groups. Interestingly for sTM there was no difference between 
healthy controls and mild aparasitaemic illness or non-malarial coma indicating that 
an acute febrile illness even if it is severe enough to cause coma does not 
necessarily induce raised sTM. This supports that the increase in shed sTM relates 
to a difference pathogenic process between cerebral malaria and the other 
syndromes and is not just a bystander effect. In the context of the loss of 
thrombomodulin receptor on the endothelial surface it is suggestive of a mechanism 
that involves increased receptor shedding. 
While sTM data supports cleavage as a mechanism for the decreased levels of 
thrombomodulin on the microvasculature, the pattern of sEPCR does not. sEPCR is 
raised in uncomplicated malaria and in retinopathy negative cerebral malaria but is 
not raised in retinopathy positive cerebral malaria. These differences in soluble 
receptors may be explained by the different constitutive expression patterns of the 
different receptors; with thrombomodulin being expressed at high levels in the 
microvasculature and low levels in larger vessels and EPCR being expressed at low 
levels in the microvasculature and high levels in larger vessels. This may either: (1) 
result in the levels of sEPCR being more reflective of events in larger vessels and 
hence even large relative changes in shedding in the microvasculature make a very 
small contribution to the total sEPCR pool; (2) result in exhaustion of the EPCR 
receptor levels in the microvasculature in cerebral malaria by the point of 
presentation in coma and hence despite increased cleavage as a process compared 
with the other diagnostic categories the absolute levels are less. Another possibility 
is that while thrombomodulin is cleaved EPCR is reduced by downregulation either 
by soluble factors or by cell-signalling induced by iRBC cytoadherence. Clarifying 
which mechanism explains the loss of EPCR and thrombomodulin observed 
requires further work and would be most elegantly demonstrated using a co-culture 
model.  
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6.5.2 What does soluble TNF tell us about cerebral malaria pathogenesis 
General 
One of the early and highly cited studies looking at TNF in cerebral malaria 
commenced by suggesting that TNF: 
 ‘may affect the outcome of malaria in either of two ways: (a) TNF promotes various 
host responses… that may suppress parasite growth; (b) TNF induces metabolic 
and inflammatory changes…involved in the pathogenesis of cerebral malaria’ 
(Kwiatkowski, Hill et al. 1990) 
This opposing balance between protective and detrimental effects still remains 
ambiguous over 20 years later. As discussed in Chapter 1 and above in this chapter, 
the Kwiatkowski, Hill et al., study found higher TNF levels in cerebral malaria than in 
uncomplicated malaria and found an association between higher TNF levels and 
fatal outcome. The authors suggested that their data might indicate that TNF is 
important in the clinical progression from coma to death. However in a later study by 
many of the same authors, anti-TNF therapy in a randomized placebo controlled trial 
not only failed to prevent fatality in cerebral malaria, but also significantly increased 
neurological sequelae (van Hensbroek, Palmer et al. 1996). Studies in adults have 
found much lower levels of TNF in cerebral malaria and have found higher levels of 
TNF in P. vivax infection than in P. falciparum (Yeo, Lampah et al. 2010). And as 
mentioned above, a more recent study on cerebral malaria in Ugandan children 
found no difference in TNF levels between uncomplicated malaria and cerebral 
malaria (Lovegrove, Tangpukdee et al. 2009). Taken together these newer 
publications seem to indicate that the very high TNF levels found in Kwiatkowski et 
al., and in Grau et al., are neither necessary for cerebral malaria (non-immune 
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adults get cerebral malaria without large increases in TNF) nor sufficient (TNF is just 
as high in uncomplicated malaria and coma is not reversed by blocking TNF). Yet to 
dismiss that TNF might be important in cerebral malaria in African children might 
also be incorrect. As discussed in chapter 1 the phenotype of disease is different 
between non-immune adults and African children and hence the lower TNF levels in 
adult disease compared with children might, rather than indicating it to be 
unimportant, instead contribute to this difference in phenotype. The pleotropic 
effects of TNF (Beutler and Grau 1993) including the upregulation of adhesion 
molecules are very plausibly linked with pathogenesis and it should be considered 
that the determinant of disease syndrome and outcome between individuals may not 
be the absolute levels of TNF in the plasma but by differences in response between 
individuals. In this light we have shown that endothelial cells isolated from children 
with cerebral malaria are more responsive to TNF than endothelial cells from 
children with uncomplicated malaria (Wassmer, Moxon et al. 2010). 
Before discussing what our data adds to this evolving picture it should be 
emphasized that analysis of our TNF data has revealed the anomaly of decreasing 
median levels between 2008 and 2010 and between 2010 and 2011. As considered 
above while this may be due to artefact, on balance this is likely to be a genuine 
biological finding. As per our standard procedure for ELISA (see chapter 2) we have 
carried out repeat determination of TNF levels on the same samples. Results were 
internally consistent and still showed a reduction in TNF over the years 2008 to 
2011. However because this finding is unexpected and does not have a definite 
biological explanation, in this case a further set of repeats of a cross section of 
samples may be warranted to ensure that the results were not due to measurement 
bias.  
Assuming that the data are correct, the lack of a significant association between 
TNF levels and fatal outcome (or looked at differently a non-significant trend 
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towards higher TNF levels in cases with fatal outcome) when significant differences 
were demonstrated in previous studies in African children (Grau, Taylor et al. 1989; 
Kwiatkowski, Hill et al. 1990) indicates the complexity of the disease. Since the Grau 
study was done at the same unit as ours the difference are unlikely to be explained 
by racial factors. However over 20 years separates the studies and the differences 
might be due to epidemiological changes and this is supported by changes in TNF 
in our cohort over time (see below) and by the markedly lower TNF levels in HIV 
positive children. That HIV positive African children have retinopathy positive (i.e. 
definitive) cerebral malaria despite low absolute TNF levels (median 6.5 pg/ mL) 
strongly indicates that high TNF levels are not necessary for the development of 
cerebral malaria and challenge the proposed central role for it in cerebral malaria 
pathogenesis. This finding is particularly credible since it was found in a pilot and 
reproduced with a prospective hypothesis, making it unlikely that this is merely due 
to artefact or due to variation in TNF in individuals over time between pulsatile 
releases (Kwiatkowski, Hill et al. 1990). While HIV is associated with excessive 
background inflammation (Aukrust, Liabakk et al. 1994), it is also associated with 
decreased Th1 levels and with decreased monocyte/ macrophage function 
peripheral blood mononuclear cells from Canadian adults with HIV infection showed 
a decreased TNF and IL-10 response to challenge with P. falciparum infected iRBC 
than those from non-infected individuals (Finney, Kodjo et al. 2011). Further the lack 
of cytokine response is accompanied by lower cleaved sICAM-1 levels, indicating 
lower level of endothelial activation; raising the possibility that HIV positive children 
might have differences in the phenotype of cerebral malaria disease than HIV 
negative children. In support of this concept of a different disease phenotype in 
cerebral malaria in HIV positive individuals, in fatal cerebral malaria HIV positive 
children are more likely to have CM1 (Terrie Taylor, personal communication; i.e. 
sequestration but no haemorrhagic lesions or perivascular pathology) whereas HIV 
negative children are three times more likely to have CM2 than CM1 (Taylor, Fu et 
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al. 2004). Furthermore data on the pattern of PfEMP1 cytoadherence molecules 
expressed by the sequestered parasite populations infecting different individuals 
with fatal disease indicates a different pattern of PfEMP1 expression in parasites in 
cerebral vessels in HIV positive patients than in HIV negative patients (Dumizulu 
Tembo, personal communication).   While the numbers of children with HIV infection 
in our cohort are too low to convincingly explore clinical phenotype, in parallel to this 
study of TNF response in HIV positive children, we have investigated the clinical 
presentation of all HIV positive and negative children with retinopathy positive 
cerebral malaria over the past 9 years (data not shown). Intriguingly comparing a 
large number of clinical and laboratory characteristics and indicators of outcome 
between the 111 HIV positive and 639 HIV negative children with retinopathy 
positive cerebral malaria, the only statistically and clinically significant differences 
found were a longer duration of coma (median 42 hours compared with 34 hours) 
and a longer duration of hospital stay (median 4 days compared with 3 days) in the 
HIV positive children (Mbale, Chimallizeni et al. 2011). Mortality and sequelae were 
not significantly different although the proportion of children who died in the HIV 
positive group showed a trend toward being higher (17.1% in HIV positive compared 
with 12.7%; p=0.23).  
These data add to the picture that there is a complex balance between TNF 
assisting in defence of the host through parasite killing and on the other hand 
harming the host by causing metabolic dysregulation through inflammation. 
Considering all the available data it seems that broadly speaking a host response 
that results in very high TNF levels in a variety of diseases is associated with an 
excessive inflammation, endothelial damage (with microvascular thrombosis) and an 
increased risk of death (Beutler and Grau 1993). In contrast a host response 
associated with failure to raise plasma TNF levels is associated with delayed 
resolution of coma (longer coma in HIV positive ((Mbale et al unpublished) and in 
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2011 when TNF levels were lower; Table 6-1) and with an increased risk of 
neurological sequelae (increased neurological sequelae in ((van Hensbroek, Palmer 
et al. 1996) and a non-significant trend toward lower TNF levels in patients with 
neurological sequelae in our cohort Figure 6.7). We suggest a combined model 
incorporating this picture in Chapter 7. However the mechanism that dictates these 
differences in the levels of TNF remains unclear and may be due to either variations 
in the parasite or in the host. 
While recognizing that it is speculative and the potential contribution of 
methodological differences notwithstanding, there was a significant trend 
downwards over time in TNF levels over the 3 years measured (Figure 6.10). While 
this may well be a coincidence, with rises and falls between years, it is also possible 
that this trend is informative. While TNF factors included in the multiple logistic 
regression model only explained between 20% to 27% of the data, logistic 
regression models are necessarily reductive. Yet the demonstration among children 
admitted with cerebral malaria at QECH of lower lactate levels, a higher proportion 
of children having received artemisinin containing antimalarials before presenting to 
hospital, a lower proportion of children with fatal outcome among children admitted 
with cerebral malaria in our cohort and lower levels of systemic inflammation may 
indicate that in the context of numerous national malaria control and treatment 
programmes that cerebral malaria is becoming less severe in Malawi. The increased 
use of artemisinin containing drug prior to presentation in particular provide a 
biologically plausible explanation as artemisinin containing drugs not only reduce 
parasitaemia more rapidly but it has recently been shown that artemisinin decreases 
TNF transcription and secretion via inhibition of NFκB (Wang, Huang et al. 2011).  
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6.5.3 What do soluble factors tell us about the residual impact of malaria 
infection? 
 
We have shown that endothelial activation and systemic inflammation persists after 
malaria parasites are cleared from the circulation. This effect was most pronounced 
in cerebral malaria, in which CRP remained raised 22-fold at 28 day follow up when 
compared to the healthy controls. However even in uncomplicated malaria, CRP 
remained raised 13-fold at 7 day follow up and ICAM-1 remained significantly raised 
at 28 days. 
That the inflammatory response and marked endothelial activation induced by 
malaria do not immediately recover is to be expected, particularly since the effect 
was not pathogen specific, as non-malarial illness induced a similar effect. 
Furthermore, that E-selectin associated in other studies with a rapid rise in response 
to inflammatory stimuli (Kumpers, van Meurs et al. 2009; Paize, Sarginson et al. 
2012) reduced more rapidly than factors associated with a later peak in levels (CRP, 
ICAM-1) is physiologically predictable. However prolonged levels a month later of 
ICAM-1, Ang-2 and CRP cannot be explained by longer half lives alone. Although 
there are not published data for the half lives of ICAM-1 or E-selectin in plasma, 
Ang-2 has a half life of 18 hours (Fiedler, Scharpfenecker et al. 2004) and CRP of 
19 hours (Ho and Lipman 2009) and therefore on-going production is necessary to 
explain higher levels relative to the controls weeks after the acute illness. We 
hypothesise that this is due to a residual inflammatory insult from the disease 
process. An alternative explanation is that the differences in levels of these factors 
are due to innate differences between groups and that higher levels of these factors 
may be a risk factor in children acquiring disease. However, although this is a 
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plausible explanation for differences in the cerebral malaria group it seems less 
plausible in explaining the differences in ICAM-1 and Ang-2 in mild aparasitaemic 
illness and uncomplicated malaria.  
The indication that there is persistent inflammation and endothelial activation after 
malaria infection has important implications in malaria endemic countries because 
the burden of this infection is so large. The significant latent period of inflammation 
and endothelial activation demonstrated here, in the context of repeated infection, 
may be sufficient to prevent return to baseline before the next infection; leading to 
some individuals having a constantly dysregulated endothelial state. In the short 
term this may affect the response to exposure to a subsequent malarial or non-
malarial infections and may be important in explaining increased mortality in children 
with co-infection with several common viral pathogens and malaria when compared 
with either infection individually (Mallewa, personal communication). A persistent 
dysregulated endothelial state may also be important in understanding the reduction 
in all cause morality over and above that which can be explained by reduced deaths 
from acute parasitaemic illness demonstrated in studies in regions where malaria 
incidence has been reduced (Snow and Marsh 2002; Bhattarai, Ali et al. 2007; Scott, 
Berkley et al. 2011). In the context of malaria, residual endothelial activation may 
enhance the cytoadherence and sequestration of a new malarial infection and lead 
to the development of more rapid disease. In the context of a non-malarial pathogen, 
residual endothelial activation may facilitate invasion of enteric pathogens into the 
blood stream through vessels in the gut or potentially respiratory pathogens in the 
nasopharynx and indeed increased enteric invasion has been implicated in 
explaining a decrease incidence of bactaeremic illness in Kenya alongside the 
decreased incidence of P. falciparum infection (Scott, Berkley et al. 2011). In 
addition chronic endothelial activation and inflammation have been shown to be 
associated with the development of several chronic diseases including diabetes 
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(Goldberg 2009; Libby, Ridker et al. 2009) coronary artery disease (Libby, Ridker et 
al. 2009) and stroke (Granger and Laskowitz 2010). As illustrated in Chapter 7, 
there is considerable similarity between the endothelial activation in the context of 
inflammation that occurs in P. falciparum malaria and the inflammation and 
endothelial activation processes implicated in the development of atherosclerosis, 
particularly given the lipid dysregulation demonstrated by the biphasic waveform in 
Chapter 5.  
A limitation of this study was its small size. While it is possible that this has led to 
overestimation of the endothelial effects explored it is more likely that it has led to 
underestimation; as the small sample size gave us power only to detect relatively 
large differences between groups. Because of this we may have failed to detect 
differences between groups that may be of biologically significance.  For example in 
a Finish study, healthy children with CRP > 0.7 mg/mL had increased evidence of 
atherosclerosis as compared to those with CRP < 0.7 mg/mL (Juonala, Viikari et al. 
2006) however in our study a geometric mean of 0.73 mg/mL (95% CI 0.48-1.1) for 
CRP in uncomplicated malaria at 28 days was not statistically significantly different 
from that of healthy controls (0.41 mg/mL; 95% CI 0.23-0.74). An additional 
limitation of the study is that the soluble endothelial factors measured in peripheral 
blood are only surrogate markers of events on the endothelium itself and may lack 
sensitivity to detect events in the microcirculation where P. falciparum interacts 
directly with the endothelium.  
The inability of this study to measure focal effects might be particularly important in 
malaria since endothelial pathology is restricted to the microvasculature in which 
iRBC sequester (Ponsford, Medana et al. 2012). In cerebral malaria there is 
evidence that this is further restricted, as although iRBC sequester in multiple 
organs, tissue compromise is concentrated in the brain in which thrombi and 
microhaemorrhages occur; implying that the cerebral microvasculature is vulnerable 
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to the endothelial insult induced by malaria infection (Chapter 3). This vulnerability 
might be particularly relevant in the aetiology of stroke; for which there has been a 
rapid rise in incidence in sub Saharan Africa in recent years (Connor, Walker et al. 
2007), as people are tending to live longer. Common infections have been 
frequently found to be associated with stroke in epidemiological studies in 
developed countries (Grau, Urbanek et al. 2010). While individual pathogens such 
as Chlamydia pneumoniae and Influenza have been implicated, increasingly 
evidence indicates that rather than a single causal pathogen, risk is related to an 
aggregate infectious burden, with repeated infections triggering the interdependent 
inflammation, coagulation and lipid handling pathways (Grau, Urbanek et al. 2010). 
Because studies have been in high-income countries the effect of malaria has not 
been considered. However the inflammatory and endothelial derangements that we 
have demonstrated directly in Chapters 3 and 4 and indirectly in this chapter and the 
specific vulnerability of the brain to some of these effects imply that in endemic 
countries malaria may play a significant role in this aggregate burden. If further 
studies confirmed malaria as a risk factor in the development of stroke (or indeed in 
other cardiovascular disease through the development of atherosclerosis in 
peripheral or coronary arteries) this would have important implications for health 
policy, indicating a wider impact of preventing or early treatment of malaria infection. 
In this light, larger studies with longer periods of follow up are needed to clarify the 
significance of this for long-term health.  
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7                                    
GENERAL DISCUSSION 
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7.1 Introduction 
In each results chapter we have briefly discussed the data in that chapter, indicated 
our interpretation of the data and also the limitations of the approach used. In 
contrast in this final chapter we integrate the data from all the chapters and take a 
more speculative approach.  We first consider how the data considered together 
contributes to our understanding of cerebral malaria pathogenesis in African 
children by considering an integrated model (section 7.2; Figure 7.1). We then 
review how this model and the data from malaria in African children compares and 
contrasts with related conditions, each of which helps illustrate a different aspect of 
the data: protein C dysfunction and dysregulation of coagulation in malaria in 
comparison with bacterial sepsis (section 7.4); endothelial dysregulation in malaria 
in comparison with that implicated in atherosclerosis (section 7.5) and the role of 
inflammation in cerebral malaria in African children in comparison with non-immune 
South-East Asian and adults and with the murine model of cerebral malaria (section 
7.6). We finally consider how this new data on dysregulation of coagulation in 
malaria might inform new therapeutic approaches to adjunctive therapy in cerebral 
malaria (section 7.7). In addition, we identify four key areas for future research, 
which are presented in boxes interspersed with the text.   
 
 
7.2 Loss of protein C receptors links coagulation and 
inflammation with sequestration 
We have demonstrated a localized defect in a key endothelial homeostatic pathway 
in African children with cerebral malaria, occurring in the microvasculature at sites of 
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iRBC sequestration. In post-mortem (Chapter 3) and ex vivo (Chapter 4) samples 
we observed loss of the protein C receptors EPCR and thrombomodulin and in the 
brain, loss of EPCR was accompanied by fibrin thrombi and ring haemorrhages. In 
contrast and despite increased thrombin generation in cerebral malaria, in 
peripheral blood coagulation was compensated (Chapter 5), with functional 
coagulation tests only subtly prolonged and with appropriately raised aPC. These 
data demonstrate a unique pattern of impairment in the thrombin - protein C axis, 
induced at sites of iRBC sequestration. Because the fibrin deposition described is 
likely to markedly increase cerebral vascular congestion and because the protein C 
pathway regulates coagulation (Esmon 2000), inflammation31, endothelial 
permeability (Niessen, Furlan-Freguia et al. 2009) and protection against neuronal 
damage (Zlokovic and Griffin 2011), this previously unrecognized defect links 
principle microcirculatory (Ponsford, Medana et al. 2012) and cellular pathogenic 
components of the disease. 
The development during this project of a method to sensitively examine endothelial 
receptor expression ex vivo (Chapter 4) enabled us to show that loss of protein C 
receptors is already present at the point of presentation to hospital, indicating that 
this process is not purely associated with fatal or end-stage disease.  
We therefore propose a mechanism in paediatric cerebral malaria in which 
interaction between iRBCs and the endothelium increases both thrombin generation 
(Chapter 5) and, at the same time, the major endothelial negative feedback pathway 
for thrombin – the protein C pathway. Thrombin generation is probably initiated by 
the contact dependent induction of tissue factor on the endothelial surface 
(Francischetti, Seydel et al. 2007) and this is also supported by activation of the 
intrinsic pathway of coagulation (chapter 6). However increased tissue factor 
induction is not sufficient to explain pathology as, were the protein C pathway intact, 
thrombin induced activation of protein C would – through cross-activation of PAR1 - 
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induce anti-inflammatory, endothelial protective effects (Mosnier, Zlokovic et al. 
2007) (Figure 7.1, Panel A). Indeed, exogenous administration of thrombin to dogs 
provided protection from sepsis mortality through protein C activation (Taylor, 
Chang et al. 1984). However if the protein C pathway is impaired, thrombin signals 
directly to PAR1 with potent inflammatory effects through NFκB including: (1) 
upregulating cytokine production including endothelial and leukocyte TNF 
production and endothelial IL-6 production (Coughlin 2000), (2) inducing Weibel 
Palade body exocytosis leading to increased von Willebrand Factor and Ang-2 
production (Lovegrove, Tangpukdee et al. 2009). Since these factors act to increase 
endothelial adhesion molecules including ICAM-1 and VCAM-1, they augment 
cytoadherence and iRBC sequestration. This leads to further contact induced tissue 
factor expression and since TNF and thrombin have a synergistic effect on tissue 
factor induction (Liu, Pelekanakis et al. 2004) a positive feedback cycle is induced. 
This positive feedback cycle does not happen globally in cerebral malaria. In most 
tissues, despite reduction in EPCR and thrombomodulin by iRBC, there is sufficient 
reserve of surface-expressed EPCR and thrombomodulin. In contrast in the brain, 
where constitutive levels of these receptors are low, the reduction in EPCR and 
thrombomodulin is sufficient to lead to loss of protein C pathway function and a 
localized decompensation. This results in fibrin deposition, inflammation and fluid 
leak (see section 7.3) around cerebral vessels that have high levels of iRBC 
sequestration. These thrombin-induced effects correspond closely with the iRBC-
associated perivascular pathology observed in a recent comprehensive post-
mortem paediatric cerebral malaria study (Dorovini-Zis, Schmidt et al. 2011).  
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Figure 7.1: Sequestration induced loss of protein C receptors links coagulation, inflammation 
and endothelial permeability.  
PAR1 acts as a molecular switch - inhibiting or promoting inflammation and leakage - depending on 
whether or not there is a modifying signal from the protein C pathway. Panel A shows thrombin/ PAR1 
signalling when the protein C system is intact: 1) Thrombin initiates the thrombomodulin (TM)/ EPCR 
facilitated activation of protein C, which inhibits thrombin production upstream; 2) aPC modifies the 
effect of PAR1 through EPCR; 3) aPC/EPCR modified PAR1 signalling decreases endothelial 
permeability and has pleotropic anti-inflammatory effects. Panel B shows thrombin/ PAR1 signalling in 
a vessel with sequestered malaria infected red blood cells (iRBC) when there is complete loss of 
protein C receptors, such as in microvessels in the brain, and therefore no modification of PAR1 
signalling: 1) Malaria infected red blood cell sequestration is associated with a loss of TM and EPCR; 
protein C is therefore not activated; 2) Thrombin signals through PAR1, without modification by EPCR 
signalling 3) Unmodified PAR1 signalling increases endothelial permeability and leads to pleotropic 
pro-inflammatory effects; 4) these include: endothelial production of pro-inflammatory cytokines such 
as TNF and IL-6, the pro-inflammatory angiogenic factor Angiopoeitin 2 (Ang-2) and activation of 
platelets with the production of platelet microparticles; 5) In the absence of inhibition from aPC, 
thrombin triggers the production of fibrin from fibrinogen and fibrin and platelets coalesce to form 
thrombi; augmenting congestion and the impairment of cerebral circulation. 
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FURTHER RESEARCH (Box 1): Loss of protein C receptors links coagulation 
and inflammation with sequestration 
 
Question: By what mechanism does malaria decrease the receptors EPCR and 
thrombomodulin on the endothelial surface? 
Potential approach: Tissue culture; iRBC and endothelial co-culture model.  
Variations:  
• Potential! to! assess! importance!of! contact! by! the! use!of! transwell!plates! that! incorporate!a!
sieve!that!allows!free!solute!movement!between!iRBC!and!endothelial!cells!but!doesn’t!allow!
contact!between!the!cell!types!
• Potential! to! assess! the! importance! of! binding! by! cleaving! PfEMP1! or! by! blocking! key!
endothelial!cytoadherence!receptors.!!
Outputs:  
• Receptor!levels!(protein)!by!FACS!or!immunofluorescence!microscopy.!!
• Shed!receptor!in!supernatant!by!ELISA!
• mRNA!expression!levels!of!receptors!(EPCR!and!thrombomodulin)!by!real!time!PCR!
!
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FURTHER RESEARCH (Box 4): Phenotype of cerebral versus non-cerebral 
endothelium. 
 
Question:  
• What!are!the!different!expression!patterns!of!key!endothelial!receptors!in!the!vasculature!in!
the!human!brain.!Does!this!change!with!age?!
Potential approach:  
• Tissue!from!brain!and!other!organs!at!postWmortems!from!children!and!adults!who!have!died!
from! nonWneurological! illnesses! by! histology.! Exploration! of! endothelial! expression! by!
histology! and! adaptation! of! flow! cytometry! method! used! for! subcutaneous! endothelial!
phenotype!here.!!
Outputs:  
• Histology:!Immunohistochemistry!on!frozen!tissue!W!to!improve!antigenicity.!Distribution!and!
staining! intensity! –! brain! compared! with! nonWbrain! W! of! different! receptors! e.g.! EPCR,!
Thrombomodulin,!TAFI,!PAR1,!S1P1,!S1P3)!
• Flow!cytometry:!Fluorescence!intensity!of!different!endothelial!receptors!(as!above)!
• mRNA!levels!of!different!endothelial!receptors!in!digests!of!endothelial!cells! isolated!by!cell!
sorting.!!
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Figure 7.2: Mechanism of ring haemorrhage formation in brain microvessels in cerebral malaria.  
At sites of intense iRBC sequestration in cerebral microvessels activation of Inflammation and 
coagulation and loss of a major endothelial protective pathway (adapted from Moxon, Heyderman et 
al., 2009) leads to a positive feedback cycle of inflammatory and coagulopathic events. Inflammatory 
damage, and through the action of TGF-β and Ang-2 there is loss of cell-cell junctions and loss of 
endothelial integrity. In the context of excessive local consumption of coagulants there is haemorrhage 
through the endothelial breach.  
 
7.3 The protein C pathway and link to endothelial permeability 
As well as providing a mechanism that might explain cerebral specific coagulopathy 
and inflammation the loss of EPCR in cerebral vessels in the context of its low 
constitutive expression in microvessels in the brain (Chapter 3) provides a 
mechanism that might explain neurovascular specific fluid leak. The protein C 
pathway has been shown to be a critical mediator of endothelial permeability 
through PAR1 (Feistritzer, Lenta et al. 2005; Feistritzer and Riewald 2005). As with 
inflammation the same receptor regulates opposing functions (Figure 7.3). High 
levels of thrombin, unmodified by the protein C pathway signalling through PAR1, 
activates S1P3, which promotes vascular leak. Conversely in the presence of aPC- 
Chapter 7: Discussion 
 225 
EPCR signalling, PAR1/ EPCR signalling activates S1P1; reducing vascular leakage 
(Feistritzer and Riewald 2005).  
In mouse models of sepsis, leakage (in multiple organs including the lungs, gut and 
kidney) is associated with increased thrombin generation. Leakage is enhanced by 
anti-aPC antibodies and in a mouse mutant with diminished EPCR activity 
(EPCRlow) and is attenuated by aPC treatment and by blocking thrombin generation 
with hirudin (Niessen, Furlan-Freguia et al. 2009). Leakage is not attenuated by aPC 
treatment in EPCRlow mice.   
 
Figure 7.3: Protease Activated Receptor 1 regulates endothelial permeability through 
sphingosine 1 phosphate receptor subtypes.  
(a) When the endothelial protein C pathway is intact thrombin stimulates the activation of protein C and 
activated protein C (aPC) binds to Endothelial Protein C Receptor (EPCR). Cross-signalling of 
Protease Activated Receptor 1 (PAR1) from thrombin and aPC-EPCR results in activation of 
Sphingosine 1 phosphate type 1 receptor (S1P1) which enhances endothelial barrier function and 
decreases vascular leak. (b) Direct stimulation of PAR1 by thrombin without cross-signalling from 
activated protein C- EPCR results in S1P3 activation, which increases endothelial permeability and 
increases vascular leak. After (Niessen, Furlan-Freguia et al. 2009).  
 
While cerebral malaria does not lead to the widespread oedema that occurs in gram 
negative sepsis (in either mice or humans), the availability of MRI has revealed the 
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surprising finding that swelling of the brain is a common feature of cerebral malaria 
in African children (Figure 7.4; (Potchen, Kampondeni et al. 2012)) and indeed while 
a remarkable degree of swelling sometimes occurs in children who go on to survive 
(Figure 7.4), in the MRI study in Malawi thus far some brain swelling has been 
detectible in all children with cerebral malaria who go on to die (Terrie Taylor, 
personal communication). Further recent data from post-mortem studies (Dorovini-
Zis, Schmidt et al. 2011) and from retinal angiography (Figure 7.5; Simon Glover, 
personal communication) indicate that leak occurs at sites of high iRBC 
sequestration and particularly at sites of haemorrhage. The bottom right image in 
Figure 7.5 shows leakage of fluorescein at the site of a haemorrhage that has 
developed during the 30 minutes while angiography was being performed.  
Further support for the involvement of the PAR1 – S1P system in regulating 
endothelial permeability in cerebral malaria comes from data in the P. berghei 
mouse model of cerebral malaria. A mouse mutant in which S1P bioavailability is 
increased has improved survival and treatment of wild type mice with a the drug 
S1P1 agonist FTY720 results in improved survival and also in markedly decreased 
vascular leak in the brain as detected by Evans blue dye (Finney, Hawkes et al. 
2011). While many mechanisms demonstrated in the mouse model of cerebral 
malaria have not proved relevant in human cerebral malaria, the same study also 
demonstrated decreased S1P in Ugandan children with cerebral malaria when 
compared to children with uncomplicated malaria indicating that a similar 
mechanism might be implicated in human disease. Further investigation of the 
balance between S1P1 and S1P3 in the mouse model and the association between 
S1P and coagulation and leak in human disease is warranted.  
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Figure 7.4: Magnetic resonance imaging during acute illness and at 1 month follow up in a 
Malawian child with retinopathy positive cerebral malaria.  
Panel A shows an MRI taken while the child was comatose in the first 24 hours of admission. The brain 
is diffusely swollen including the brain stem, which has completely filled the posterior fossa and is 
impinging on the foreman magnum (arrow). Panel B shows a repeat MRI when the child had 
recovered. The brain looks normal with clear delineation of sulci and there is a clear space between 
the brain stem and foreman magnum (arrow). Images reproduced with permission courtesy of Terrie 
Taylor.  
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Figure 7.5: Retinal angiography and photographs of retina in child with cerebral malaria.  
All images are from one child. Panels A-C show images from the left eye and D and E the right. Panel 
A shows area of non-perfusion at the site of a retinal haemorrhage (red arrow; haemorrhage seen in 
Panel B and C) and an area of vascular leak (white arrow). Panel B is a photograph of the same area 
of retina prior to injection of fluorescein and angiography; a large red retinal haemorrhage is apparent 
near the top of the image. Panel C shows leakage of green fluorescein out of the vessel (white arrow) 
close to the haemorrhage. Panel D shows a photograph of the retina prior to angiography with a 
haemorrhage on the right side of the image. Panel E shows the same area of retina approximately 30 
minutes later after angiography has been performed; there is a new haemorrhage and leak of 
fluorescein from the vessel at the same site (white arrow). Images reproduced with permission 
courtesy of Simon Glover.  
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FURTHER RESEARCH (Box 2): The protein C pathway and link to 
endothelial permeability 
 
Question:  
• Is!increased!vascular!permeability!in!cerebral!malaria!mediated!through!EPCR?!
Potential approach:  
• Tissue!culture;! iRBC!and!endothelial! coWculture!model!using!transwell!plates!and!Evans!blue!
dye.!!
• Mouse!model;!P.#berghei! infection! in!wild! type!and!knockout!mice!using!Evans!blue!dye! to!
demonstrate! differential! leak! in! the! different! phenotypes! to! characterize! the! role! of! the!
thrombinWEPCRWPAR1WS1P!axis!in!vascular!permeability!in!murine!CM.!!
Variations:  
• CoWculture:! either! aPC! or! antibodies! against! EPCR,! PAR1,! S1P1! and! S1P3! can! be! used! to!
stimulate!or!block!various!components!of!the!pathway.!
• Murine!model:!EPCRlow,!PAR1W/W!and!S1P3W/W!mouse!mutants!and!pharmacological!blockade!of!
EPCR,!PAR1,!S1P1!and!S1P3!are!possible.!
Outputs:  
• CoWculture:!Receptor!expression!by!FACS!and!leak!by!Evans!blue!dye!
• Murine! model:! Plasma! markers! of! thrombin! generation! (TAT)! and! of! shed! EPCR! and!
thrombomodulin.!Receptor!expression!in!vasculature!by!immunohistochemistry!in!mice!post!
mortem.!Evans!blue!dye!leak!in!the!brain.!!!
Chapter 7: Discussion 
 230 
7.4 Comparison of paediatric cerebral malaria and severe 
bacterial sepsis  
 
Our findings in cerebral malaria are in contrast to the wide-ranging coagulation 
abnormalities associated with Gram-negative bacterial sepsis, where protein C 
pathway impairment is also strongly implicated in pathogenesis. In sepsis, loss of 
protein C receptors is accompanied by reduced plasma aPC-to-F1+2 ratio (Liaw, 
Esmon et al. 2004), indicating global impairment in aPC production, whereas in 
cerebral malaria a normal plasma aPC-to-F1+2 ratio indicates that disruption of 
coagulation is more localized and that there is sufficient retained capacity in the 
circulation overall to balance thrombin generation (Chapter 5). This is in keeping 
with retained thrombomodulin and EPCR in iRBC free vessels (Chapter 3). It also 
conforms with endothelial impairment being predominantly microvascular in cerebral 
malaria (Turner, Morrison et al. 1994); supported here by increased levels of 
cleaved sICAM-1 and sTM, receptors normally expressed at high levels in the 
microvasculature (Smith and Thomas 1990; Laszik, Mitro et al. 1997) but not of 
sEPCR (Chapter 4 and Chapter 6), a receptor which is principally expressed in 
larger vessels (Laszik, Mitro et al. 1997). This contrast between localized endothelial 
dysfunction in cerebral malaria and widespread dysfunction in sepsis is consistent 
with the clinical phenotypes (Table 7-1). Bacterial sepsis in children is frequently 
complicated by gross tissue oedema, hypotension and global coagulation 
abnormalities including purpura fulminans (Faust, Levin et al. 2001). In contrast, in 
African children with cerebral malaria, tissue oedema occurs specifically in the brain 
(Potchen, Kampondeni et al. 2012), hypotension is rare (Marsh, Forster et al. 1995) 
and here we show that coagulation in the systemic circulation is largely 
compensated (Chapter 5).  
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Table 7-1: Similarities and differences between meningococcal sepsis in children and cerebral 
malaria in children.  
Images of children with meningococcal sepsis and cerebral malaria reproduced with permission 
courtesy of Robert Heyderman and Terrie Taylor respectively.  
 
 
 
Meningococcal sepsis 
 
Cerebral malaria 
 
Similarities 
High mortality and sequelae despite effective antibiotics/ antimalarials 
Raised inflammatory cytokines 
Activation of coagulation and evidence of endothelial damage 
 
 
Differences 
Widespread tissue oedema Tissue oedema restricted to brain 
Severe shock – frequently multiple 
inotropes required 
Blood pressure usually normal 
Multiple organ failure (kidneys, 
lungs, heart) 
Specifically effects brain, failure of 
other organs rare 
Disseminated intravascular 
coagulation with purpura 
fulminans  
Intravascular coagulation 
localised to brain 
microvasculature  
 
 
It might be questioned why, given the vulnerability of the brain discussed here, that 
cerebral coagulopathy is not seen more often in Gram-negative sepsis. Although it 
has been described (Dixon 2004) it seems likely that the relative paucity of brain 
specific thrombosis in sepsis is related to the protection of the blood brain barrier in 
a condition in which invasion of the parenchyma is critical to pathogenesis. In 
contrast in malaria the pathology is intravascular. iRBC do not invade the 
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parenchyma and the pathology is related to interactions with the endothelium and 
with blood components; therefore the blood brain barrier does not provide protection 
against disease.  
 
 
7.5 Persistent endothelial activation; a link between malaria and 
atherosclerosis? 
 
It is now clear that the endothelium is a dynamic organ, tightly regulated by a 
network of communicating systems and capable of adapting in response to external 
stimuli (Aird 2007). Inflammatory, angiogenic and coagulation pathways are 
essential determinants of the status of the endothelium and there is considerable 
cross-talk between these pathways, with the protein C pathway being a key 
intersection (Esmon, Taylor et al. 1991; Mosnier, Zlokovic et al. 2007)Figure 7.6).  
During infection activation of the endothelium allows the endothelium to rapidly 
adapt to aid localization of the immune response to a pathogen. Upregulation of cell 
surface adhesion receptors and increased endothelial permeability assists in 
recruitment and trafficking of leukocytes across the endothelium to a site of an 
invasive pathogen. P. falciparum malaria, which is an intravascular disease and 
does not transmigrate (Ponsford, Medana et al. 2012), exploits this physiological 
system to improve its fitness Figure 7.6). By inducing endothelial activation and 
upregulation of adhesive surface receptors such as ICAM-1 it increases the 
adhesiveness of the endothelial surface and thereby enables iRBC to cytoadhere 
and sequester, thereby avoiding splenic clearance. That endothelial activation, 
cytoadherence and sequestration occur in P. falciparum malaria is well established 
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and while the potential for this to be induced by inflammatory cytokines has long 
been realized (Berendt, Simmons et al. 1989) more recently the involvement of 
angiogenic factors (Casals-Pascual, Idro et al. 2008; Yeo, Lampah et al. 2008) and 
iRBC-endothelial cell-cell signalling has become apparent (Tripathi, Sullivan et al. 
2006; Jenkins, Wu et al. 2007).  
Similarly the process of atherosclerosis involves pathological consequences through 
this same physiological process (Figure 7.6). Inflammation caused by a number of 
different exposures including smoking (Auerbach, Hammond et al. 1965; Garbin, 
Fratta Pasini et al. 2009), chronic disease such as diabetes (Kanter, Kramer et al. 
2012) and through a number of infectious diseases (Tufano, Di Capua et al. 2012) 
induces expression of surface adhesion molecules. Dysfunction in coagulation 
(Croce and Libby 2007) and specifically in the protein C pathway (Laszik, Zhou et al. 
2001) is also implicated possibly through inflammation induced downregulation. 
Blood monocytes are recruited by adhesion receptors and are trafficked through 
gaps in the endothelium to the intimal layer (Libby, Ridker et al. 2011). Here they 
differentiate to become macrophages, and by uptake of lipid they become foam cells 
(Adams, Abdulla et al. 1971). On cell death these foam cells release their content 
into the intimal layer. On-going inflammation in the intima, in part maintained by 
foam cells themselves induces rearrangement of the intimal structure, recruiting 
smooth muscle cells and eventually forming a ‘lipid core’ (Libby, Ridker et al. 2011).  
While we have demonstrated inflammation and endothelial activation in malaria, a 
third key component of atherogenesis is disordered lipid handling that enables the 
uptake of LDL and VLDL into the intima. Excess LDL and VLDL might seem unlikely 
in sub Saharan Africa as we generally associate these with excessive Western diets 
high in animal fats. However we have shown raised CRP-VLDL complexes as 
indicated by a biphasic waveform in the majority (57%) of cerebral malaria cases 
and also in 40% of cases of uncomplicated malaria (Chapter 5, Table 5.1). Although 
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this does not necessarily indicate increased total VLDL quantity, CRP-LDL 
complexes are detected in atherosclerotic plaques (Matsuura, Hughes et al. 2008) 
and in addition the CRP-VLDL complex itself increases uptake of VLDL by 
macrophages and in an experimental model leads to the development of foam cells 
(Simon Abrams, personal communication). It remains to be determined whether 
malaria infection is associated with increased oxidation of LDL, which occurs in 
bacterial sepsis (Behnes, Brueckmann et al. 2008) and is also associated with 
atherogenesis (Matsuura, Hughes et al. 2008). 
It is important to state that we have no direct evidence of an association between 
malaria and atherosclerosis. Further against the potential role for malaria to 
influence atherogenesis is that malaria primarily causes endothelial effects in the 
microvasculature and atherosclerosis primarily a process of medium sized and 
larger vessels. Nonetheless: (1) the similarity between the inflammatory and 
endothelial events in malaria infection and atherosclerosis Figure 7.6); (2) our 
demonstration that the inflammatory process and endothelial activation initiated 
during acute malaria infection is still present a month later (Chapter 6); (3) 
considered in the context of a disease that individuals in sub Saharan Africa may 
get several times per year, led us to wonder whether malaria infection might be an 
important risk factor for the development of atherosclerosis in endemic areas. 
Although now a major and rising cause of death, attention on cardiovascular 
disease in sub Saharan Africa is recent and the aetiology of stroke and coronary 
artery disease are poorly understood. We suggest that careful consideration of the 
contribution of malaria in epidemiological studies is warranted and should this show 
an association with malaria, consideration of the mechanism using a tissue culture 
model that incorporates co-culture of iRBC and endothelium with established tissue 
culture models of atherosclerosis and/ or using a mouse model would be indicated.  
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Figure 7.6: Pathological consequences of a physiological process; similarities between acute 
endothelial events in malaria and chronic endothelial events in atherosclerosis.  
Panel A shows quiescent endothelium. Cytokines are not secreted and there are minimal levels of 
adhesion molecules, the protein C pathway is intact. Panel B shows key events implicated in 
atherosclerosis. Chronic inflammation induced by a number of different risk factors such as cigarette 
smoking, hyperlipidaemia, periodontitis (leading to chronic bacteraemia) and other infectious diseases 
such as chlamydia pneumoniae lead to secretion of cytokines such as TNF, IL-6 and IL-1β and to 
upregulation of endothelial adhesion molecules such as VCAM-1 and ICAM-1. Chronic inflammation 
also impairs endothelial anticoagulant function – through the protein C pathway – and via cross-talk 
with inflammation this further upregulates adhesion molecules and increases endothelial permeability. 
Monocytes, assisted by signalling from activated platelets, are recruited and pass through the 
endothelial layer into the intima. Monocytes differentiate into macrophages and take up VLDL and LDL 
lipid to form foam cells. Release of free lipid into the intima by apoptosed foam cells and foam cells 
themselves induce inflammation in the intima leading to reorganisation of the intimal structure with 
migration of smooth muscle cells and the formation of a lipid core (not shown). Panel C shows 
endothelial and inflammatory events in malaria infection. iRBC induce increased cytokine production 
and lead to upregulation of endothelial adhesion molecules. iRBC also activate coagulation, through 
the induction of tissue factor on the endothelial surface (not shown) and also by reducing 
thrombomodulin (TM) and EPCR expression. Thrombin further upregulated adhesion molecules 
through cross-talk with inflammation. iRBC cytoadhere to the upregulated adhesion molecules. During 
acute infection there is some monocyte adhesion but iRBC probably compete with monocytes for 
adhesion receptors. However, inflammation and adhesion molecule upregulation persist after parasites 
are cleared and monocyte recruitment may occur more effectively (or continue to occur at low levels). 
Whether monocytes enter the intima needs following malaria infection is yet to be determined. CRP-
VLDL complexes are present in both uncomplicated and cerebral malaria but whether this is 
associated with lipid uptake and foam cell formation in vivo is yet to be determined.  
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7.6 Of mice and men (and children)  
The contribution of mouse models of malaria to our understanding of human 
disease have been a cause of controversy and a matter of recent debate (de Souza, 
Hafalla et al. 2010; Hunt, Grau et al. 2010; Riley, Couper et al. 2010; White, Turner 
et al. 2010). Critics of the utility of mouse models in cerebral malaria site the lack of 
sequestration in murine cerebral malaria, a defining component of cerebral malaria 
pathogenesis in human disease, and also highlight that numerous treatments that 
have been highly effective in murine models have shown no translational benefit in 
humans (White, Turner et al. 2010). Proponents of mouse models highlight the 
obvious advantages of animal models for the study of disease and, despite a lack of 
sequestration, site numerous similarities between human and murine disease (de 
Souza, Hafalla et al. 2010; Hunt, Grau et al. 2010). While a resolution between 
these two camps is unlikely, some middle ground has been achieved (Craig, Grau et 
al. 2012) and it seems reasonable to consider that the murine model assists in our 
understanding as long as the concepts are shown to be relevant in disease in 
humans.  
In the context of inflammation it seems clear that in murine cerebral malaria 
inflammation is a critical component of pathogenesis and determinant of disease 
outcome as TNF and other cytokine levels are highly elevated (Hunt, Golenser et al. 
2006) anti-TNF antibody reverses cerebral malaria symptoms and attenuates 
mortality (Grau, Fajardo et al. 1987) and lymphotoxin knockout mice don’t get 
cerebral malaria at all (Parekh, Bubb et al. 2006). In human cerebral malaria the role 
of inflammation is less clear-cut. Indeed higher levels of TNF and other inflammatory 
markers in P. vivax infection than P. falciparum (Yeo, Lampah et al. 2010) despite 
much lower levels of severe disease and cerebral involvement in P. vivax, low 
absolute TNF levels in adults with cerebral malaria (Lovegrove, Tangpukdee et al. 
2009), the failure of anti-TNF therapy to decrease mortality (van Hensbroek, Palmer 
Chapter 7: Discussion 
 237 
et al. 1996) and evidence here that children with HIV infection get cerebral malaria 
despite minimal TNF response (Chapter 6) might lead to the conclusion that 
inflammation and TNF is not involved at all in human cerebral malaria. Yet this 
conclusion might be too simplistic, particularly in paediatric disease. While not 
always associated with mortality (Chapter 6) or severe disease (Lovegrove, 
Tangpukdee et al. 2009), the levels of TNF in paediatric cerebral malaria are 
consistently high (Grau, Taylor et al. 1989; Kwiatkowski, Hill et al. 1990; Lovegrove, 
Tangpukdee et al. 2009) and are approximately 10 times higher than in adult 
disease (Lovegrove, Tangpukdee et al. 2009). TNF has profound effects on multiple 
metabolic pathways (Beutler and Grau 1993) and, of particular relevance, it causes 
potent upregulation of endothelial adhesion receptors – and indeed in tissue culture 
models of malaria upregulation of adhesion molecules by a cytokine such as TNF is 
frequently necessary to induce effects by iRBC on other cell types. It therefore 
seems unlikely that the significantly increased levels found would be unimportant. 
We suggest that the discrepancy between an involvement in pathogenesis and an 
inconsistent association with outcome may be reconciled by the following 
considerations: (a) that an adequate TNF response is important in clearing parasites 
and hence its presence may be both protective and detrimental (b) that TNF levels 
in the periphery, as discussed with endothelial markers (Chapter 4 and 6), may be a 
poor proxy for levels in microvasculature in the brain (c) that there are inter-
individual difference in response to TNF at the endothelial level (Wassmer, Moxon 
et al. 2010) and this may be critical in determining the progression not only from 
uncomplicated to severe disease but also from coma to death. In light of this we 
propose that there is a spectrum in the extent of involvement of systemic 
inflammation in disease pathogenesis and determination of outcome from mice 
(very important) to non-immune adults in South-East Asia (not very important) with 
children with cerebral malaria lying in the middle of the spectrum (Figure 7.7). Yet 
the results presented here show that among African children with cerebral malaria, 
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even once refined by the use of retinal examination, there is considerable 
heterogeneity in the extent of the inflammatory response. It is interesting to 
speculatively consider this alongside the spectrum in disease phenotypes already 
recognized in the Blantyre post-mortem study. Specifically HIV positive children with 
cerebral malaria have less inflammation and are more likely to have a post-mortem 
classification of CM1 – indicating that they have sequestration of iRBC in cerebral 
vessels but that this is not associated with ring haemorrhages or other perivascular 
pathology. In Chapter 3 we demonstrated that the lack of haemorrhages and 
perivascular pathology is not explained by a lack of involvement of coagulation as 
there was substantial fibrin deposition in the three CM1 cases examined, no 
different in extent to the CM2 cases. Since haemorrhage and perivascular pathology 
requires endothelial damage and a breach in the vessel integrity, the indication is 
that the process involved in vascular damage in CM2 is absent in CM1. We 
speculate that this is likely to be an inflammatory mechanism such as endothelial 
damage by monocytes and/or neutrophils. In support of such an inflammatory 
mechanism resulting in haemorrhages, substantial haemorrhage occurs in cerebral 
vessels in murine cerebral malaria despite the absence of iRBC sequestration and 
is associated with and occurs following monocyte accumulation (Ma, Hunt et al. 
1996). Further in murine cerebral malaria models haemorrhage and vascular leak 
does not occur in Lymphotoxin receptor deficient mice, who do not get mononuclear 
cell accumulation (Togbe, de Sousa et al. 2008) and inhaled NO treatment 
decreased leukocyte adherence and the number of haemorrhagic lesions (Cabrales, 
Zanini et al. 2011). To examine the role of inflammation and leukocyte recruitment in 
the development of haemorrhage and perivascular pathology a combined post-
mortem and in vivo approach could be used. Post-mortem it is possible to examine 
the association between leukocyte recruitment and haemorrhages and/ or 
perivascular pathology and in vivo retinal haemorrhages can be used to recognize 
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perivascular pathology/ CM1 disease and their association examined with a panel of 
pro-inflammatory cytokines.  
 
 
 Mice African child  
CM2/ HIV - 
African child  
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TNF levels Very high Moderate to high Low to moderate Low to moderate 
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Figure 7.7: Considering the contribution of tumour necrosis factor to cerebral malaria 
pathology in mice and humans. 
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FURTHER RESEARCH (Box 3): Inflammation in HIV and cerebral malaria 
 
Question:  
1. Is! decreased! TNF!production! in!HIV! positive! children!with! cerebral!malaria! associated!with!
impaired!monocyte!function?!
2. Is!the!development!of!CM1!or!CM2!related!to!the!degree!of!inflammatory!response!!
Potential approach:  
1. Stimulation!of!peripheral!blood!mononuclear! cells! from!patients!with! cerebral!malaria!with!
and!without!HIV!infection!and!measurement!of!cytokine!response.!!
2. In!vivo!and!postWmortem.!Comparison!of!cytokine!profiles!in!patients!with!and!without!retinal!
haemorrhages.!Histology!on!postWmortem!brain!samples!from!patients!with!CM1!and!CM2.!!
Outputs:  
1. Cytokine!levels!from!PBMCs!by!ELISA,!FACS!or!ELIWSPOT!
2. Cytokine! profiles! by! multiplex! or! ELISA.! Leukocytes! and! CD40! ligand! by!
immunohistochemistry!!!
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7.7 Suggestions for adjunctive therapies in cerebral malaria 
 
Currently no adjunctive therapy has been shown to improve survival in human 
cerebral malaria in randomized controlled trial (John, Kutamba et al. 2010). 
Numerous agents that have been effective in mouse models have failed to show 
efficacy in human disease in either adults or children (White, Turner et al. 2010).  
Could therapy directed at addressing the dysregulation in the protein C pathway or 
the coagulation-inflammation interface be effective? As reviewed in the introduction 
(Chapter 1) thus far only pilot studies have been conducted to look at this question 
and none were powered to show a difference in outcome.  
The data here demonstrating dysregulation in the protein C pathway provide a 
potential focus for therapies. However giving aPC, while the most obvious choice, 
may not be the best option. For several years the activated protein C conjugate, 
drotrecogin alpha (commercial name Xigris) was the source of optimism in the 
sepsis community after it was shown to reduce mortality in a phase 3 double-blind 
placebo controlled (Bernard, Vincent et al. 2001). However a larger follow up study 
of Xigris failed to confirm benefit and it was withdrawn from the market for the 
treatment of sepsis by its manufacturer Eli Lily (Ranieri, Thompson et al. 2012; 
Thachil, Toh et al. 2012). In addition because it is an anti-coagulant as well as an 
anti-inflammatory agent drotrecogin alpha did demonstrate a small increase in risk 
of bleeding, which is a potential concern. Since sepsis and cerebral malaria have 
marked differences it is possible that it would be highly effective in cerebral malaria 
despite not being in sepsis. In addition, the recent development of non-anticoagulant 
aPC variants (Niessen, Schaffner et al. 2008) would avoid risk of bleeding. Yet since 
aPC requires EPCR to activate cross-signalling of PAR1 a concern is(Patel, 
Mahaffey et al. 2011) that aPC itself might fail to counter the effects of thrombin at 
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locations of high iRBC sequestration where EPCR has been lost (specifically the 
brain): precisely in the location where it is needed. In addition the high cost of aPC 
conjugate is likely to be prohibitive, even if loss of patent and increased production 
brought costs down substantially. Considering the mechanism we have 
demonstrated, it may be necessary to either move upstream and reduce the 
generation or effects of thrombin, or downstream and act through S1P (blocking 
S1P3 or an agonist to S1P1) or PAR1.  
Considering drugs aimed at reducing thrombin generation, the advent of a new 
generation of oral anti-coagulants (Goel and Srivathsan 2012) acting either on the 
enzyme that cleaves thrombin from prothrombin, prothrombinase (factor Xa; e.g. 
rivaroxiban) or on thrombin directly (e.g. Dabigatran etexilate) offer promise. Lower 
complications of these drugs and equivalence to current therapy in large blinded 
placebo controlled trials at preventing venous thrombosis after surgery (Lassen, 
Ageno et al. 2008; Friedman, Dahl et al. 2010) or stroke in those with atrial 
fibrillation (Connolly, Ezekowitz et al. 2009; Patel, Mahaffey et al. 2011) with low risk 
of bleeding and without the need for drug monitoring suggests that these drugs are 
safe. Furthermore the non-inferiority and improved benefit-risk profile of the anti-Xa 
agent rivaroxaban when compared with enoxaparin (heparin) in the treatment of 
deep vein thrombosis (Bauersachs, Berkowitz et al. 2010) and pulmonary embolism 
(Buller, Prins et al. 2012) suggest that these drugs are useful in the treatment, as 
well as prevention, of thrombotic disorders. Clearly the safety of these agents in the 
context of the endothelial and metabolic disturbances in cerebral malaria would 
need to be investigated before trials could be considered.  
Considering drugs aimed at PAR1 and S1P1, in LPS challenged mice an S1P1 
agonist reverses vascular leakage even when aPC treatment does not (Niessen, 
Furlan-Freguia et al. 2009) and, as discussed above, S1P1 activation with FTY720 
decreases mortality and cerebral vascular leak in a mouse model of cerebral 
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malaria (Finney, Hawkes et al. 2011).   However a problem with this evidence, and 
one that is a problem with publications from most candidate drugs put forward from 
studies in mouse models of cerebral malaria (White, Turner et al. 2010) is that these 
drugs were given prior to infection and therefore before any complications have 
developed. This is of course not possible in human disease and what is required is 
an agent that reverses symptoms once they have developed; a process that seems 
to be far more difficult. In this light the attenuation of morality in polymicrobial sepsis 
(caecal ligation and puncture) by pharmacological blockade of PAR1 even after the 
development of the severe sepsis syndrome (Niessen, Schaffner et al. 2008) 
represents an important finding and indicates this as a target to prioritize. 
Nonetheless we have an incomplete understanding of the PAR and S1P receptors 
and their effects, and better characterization of the distribution of these receptors in 
the endothelium in the brain during health and during cerebral malaria and of the 
wider effects of agonists and antagonists of these receptors are required before 
progressing to studies in humans (See Further research Box 4).  
A less specific potential agent, also aimed at the inflammation-coagulation interface, 
that has shown promise in vitro and in murine cerebral malaria is Difibrotide 
(Francischetti, Oliveira et al. 2012), a deoxyribonucleic acid (DNA) complex found in 
a number of mammalian tissues. Difibrotide has a wide variety of effects at the 
coagulation-inflammation interface that could potentially be beneficial in cerebral 
malaria including inhibition of tissue factor and adhesion molecule expression on 
endothelium, upregulation of thrombomodulin and is endothelial barrier protective 
and anti-apoptotic (Richardson, Linden et al. 2009). In culture it decreased 
cytoadherence and rosetting and in murine cerebral malaria it showed a clear 
reduction in thrombin generation and inflammatory cytokine production but, 
disappointingly, mortality was not significantly reduced (Francischetti, Oliveira et al. 
2012). Nonetheless it may be that the endothelial effects have a more important 
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effect on outcome human disease or that it proves more beneficial in combination 
with another drug and its use in clinical trials for the prophylaxis or treatment of 
vaso-occlusive disease in children without complications reassures that its anti-
coagulant properties are safe even in a condition with high risk of haemorrhage.  
A final potential treatment to consider is statins. Statins can reduce tissue factor 
expression by monocytes in vitro and also in vivo in both mouse and simian models, 
independent of lipid lowering effects (Owens, Passam et al. 2012). In addition, in 
humans statins have been shown to be anti-inflammatory, improve endothelial 
function and to decrease adhesion molecule expression (Stefanadi, Tousoulis et al. 
2009; Brili, Tousoulis et al. 2012). Statins have been used for a wide variety of 
indications in hundreds of studies, are not associated with bleeding and serious side 
effects are very rare. In favour of the potential of statins to influence outcome, in a 
UK study of pneumonia in adults it was observed in post-hoc analysis that 
individuals on statins had a lower mortality than those who were not (Stephen 
Gordon, personal communication). Even if not effective at influencing outcome in 
cerebral malaria, statins may prove useful in combination with another agent or 
alternatively, if persistent endothelial activation and inflammation following malaria 
infection proves to be important, may be indicating during recovery to protect 
against subsequent acute illnesses or chronic health effects. The biological 
plausibility of statins protecting against endothelial dysfunction and the sequalae 
following malaria infection could be tested in a clinical trial by assessing the effect of 
statin treatment on endothelial parameters in blood, and potentially the endothelium 
directly in subcutaneous biopsies, during acute malarial infection and during 
recovery. If statins did effectively reduce endothelial dysfunction the medium-term 
effects could potentially be tested in a longitudinal study of children who have 
presented with severe malaria in which children are randomized to either statins or 
placebo and followed up to assess the number of cases of severe infection in each 
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group. However it is difficult to conceive how the protective effects of statins over 
the long-term could be objectively assessed.  
 
7.8 Conclusions 
(also see Further research: Boxes 1- 4 in this chapter).  
In cerebral malaria in Malawian children we have demonstrated an acquired 
endothelial defect in a key anti-coagulant pathway at sites of iRBC sequestration. 
The mechanism by which this occurs remains to be determined and we have 
proposed a strategy to investigate this (Further research Box 1 of this chapter). It is 
also of interest whether the mechanism demonstrated here in African children is 
also implicated in cerebral malaria in non-immune adults. Since adults in South East 
Asia more frequently have associated disease in other organs including the lungs 
and kidney it would be interesting to explore whether loss of protein C receptors 
also underlies extra-cerebral adult disease. While it seems likely that differences in 
disease phenotype between adults and children is due to multiple factors - one of 
which is likely to be related to immunity - we propose that differences in endothelial 
phenotype and endothelial response are both likely to contribute.  
Since endothelial alterations lie at the centre of cerebral malaria pathogenesis a 
major barrier to fully understanding disease pathogenesis in adults and children is 
how little known about vascular bed specific variations in endothelial expression of 
receptors. There has been surprisingly little human data on endothelial phenotype in 
healthy individuals in vivo in different organs and on how this changes during life 
(available literature reviewed in Chapter 1). As a result current knowledge is largely 
based on assumptions of vascular bed specific expression in animal models or 
expression in isolated endothelial cells that have been cultured and passaged and 
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which undergo significant expression changes from their 'native' state (Amatschek, 
Kriehuber et al. 2007). The paucity of information in this area is partly due to the 
difficulty of obtaining human endothelium from different organs and partly from the 
lack of a sensitive and quantitative technique that allows comparison between 
organs. Adapting the digestion and flow cytometry technique for determining 
endothelial phenotype in subcutaneous tissue developed here (Chapter 4) would 
enable this comparison and we have outlined an approach for the exploration of the 
expression of coagulation receptors in the brain compared to other organs (Further 
research Box 4); a tissue in which research on receptor expression is particularly 
lacking. However a similar approach could also be used to explore the pattern of 
other endothelial surface receptors, in other organs and also to explore differences 
in specific organs between adults and children. In conjunction the differences in the 
endothelial response between adults and children could be explored using a similar 
approach to (Wassmer, Moxon et al. 2010) in which endothelial cells were isolated, 
cultured and then their responses to different stimuli measured (such as level of 
adhesion molecule upregulation following cytokine stimuli).  
Such research would have wide applicability for other diseases and in developed 
countries as well as in developing countries. For example understanding the 
expression of endothelial anticoagulant receptors in the brain and their differing 
distribution in large and small vessels might be of considerable use in understanding 
the aetiology of, and in developing treatments for, stroke.  
In conclusion we have identified a previously unrecognized defect in a critical 
endothelial homeostatic pathway that has the potential to link key pathogenic 
components and to explain the cerebral specificity of the disease. It remains to be 
seen whether this finding will assist in the identification of an effective adjunctive 
therapy and translate to improved outcome in children with the disease.
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Appendix A-2: Example consent form20 
 
 
 
Patient information: 
Request to take a fat sample and follow up blood samples on the 
research ward vs1.1 (March 2010) 
 
Investigating coagulation in Malawian children with severe 
malaria 
 
1. Purpose of this study 
Malaria attacks the inside of blood vessels and when it is severe it can cause clots in these small 
vessels. We can look at the blood vessels of children with malaria by taking a small sample of fat from 
under the skin. This may give us clues about why some children become so sick with malaria or what 
causes the blood to clot in these vessels in some children.  
 
2. Why your child has been chosen 
Your child has a complication of malaria that we are studying called cerebral malaria that makes them 
unconscious. Your child is already enrolled on the main study on research ward that this 
supplementary study is part of.  
 
3. Is my child eligible to take part in this study? 
Yes - your child is suitable to take part in this study because they are unconscious and have parasites 
in their blood and there is no other obvious cause for them being unconscious. 
 
                                                
20 Three different consent forms following the same layout and style were used for patients with cerebral malaria 
(this one), uncomplicated febrile illness and healthy controls.  
! Malawi-Liverpool-Wellcome Trust  
Clinical Research Programme 
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4. Do I have to take part in the study? 
No - your agreement to help with this study is completely optional and if you would prefer not to have 
an additional sample taken your child will continue to be treated on the research ward. They will 
continue to be in the main study unless you ask for them not to be.  
 
5. What will be involved if I agree to be involved in this study? 
If you agree for your child to be in the study we will put some cream on to numb the skin to minimize 
any pain that taking the sample might cause. We will leave the cream for at least 30mins to make 
sure it works. We will then take a small sample of fat from just under the skin using a large needle (a 
similar size needle to the one used when adults give blood). This will not harm your child and they will 
not remember it because they are unconscious.  
 
To look at some specific tests that tell us about blood clotting and about blood vessels we would also 
like to take a small amount of blood (1.5ml) [nurse will indicate amount to guardian in a syringe] using 
a needle and syringe on four different days. These will be tomorrow, the day after, in one week’s time 
and then finally one month later when your child comes back to hospital for a follow up. You will be 
reimbursed for the entire cost of travelling to the hospital for follow up. We will freeze the samples to 
process them at a later date. We will transport some of the blood out of Malawi to collaborators in the 
United Kingdom and America to do some additional tests that tell us about coagulation and about 
blood vessels.  
 
6. Will there be any risks involved in the study? 
The samples of blood and fat we are taking are small and the risk to your child is minimal. There is a 
very small risk that the area where the fat sample has been taken from might get infected but this is 
unlikely and can be treated with antibiotics if it does. There is also a very small risk that there will be a 
small scar after the wound heals. These have not happened on other children when we have done 
this procedure before. If your child is conscious when the blood is taken they will feel some discomfort 
as the needle is inserted into the vein.  
  
7. Will there be any benefits involved in the study? 
Your child will receive the same treatment whether they are in the study or not. This study will not 
help with the treatment of your child on this occasion. The results of this study may help us to improve 
the treatment of malaria for children in the future. 
 
8. Who is organizing the study 
The research is being done jointly by a group at MLW in Blantyre - based at the College of Medicine - 
and a team in Liverpool in England. 
 
9. Who will know what we find out? 
We will use a number rather than your child’s name to label the samples. Only the investigators will 
know which number is for which child. This way the information about your child will be kept 
confidential. 
10. What happens if you change your mind? 
If you agree to join the study you can change your mind and withdraw your consent at any time, you 
do not need to give a reason for withdrawing from the study.  
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11. Will my transport costs be reimbursed? 
Yes we will pay for your full transport costs by for you and your child to travel to the hospital by 
minibus for each follow up visit. In addition we will give your child a small toy – usually a small toy car 
– on each follow up visit as a thank you for participating in the study.    
 
 
 
 
 
 
 If you have any questions about this study, please contact  
 
Dr. Christopher Moxon  
Malawi-Liverpool-Wellcome Trust 
Clinical Research Programme, 
PO Box 30096, 
Chichiri, Blantyre 3 
Malawi 
Tel: 0993825862 
 
Or the study nurse: 
Grace Matimati Tel  0999981519 
Patricia Phula 0999163366 
 
For any questions regarding patient rights in the scope of this study, please contact the chairman of 
the local ethics committee (COMREC).  This committee has reviewed and approved all of these 
studies.  The chairman’s name is Dr. Joseph Mfutso-Bengo, and he can be reached on 0999 957 805, 
or at this address:   
University of Malawi College of Medicine, P/B 360, Blantyre 3, Malawi.   
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Consent form for parent or guardian 
 
 
Name................................................................................................................................ 
 
Relationship to Child (mother/father/guardian)________________________ 
 
Address............................................................................................................................ 
 
........................................................................................................................................... 
 
1  Have you read or listened to the patient information sheet?  Yes / No 
 
2 Have you had the opportunity to ask questions?    Yes / No 
 
3 Have your questions been answered, and do you feel that you have  
 had enough information about this study?    Yes / No 
 
4 Do you understand that you are free to withdraw from the study 
 at any time without giving a reason and  without affecting your  
      future care at this hospital?      Yes / No 
 
5 Do you agree for us to take a small fat sample with a needle and syringe?  
                                                                                                                      Yes/ No                                                                                                                                   
 
6     Do you agree for us to take a small sample of blood from your child with a needle and syringe four 
times?   
                                                                                        Yes/ No                                                                              
7 Do you agree for us to send some of the blood sample to laboratories  
 outside Malawi for tests that tell us about coagulation and blood vessels ? 
                                                                             Yes/ No 
 
If you have answered ‘yes’ to these questions, please sign the form, or place a thumbprint below, which 
means that you agree to enter the study.  
 
 
Signature.............................................................          Date……………… 
 
 
Investigator obtaining consent (name in capitals)………………………… 
 
 
Signature  ...........................................................          Date ……………….. 
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!
Coagulation*in*malaria*study*
Information*leaflet*for*patients*who*have*had*a*fat*
biopsy*taken*
 
• With your permission we took a small sample of fat from the top of 
the leg on your child. You can take the plaster off after 24 hours 
(one day).  
• Please keep the site clean with soap and water. 
• If it becomes very red or very painful please contact one of the 
study nurses or doctor: 
o Nurses  - Patricia Phula:   Tel 0999163366 
 - Grace Matimati:  Tel 0999862678 
o Doctor – Chris Moxon:     Tel 0993825862 
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APPENDIX A-3: Case report form21 
*
*
Coagulation*in*malaria**
!
Case*Report*Form*
version(1.0((16/11/2009)(
!
GROUP!2:!Elective!surgical!controls!
Principal!Investigator! Christopher!Moxon!
!
!
Study&number& !
! !
                                                
21 Three different case report forms, based on the same format were used for 
cerebral malaria, uncomplicated febrile illness and healthy controls.  The paper 
version was used as a backup only. Patient data was entered into a database 
directly using a MySQL platform.  
APPENDIX A-3: Case report form 
 294 
Study&checklist&
Please!complete!this!checklist!as!the!volunteer!progresses!through!the!study.!
( ! Done* Date*
Clinical(
information(
Patient!information!completed! ! !
Observations!recorded! ! !
Type!of!operation!recorded! ! !
! !
( ! Done* Date*
HIV(testing(
PreEtest!counselling! ! !
HIV!test! ! !
PostEtest!counselling! ! !
! !
( ! Done* Date*
Blood(tests(
Bedside!lactate!&!Glucose! ! !
Bedside!rapid!diagnostic!test! ! !
Malaria!smear!and!PCV!sent!to!diagnostic!lab!
next!to!research!ward!
! !
Results!for!malaria!smear!and!PCV!chased!
and!recorded!!
! !
Green,!blue,!purple!and!white!bottle!sent!to!
diagnostic!lab!
! !
( ! ! ! !
&
 
Section&1:&Inclusion&criteria&
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• Patients!who!meet!the!following!inclusion!criteria!should!be!identified!by!
discussion!with!the!surgical!and!anaesthetic!team!and!nursing!staff:!
Only(if(‘yes’(to(all(above(should(child(and(their(guardian(be(approached(to(seek(informed(
consent.! (
• Section&2:&Seek&informed&consent&&
• Introduce!yourself!to!child!and!their!guardian!
• Briefly!explain!purpose!of!study!
• Explain!that!there!is!a!patient!information!leaflet!and!ask!if!the!guardian!would!like!to!read!
it!themselves!or!if!they!would!like!you!to!read!it!for!them!
• If!they!would!like!to!read!it!themselves!explain!you!will!return!and!in!how!long!(minimum!
30!minutes)!
• If!you!have!read!it!to!them!ask!if!they!would!like!some!time!to!think!about!it!and,!if!they!
would,!tell!them!when!you!will!return.!If!they!have!read!and!you!have!any!concerns!about!
their!ability!to!read!please!read!it!through!with!them!as!well.!
• Answer!any!questions!the!guardian!has.!
• If!the!child!is!older!than!7!ensure!the!child!also!understands!the!study!and!their!
involvement.!Answer!any!questions!the!child!has.!!!
!
!
!
!
! !
Yes!
!
No!
1.1!
!
Is!the!child!aged!between!2!and!12!years!old?! ! !
1.2!
!
Is!the!child!scheduled!for!an!elective!surgical!procedure!under!general!
anaesthetic?!!
! !
1.3! Has!the!operation!of!this!child!been!deemed!low!risk!by!the!surgery!and!
anaesthetic!team:!
E!check!that!the!child!has!no!serious!illness!that!they!receive!regular!
treatment!for!!
! !
1.4! Child!is!accompanied!by!legal!guardian!(mother,!father!or!someone!
with!legal!custody!of!child)!
! !
!
!
! !
Yes!
!
No!
2.1!
!
Has!the!child’s!guardian!given!informed!consent!to!enter!the!study! ! !
2.2! Either:! ! !
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!
• Step&3:&Screening&for&Exclusion&Criteria&&&&
• & & &
Is*any*shaded*box*in*the*above*tables*ticked?*
! Yes:!Do!NOT!include!child!in!this!study!–please!explain!what!you!have!found!and!that!
because!you!have!found!this!the!child!cannot!be!included.!Reassure!that!this!will!have!no!effect!on!
their!clinical!care.!
! No:!Child!may!be!included!in!this!study.!Please!continue!to!complete!the!form.! !
! (
! !
!(a)!The!child!is!under!7!years!old!!
OR!!
(b)!The!child!has!given!assent!to!be!included!in!the!study!!
!
!
! !
Yes!
!
No!
1.5!
!
Does!the!child!have!any!of!the!signs!below:!
!
! !
E!oedema!(feet,!face,!hands)! ! !
E!skin!rash!on!large!part!of!body!(including!flaky!paint!skin)! ! !
E!missing!patches!of!hair!! ! !
E!clubbing!of!fingers!or!toes! ! !
E!jaundice!(yellow!whites!of!eyes)! ! !
!E!Temperature!greater!than!37.5!(check!temperature!and!record!
below)!
! !!
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!
Section*4:*Clinical*information* * * * * * *
!
Date!of!birth!(dd/mm/yy)! __!__!/__!!__!/!__!__! ! Age!!! !!!!!!!Years!
!
!
Sex:! ! ! M! F!
*
*
Type!of!operation:__________________________________________________________!
*
*
Past*History* * * * * * !
!
1. Hospital!admissions!in!last!year!! ! ! Y******* **N! ! !
!
If(Yes:(
Date!of!Admission!1!(dd/mm/yy)!!!__!/!__!/!__!!!!
!
Reason!for!admission!1!
!
!
!
Date!of!Admission!2!(dd/mm/yy)!!!__!/!__!/!__!!!!
!
Reason!for!admission!2!
!
!
!
Date!of!Admission!3!(dd/mm/yy)!!!__!/!__!/!__!!!!
!
Reason!for!admission!3!
!
!
Date!of!Admission!4!(dd/mm/yy)!!!__!/!__!/!__!!!!
!
Reason!for!admission!4!
!
*
*
*
*
*
*
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Medications*in*last*2*weeks*
*
! Medication! ! Dose! ! How!long!on!this!treatment?!
!
! __________! ! _______! _________________Weeks!
!
! __________! ! _______! _________________Weeks!
!
! __________! ! _______! _________________Weeks!
!
__________! ! _______! _________________Weeks!
!
• Observations&
Weight! !! ______Kg!!! Height!!!______cm! !!!!Wasted!!!!!!!!Y*** N*
!
Axillary!temperature! ! _______ºC!!!!!!!!!
!
Respiratory!rate!!!!!!!!!! ! _________/min!!
!
Oxygen!saturations! ! _________%!
!
Capillary!refill!time! ! __________seconds!
!
Cold!hands!and!feet!!!!! ! !!!!Y*** * N*
!
Blood!pressure! ! ! !_____/_____mmHg!
!
!
!
!
! !
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Section&5:!Bedside&tests&and&tests&at&diagnostic&laboratory!
• Take*4ml*of*venous*blood.!!
• Put!in!blood!tubes!immediately!as!detailed!in!box.!
!This!should!leave!0.5ml!of!blood!for!bedside!tests!and!for!2!capillary!tubes!for!(1)!malaria!
smear!and!(2)!packed!cell!volume.!!
Tube Volume of Blood Tick if Sample Obtained 
Blue (sodium citrate) 1.5ml  
Green (benzamidine citrate) 0.5ml  
Purple    (EDTA)  0.5ml               
White (serum) 0.5ml  
Capillary tube (for PCV) Fill  
Capillary tube (for malaria 
smear) 
Fill  
!
Blood!Glucose! ! ! __________mmol/!L!
Plasma!Lactate! ! ! __________mmol/!L!
Malaria!rapid!diagnostic!test!!!! Positive** * Negative*
!
HIV!test!!!! ! ! ! Positive** * Negative*
If!positive!second!test!! ! ! Positive** * Negative*
If!disparate!results!3rd!test! ! Positive** * Negative*
IF(HIV(POSITIVE,(IN(ADDITION(TO(POSTSTEST(COUNSELLING,(ENSURE(REFERRAL(TO(HIV(CLINIC(
• &
• Check&lab&for:&&
Packed!cell!volume! ! __________seconds!
!
Malaria!smear!result! ! Positive** * Negative*
If!positive! ! ! !__________+!!(semiEquantitative)!
____________!!(quantitative)!!!!_________________(!
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APPENDIX A-6: Slide scoring sheets 
Scoring for Lendrum
Version no: 0.9
TM
Last modified by dt: 08/29/2011 08:17:22 AM Page 1 of 2
SIDL01 Participant ID Number
PLACE ID
BARCODE HERE
Yes
No
L02 SCOR Initials of scorer
0 1 2IntegrityINTL03 L04 BG Background 0 1 2
L08 Parasites 0 1 2 3 L08 STAIN 0 1 2 L08 Hemorrhage
L09 Parasites 0 1 2 3 L09 STAIN 0 1 2 L09 Hemorrhage Yes
No
L10 Parasites 0 1 2 3 L10 STAIN 0 1 2 L10 Hemorrhage Yes
No
L11 Parasites 0 1 2 3 L11 STAIN 0 1 2 L11 Hemorrhage Yes
No
L12 Parasites 0 1 2 3 L12 STAIN 0 1 2 L12 Hemorrhage Yes
No
L13 Parasites 0 1 2 3 L13 STAIN 0 1 2 L13 Hemorrhage Yes
No
L14 Parasites 0 1 2 3 L14 STAIN 0 1 2 L14 Hemorrhage Yes
No
L15 Parasites 0 1 2 3 L15 STAIN 0 1 2 L15 Hemorrhage Yes
No
L16 Parasites 0 1 2 3 L16 STAIN 0 1 2 L16 Hemorrhage Yes
No
L17 Parasites 0 1 2 3 L17 STAIN 0 1 2 L17 Hemorrhage Yes
No
L18 Parasites 0 1 2 3 L18 STAIN 0 1 2 L18 Hemorrhage Yes
No
L19 Parasites 0 1 2 3 L19 STAIN 0 1 2 L19 Hemorrhage Yes
No
L20 Parasites 0 1 2 3 L20 STAIN 0 1 2 L20 Hemorrhage Yes
No
L21 Parasites 0 1 2 3 L21 STAIN 0 1 2 L21 Hemorrhage Yes
No
L22 Parasites 0 1 2 3 L22 STAIN 0 1 2 L22 Hemorrhage Yes
No
L23 Parasites 0 1 2 3 L23 STAIN 0 1 2 L23 Hemorrhage Yes
No
L24 Parasites 0 1 2 3 L24 STAIN 0 1 2 L24 Hemorrhage Yes
No
L07 Parasites 0 1 2 3 L07 STAIN 0 1 2 Hemorrhage Yes
No
L06 Parasites 0 1 2 3 L06 STAIN 0 1 2 Hemorrhage Yes
No
L05 PAR Parasites 0 1 2 3 L05 STA STAIN 0 1 2 L05 HEM Hemorrhage Yes
No
L07
L06PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
PAR STA HEM
Description
Results
L25 PAR Parasites 0 1 2 3 STA STAIN 0 1 2 HEM Hemorrhage Yes
No
L25 L25
2213237987
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Scoring for parasites and Immunostaining - ORANGE TAPE
Description
PIDP01 Participant ID Number
PLACE ID
BARCODE HERE P02 SCOR Initials of scorer
IntegrityINTP03 0 1 2 P04 BG Background 0 1 2
Results
P05 OSTA Overall Staining 0 1 2
P06 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P07 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P08 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P09 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P10 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P11 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P12 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P13 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P14 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P15 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P16 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P17 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P18 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P19 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P20 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P21 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P22 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P23 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P24 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P25 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P26 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P27 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P28 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P29 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P30 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
P31 PAR Parasites 0 1 2 3 STA STAINING 0 1 2 3
Version no: 0.9
TM
Last modified by dt: 08/29/2011 09:18:04 AM Page 1 of 2
P06
P07
P08
P09
P10
P11
P12
P13
P14
P15
P16
P17
P18
P19
P20
P21
P22
P23
P24
P25
P26
P27
P28
P29
P30
P31
0658528138
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Brief report for Parasites and Immunostaining - GREEN TAPE
Number
G04
Damage Background
G06
Staining
G07
Comments
G09G05
G01
Initials
of scorer Data
G02 2 0 1 1
  d        d          m      m     m         y        y      y       y
Association
G08
INSTRUCTIONS :
Use the attached sheet to check for detailed instructions.
Page 1 of 109/05/2011 11:28:12 AMDesigned by dthindwa
G05
Damage e.g.
0 or 1 0r 2
G06
Background e.g.
0 or 1 or 2
G07
Staining e.g.
0 or 1 or 2 or 3
Association e.g.
-1 or 0 or +1
G08
PLACE ID
BARCODE HERE
PLACE ID
BARCODE HERE
PLACE ID
BARCODE HERE
PLACE ID
BARCODE HERE
PLACE ID
BARCODE HERE
PLACE ID
BARCODE HERE
G03
Date
2254595350
